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1. Introduction 
Human illness due to infection with enterohemorrhagic Escherichia coli (EHEC) is 
frequently occurring in developed countries (9652 cases in Europe in 2004) (Stein 2005). 
The clinical manifestations can range from mild symptoms such as abdominal 
convulsions and self-limited watery or bloody diarrhea, to severe cases such as 
hemorrhagic colitis (HC), acute renal failure and hemolytic uremic syndrome (HUS) 
(Sheng et al. 2006).  
Consumption of contaminated meat and dairy products, as well as contaminated 
vegetables or water are a common source of infection (Torso et al. 2015; Buvens et al. 
2011; Armstrong et al. 1996). Furthermore, direct contact with infected animals 
(Heuvelink et al. 2002) and person-to-person transmission (O’Donnell et al. 2002) has 
been described. Since infected cattle do not show clinical symptoms, their infection status 
is often unknown, augmenting the risk of bacterial transmission to humans. Outbreaks in 
the past have shown that not only EHEC put people in jeopardy of developing severe HC 
and HUS (characterized by thrombocytopenia, hemolytic anemia, and kidney failure), 
but also other seemingly harmless E. coli strains can acquire virulence factors after 
horizontal transmission, evolving into life-threatening pathogens. The outbreak of 2011 
in Germany in which 3,816 cases were reported (including 54 deaths, and 845 cases of 
HUS) shows how readily enteroaggregative E. coli (EAEC) strains that do not produce 
Shiga toxins (Stx) can evolve into a serious threat for human health by the acquisition of 
an Stx2a-converting phage (Karch et al. 2012). This transduction changed an etiologic 
agent of diarrhea into one that also causes HC and HUS. The highly versatile nature of 
Escherichia coli makes them an interesting object for research.  
This introductory chapter summarizes the current knowledge on the pathogenic E. 
coli with special focus on the E. coli O157:H7 serotype, which is often related to human 
disease. Insights into animal reservoirs of EHEC and their immune responses against the 
bacteria are discussed. Furthermore, a possible treatment strategy using a naturally 
occurring antibacterial agent, bovine lactoferrin (bLF), will be reviewed. 
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2. Shiga toxin-producing Escherichia coli 
2.1 Nomenclature and taxonomy of Shiga toxin-producing Escherichia coli  
E. coli strains can be subdivided in six categories depending on phenotypic traits, 
clinical features of caused disease, and specific virulence factors. The diarrheagenic E. coli 
can be split into enteropathogenic E. coli (EPEC), Shiga toxin-producing E. coli (STEC) or 
verocytotoxin-producing E. coli (VTEC) – including enterohemorrhagic E. coli (EHEC)-, 
enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), enteroinvasive E. coli 
(EIEC), and diffusely adherent E. coli (DAEC) (Kaper et al. 2004). In 1977, 
Konowalchuk et al. (1977) described for the first time a verocytotoxin that was found to 
be biologically and structurally similar to the Stx produced by Shigella dysenteria Type I 
(O’Brien et al. 1982). Later on, two forms of cytotoxins were described that could be 
found in different E. coli serotypes (Scotland et al. 1985). STEC or VTEC strains are 
characterized by the bacteriophage-mediated production of one or both of these 
cytotoxins, referred to as Stx1 or VT1 (first described as Shiga-like toxin I) and Stx2 or 
VT2 (first described as Shiga-like toxin II) (Scotland et al. 1983). The term EHEC was 
established to refer to strains such as E. coli O157:H7, that give rise to severe clinical signs 
such as HC, renal failure, and HUS. Many other STEC strains that actually belong to the 
classical EPEC serotypes, such as O26, O111, and O126 were more sporadically linked 
to human cases as they were found to produce Stx (Levine et al. 1987; Wade et al. 1979; 
Scotland et al. 1980).  The classification of strains based upon serogroups is inconclusive 
as outbreaks with emerging or new hybrid strains demonstrate how versatile the strains 
are. The 2011 outbreak in Germany was an example of a highly virulent EAEC strain 
that was never before associated with outbreaks and had acquired the mechanism for 
toxin production.  
Many studies have tried to correlate specific virulence factors with severity of 
disease: the combination of the locus of enterocyte effacement (LEE)-encoded eae gene 
for intimin and stx2 is more frequently found in isolates from serotypes found in humans 
and is strongly associated with severe disease. The opposite is true for stx1, which is more 
frequently found in bacteria isolated from animals (Boerlin et al. 1999). Animals often 
carry STEC but do not show any clinical symptoms, demonstrating that the clinical 
course of disease is host associated. 
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The E. coli genome contains 4,200 to 5,500 genes, with less than 2,000 genes 
conserved among all strains of the species – the core genome. The variable genes, 
sometimes collocated on genomic islands, make up more than 90 % of the pan-genome 
(all genes in a group of organisms consisting of a common ancestor and all lineal 
descendents) and about 80 % of a typical genome. Continuous gene flux, due to 
horizontal gene transfer and deletions, occurred during E. coli divergence. This genetic 
plasticity accelerates the adaptation of E. coli to a wide range of environments and 
lifestyles, and allows multiple gene combinations that result in phenotypic diversification 
and the emergence of new hypervirulent strains (Lukjancenko et al. 2010). 
Classification of strains based upon toxin types is carried out as Stxs can be divided 
into two types: Stx1 (almost identical to Stx from Salmonella dysenteriae Type 1) and Stx2, 
which can be subdivided into three (a,c,and d) and seven (a-g) subtypes, respectively. Stx 
types and subtypes exhibit significant differences in biological activity, receptor binding, 
and the capacity to be activated by elastase in intestinal mucus (Scheutz et al. 2012). The 
Stx subtypes are clinically relevant as they are associated with milder or more severe 
clinical cases. Stx2a was found to be highly associated with HUS (Friedrich et al. 2002). 
Furthermore, in vitro studies with Vero cells showed that Stx2a and Stx2d were at least 25 
times more potent than Stx2b and Stx2c. In mice, the in vivo potency of Stx2b and Stx2c 
was found to be similar to that of Stx1, whereas Stx2a and Stx2d were 40 to 400 times 
more potent than Stx1 (Fuller et al. 2011). The capacity to produce Stx is encoded by 
genes on bacteriophages. Several common stx phage insertion sites have been reported in 
STEC genomes. Insertion site occupancy by stx phages depends on the host strain and on 
the availability of the preferred locus in the host strain (Ogura et al. 2009). Phages 
preferentially use one insertion site, but if this primary site is unavailable, a secondary site 
is selected (Serra-Moreno et al. 2007). In a majority of STEC strains, the expression of stx 
genes within lambdoid phages is believed to be largely under the control of the late 
promoter, pR’ and the Q-antiterminator protein (Brüssow et al. 2004). The expression is 
usually repressed and production of Stx is preceded by prophage induction (Herold et al. 
2004). Variations on the Q-gene have been proposed to influence the quantitative 
expression of Stx (Wagner et al. 2001). The Q-gene transcription is increased under 
inducing conditions allowing for increased transcription of the stx sites that are 
downstream of the Q-binding site (Brüssow et al. 2004). Inducing factors include 
nutritional stress, oxidative stress, UV-radiation, antibiotics, Ethylenediaminetetraacetic 
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acid (EDTA), hydrogen peroxide, heat shock and quorum sensing (Fortier & Sekulovic 
2013), but Stx1 production can also be induced through low-iron (Wagner et al. 2002).          
2.2 Pathogenesis 
The pathogenesis of STEC strains is related to their ability to induce the formation 
of attaching and effacing (A/E) lesions and to produce one or two Stxs. The latter is 
linked to causing HC and HUS in humans (Karmali 2009). For colonization, the Stx are 
of less importance, although they can bind to enterocytes and subsequently influence the 
colonization receptors. In the next section, the most studied virulence factors are 
described including their contribution to pathogenesis.   
2.3 Shiga toxin classification, structure, and role in pathogenesis 
Stxs are very potent biological poisons as they can cause a wide variety of severe 
symptoms in different species. Furthermore, a single molecule of Stx may be sufficient to 
kill a cell (Tam & Lingwood 2007). Two immunologically distinct groups of Stxs have 
been described. In the early nineteen hundreds, Neisser and Shiga (Trofa et al. 1999) 
described Stx from S. dysenteriae. Eighty years later, this toxin – now called Stx1- was 
found in a group of E. coli isolates that were the cause of bloody diarrhea and other 
serious sequela like HC and HUS (Karmali et al. 1983; O’Brien et al. 1983). Stx2, which 
is highly related to Stx1 and has the same mode of action, is immunologically distinct 
from Stx1. These two types of Stxs are subdivided into toxin subtypes, as listed in Table 
1.1. Only three types of Stx1 were described: Stx1a, Stx1c, and Stx1d. Stx1c and Stx1d 
are rarely found in human disease, and were associated with STEC isolated from patients 
with a mild disease course (Koch et al. 2001; Paton et al. 1995; Burk et al. 2003). For 
Stx2, seven subtypes have been described. Stx2c is also important for human disease but 
shows a reduced cytotoxicity on Vero cells compared to Stx2a (Paton et al. 1993). Stx2d 
was identified because incubation with elastase from intestinal mucus increases the Vero 
cell cytotoxicity of this toxin; this subtype is associated with cases of HUS (Persson et al. 
2007). Stx2b is associated with mild disease (Piérard et al. 1998). Stx2e, Stx2f, and Stx2g 
are associated with disease in animals as pigs, pigeons and cattle, respectively (Weinstein 
et al. 1988; Schmidt et al. 2000; Leung et al. 2003). Stx1 has a 10-fold higher affinity for 
globotriaosylceramide (Gb3) receptor in cells than Stx2 (Head et al. 1991), but Stx2 has 
an approximately 400-fold lower LD50 in mice than Stx1 (Tesh et al. 1993).   
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Table 1.1: Toxin types and their clinical outcome   
Toxin type Linked with serious human disease Reference(s) 
Stx1a 
Stx1c 
Stx1d 
Yes 
No 
No, less potent 
(Riley et al. 1983) 
(Koch et al. 2001; Paton et al. 
1995) 
(Burk et al. 2003) 
Stx2a Yes (Riley et al. 1983) 
Stx2b No (Piérard et al. 1998) 
Stx2c Yes, less toxic to Vero cells and mice (Paton et al. 1993) 
Stx2d Yes, more toxic after incubation with elastase; less 
toxic to Vero cells 
(Persson et al. 2007) 
Stx2e 
Stx2f 
Stx2g 
No, binds to GB4, associated with disease in pigs 
No, first isolated from STEC form pigeons 
No 
(Weinstein et al. 1988) 
(Schmidt et al. 2000) 
(Leung et al. 2003) 
   
(adapted from Melton-Celsa 2015) 
Stxs belong to the bacterial AB5-protein toxins and have a molecular weight of 
about 70 kDa (Fraser et al. 1994). In sensitive eukaryotic cells, the toxins can inhibit 
protein synthesis through the removal of an adenine residue from the 28S rRNA of the 
60S ribosome (Endo et al. 1988). This enzymatic activity is present in the 32 kDa A-
subunit (StxA) –composed of A1 and A2-, whereas the pentameric B-subunit (StxB) – 
which has 5 identical 7.7 kDa fragments- is important for binding to the cellular Gb3 
receptor. StxB forms a doughnut-shaped structure with a central pore into which the 
carboxylterminus of StxA inserts (Fraser et al. 1994). After receptor binding, the toxin is 
taken up by endocytosis and undergoes retrograde sorting in early endosomes, in which 
retrograde tubules are formed in a clathrin-dependent manner. Stxs are transferred from 
the early endosome, directly to the trans-Golgi network and subsequently to the 
endoplasmatic reticulum. Finally, they use retro-translocation to translocate into the cell 
cytosol (Figure 1.1). 
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Figure 1.1: Intracellular trafficking of Stxs. Toxin binding to the plasma membrane induces endocytic 
invaginations, followed by retrograde sorting in early endosomes. Stxs are transported from the early endosome 
directly to the trans golgi network (TGN) and from there to the endplasmatic reticulum (ER) and via retro-
translocation to the cytosol where the A subunit is proteolytically cleaved into an A1- and A2-fragment. (adapted 
from Johannes and Römer, 2010) 
 
Once in the cytosol, the A-subunit is proteolytically cleaved into an A1- and A2-
fragment. The A2-fragment remains attached to the B-subunit, whereas the A1-fragment, 
which is active, must avoid the proteasome until it reaches its substrate, the 60S 
ribosome. The protection against degradation by the proteasome is probably due to its 
lack of lysine residues together with its ability to refold rapidly (Johannes & Römer 
2010). Stx-mediated damage to the ribosome induces a response in cells called “ribotoxic 
stress response”, which is both proinflammatory and proapoptotic. Furthermore, an 
unfolded protein response as a result of the stress on the endoplasmatic reticulum, 
resulting in even more apoptosis has been reported (Jandhyala et al. 2012).  
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In order to develop HUS, translocation of the toxin into the bloodstream towards 
the kidney is a necessary step. In 1996, Stx translocation through the intestinal barrier 
was shown in intact polarized intestinal epithelial cells (Caco-2, and T84 cells) (Acheson 
et al. 1996). Later on, it was observed that Stx1 translocation through intestinal epithelial 
cells occurs via a transcellular route, whereas Stx2 uses a paracellular translocation 
pathway (Hurley et al. 2001; Philpott et al. 1997). In the bloodstream, Stx binds to 
monocytes, platelets and polymorphonuclear (PMN) leukocytes and is transferred to the 
kidney, inducing a prothrombotic state that contributes to the pathogenesis of HUS 
(Ståhl et al. 2009). Children are more sensitive to developing HUS, due to higher levels of 
the Gb3 receptor in the glomerular capillaries (Lingwood 1994). Furthermore, cattle lack 
the vascular Gb3 receptor, explaining why ruminants are symptomless carriers of E. coli 
O157:H7 (Pruimboom-Brees et al. 2000). However, they do have receptors on cortical 
kidney cells and crypt epithelial cells of the small and large intestine (Pruimboom-Brees 
et al. 2000; Hoey et al. 2002). A prolonged colonization in ruminants due to reduced 
epithelial shedding by the effect of Stx on crypt epithelial cells has been observed 
(Magnuson et al. 2000). Stxs can also bind to submucosal lymphoid cells suggesting a 
role for Stx in immunomodulation (Hoey et al. 2002). Furthermore, mucosal 
macrophages carry Stx-receptors and alter their chemokine and cytokine expression 
patterns in response to Stx-stimulation (Stamm et al. 2008, Menge et al. 2015). 
2.4 Colonization by formation of A/E lesions 
EPEC and EHEC strains must adhere to the intestinal epithelium in order to be 
pathogenic. This colonization requires the formation of an A/E lesion (Figure 1.2), 
which is characterized by destruction of nearby microvilli, intimate bacterial attachment 
to the apical surface and actin condensation underneath the adherent bacteria, leading to 
pedestal formation. The bacteria use a conserved type III secretion system (T3SS), 
encoded in the LEE, to form a molecular syringe (translocon) that forms a connection 
between the bacterium and the host cell spanning the bacterial inner and outer membrane 
as wells as the eukaryotic plasma membrane. This syringe translocates effector proteins 
as wells as gene regulators and chaperones into the target cell (Pallen et al. 2005).  
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Figure 1.2: (A) Transmission electron micrograph (TEM) showing A/E lesions (pedestal formation) induced by 
EHEC in the colon of a neonatal calf;  scale bar = 1 µm. Adapted from Stevens et al. (2002a); (B) Fluorescence 
micrograph showing nucleation of F-actin under EHEC strain adhering to a HeLa cell (green, F-actin detected 
with Oregon green514-phalloidin; red, bacteria stained with rabbit anti-O103 typing serum detected with anti-
rabbit immunoglobulin-Alexa568); scale bar = 5 µm. Adapted from Stevens et al. (2002b).  
 
In a three-step-process, EPEC and EHEC can colonize the epithelium: the first step 
is the initial adhesion by a not fully understood mechanism, followed by signal 
transduction and cytoskeletal rearrangements, for which the T3SS is required, and 
intimate adhesion and pedestal formation (Donnenberg et al. 1997). In the initial 
adhesion step, the H7 flagellin which is known to be important for motility, seems to be 
essential for the first adherence to the epithelium as well. Mahajan et al. (2009) have 
shown that the H7 flagellin which is upregulated first, functions as an adhesin.  
After initial contact with the host cell, the H7 flagellin expression is downregulated 
while the T3SS proteins becomes upregulated. Another study suggested a role for the 
long polar fimbriae (LPF), as it might interact with the mucus increasing the survival of 
E. coli O157:H7 in different physiological environments (Torres et al. 2007).  
The second step, mainly characterized by signal transduction and cytoskeletal 
reorganization of the host cell leading to the formation of an A/E lesion is instructed by 
the LEE. Figure 1.3 shows the T3SS apparatus encoded by LEE, resembling a molecular 
needle spanning the bacterial inner and outer membrane as well as the eukaryotic host 
membrane through which effector molecules are injected into the host cell (Pallen et al. 
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2005). E. coli secreted protein A (EspA) filaments form a transport channel between the 
bacteria and the host cell, transporting EspB and EspD to the host cell where they form a 
pore in the host cell membrane through which the bacterial effector proteins are delivered 
in the host cell. EspA is also important for the translocation of Tir (Translocated intimin 
receptor) into the host cell (Moxley 2004) which will interact with the bacterial intimin 
leading to an intimate adhesion of the bacterium with the host cell (DeVinney et al. 
1999). Tir is injected into the host cell membrane through the needle complex and adopts 
a hairpin-loop structure, allowing its extracellular domain to bind to intimin (Campellone 
& Leong 2003). After translocation of the effector proteins, the EspA filaments are 
eliminated from the bacterial cell surface, which is necessary to allow intimate bacterial 
attachment through the intimin/Tir interaction (Frankel et al. 1998). This interaction 
initiates a signaling cascade, leading to polymerization of F-actin and pedestal formation 
which results in a strong attachment of E. coli to the host cell (Kaper 1998).  
 
Figure 1.3: Schematic representation of the T3SS apparatus showing the organization of the LEE-
encoded proteins. Adapted from Pallen et al.( 2005). 
 
This cascade of events is one of the examples which demonstrate that EHEC has 
evolved an ingenious strategy to attach to the host cells, inserting its own receptor and a 
linker molecule, but also overpowers the host cell cytoskeleton in order to create a safe 
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pedestal which probably impairs the removal of EHEC by immune cells. Furthermore, 
EHEC has developed other strategies subverting the host immune response in order to 
promote bacterial colonization and survival. These will be reviewed below in section 2.6. 
2.5 The pO157 plasmid 
All EHEC strains possess a large 90kb pO157 plasmid. These plasmids are highly 
conserved amongst the different E. coli O157:H7 strains, showing only single nucleotide 
polymorphisms. The complete pO157 plasmid sequence was determined by Burland et 
al. (1998), unraveling several possible virulence factors like enterohaemolysin, KatP, 
EspP, StcE and Lymphostatin (Vande Walle 2010).  
2.6 Effector molecules 
EHEC is an extracellular pathogen that affects intracellular host cell signaling 
pathways, resulting in a more efficient colonization and evasion of host immune 
responses. These effects are coordinated by the T3SS that injects effector molecules into 
the host cell. The function of these effectors ranges from inhibitors of apoptosis, 
influencers on inflammatory signaling pathways, to phagocytosis. The study of Wong et 
al. (2011) has highlighted the multifunctional nature of the effectors and their ability to 
participate in redundant, synergistic or antagonistic relationships, acting in a co-
ordinated way on different host organelles and cellular pathways during infection. The 
first effectors discovered were LEE-encoded, but more recently also non-LEE encoded 
molecules carried on prophages or other pathogenicity islands have been described. A 
lineup of the best studied molecules and their effects are described below and in Figure 
1.4 and Figure 1.5. 
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Figure 1.4: Major T3SS effectors of EPEC/EHEC and their targets within host cells to show the multifunctional 
nature of effectors common to EPEC and EHEC and their overlapping functions. From Law et al. (2013). 
2.6.1 LEE-encoded effectors 
Tir plays a role in inhibiting host innate signaling mechanisms. A study showed 
that transient expression of Tir from EPEC in HeLa cells inhibits Tumor Necrosis Factor 
(TNF)-induced Nuclear Factor-κB (NF-κB) activation by binding and degrading the 
cytoplasmic TRAF2 (Ruchaud-Sparagano et al. 2011). Furthermore, Tir was shown to 
inhibit Toll Like Receptor (TLR)-signalling and proinflammatory cytokine expression 
during EPEC and Citrobacter rodentium infection in vitro as well as in vivo, respectively. 
This mechanism is depending on the direct binding of Tir to SHP-1, a phosphatase that 
suppresses cellular immune responses by dephosphorylation of NF-κB and Mitogen-
Activated Protein Kinases (MAPKs). Downregulation of SHP-1 increased the TNF and 
IL-6 production in EPEC-infected cells. Deletion mutants of tir showed enhanced NF-κB, 
Erk, JNK, and p38 MAPK activation when epithelial cells were infected with EPEC 
(Yan et al. 2012). 
EspB is a natively partially folded pore-forming translocon component (Hamada et 
al. 2005), through which effector proteins are translocated. After pore formation, EspB is 
translocated into the cytosol near the site of bacterial attachment and has an effector 
function regulating cytoskeletal modulation (Taylor et al. 1998). EspB is known to bind 
host proteins α-catenin, α1-antitrypsin, and myosin that regulate the actin network 
leading to alterations in cell morphology (Hamada et al. 2010). The myosin-binding 
domain of EspB inhibits the interaction of myosins with actin, leading to microvillus 
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effacement (Iizumi et al. 2007). EspB is also linked to the ability of EHEC to suppress 
NF-κB activation and synthesis of proinflammatory cytokines. However, it remains 
unclear if this is due to EspB itself or to its role in the delivery of other effectors (Hauf & 
Chakraborty 2003).  
Recent work has shown that EspF is one of the most multifunctional effector 
proteins known, comparable to a “Swiss army knife” (Holmes et al. 2010). In vitro studies 
have demonstrated that EspF from EPEC decreased the transepithelial electrical 
resistance, resulting in a higher permeability, as well as altered the intestinal epithelial 
tight junction structure (McNamara et al. 2001). Furthermore, EspF appears to be an 
effector of host cell death in epithelial cells by apoptosis. Its proline-rich structure 
suggests that it may act by binding to SH3-domains or EVH1-domains of host cell 
signalling proteins (Crane et al. 2001). Originally EspF was believed not to be involved in 
A/E lesion formation, but a more recent study has highlighted its affinity for profilin, 
Arp2/3, and actin leading to recruitment of junctional proteins into the pedestals, 
followed by the maturation of actin pedestals and the disruption of paracellular 
permeability (Peralta-Ramírez et al. 2008). EspF has also been linked to inhibition of 
apoptosis and was shown to disrupt nucleolin under regulation of mitochondrial 
dysfunction (Dean et al. 2010).      
EspG’s binding to tubulin causes localized microtubule depolymerization, resulting 
in actin fiber stress formation through an undefined mechanism. It is suggested that 
EspG contributes to the ability of A/E pathogens to establish infection through a 
modulation of the host cytoskeleton involving transient microtubule destruction and 
actin polymerization (Hardwidge et al. 2005). 
EspH, first described in 2003, is translocated into the host cell using the T3SS 
apparatus and localizes beneath the bacterium. There, it disturbs the transient filopodium 
formation which is followed by a promotion of formation of actin pedestals beneath the 
bacterium (Tu et al. 2003).   
EspZ is a control mechanism of the T3SS that prevents cytotoxicity of the host cell, 
when an unbalance of intracellular effector concentrations is detected. Following ectopic 
expression, it was found that EspZ inhibited the formation of actin pedestals as it blocked 
the translocation of Tir, as well as other effectors, including Map and EspF. Moreover, 
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during infection EspZ inhibited effector translocation following superinfection (Berger et 
al. 2012). EspZ contributes to epithelial cell survival by mechanisms that include the 
inhibition of the intrinsic apoptotic pathway (Roxas et al. 2012). This host cell 
cytoprotection probably enhances survival of infected enterocytes thereby promoting 
bacterial colonization (Wilbur et al. 2015).    
Mitochondrion-associated protein (Map) features three distinct functions: (i) 
during initial EHEC/EPEC infection, Map is in charge of the transient formation of 
filopodia at the site of bacterial infection (Kenny et al. 2002); (ii) it triggers the formation 
of deformed mitochondria, mitochondrial swelling and damage by interfering with the 
host cell mechanism to maintain the mitochondrial membrane potential (Kenny & 
Jepson 2000); and (iii) is as essential as EspF for disrupting intestinal barrier function. 
While functioning independently of EspF, it alters tight junction structure and mediates 
these effects in the absence of mitochondrial targeting (Dean & Kenny 2004).   
2.6.2 Non-LEE encoded effectors 
The Cycle inhibiting factor (Cif), which is encoded by a lambdoid prophage, 
blocks cell cycle G2/M transition and induces the formation of stress fibres through the 
recruitment of focal adhesions. Inhibition of the cell cycle might impair the integrity of 
the epithelial barrier, which eases the invasion of pathogenic bacteria into the body 
(Marchès et al. 2003) or prolonges their existence by blocking shedding of epithelial cells, 
as delayed cell death was also linked to Cif (Samba-Louaka et al. 2009).   
 
EspJ is responsible for trans-inhibition of macrophage opsono-phagocytosis by both 
EPEC and EHEC, probably through targeting of a host cell molecule normally involved 
downstream of the phagocytic receptors FcγR and CR3, as EspJ inhibits phagocytosis 
mediated by these receptors (Marchès et al. 2008). 
 
Several non-LEE encoded effectors (Nle), NleA to I, have been described. Most of 
their functions have been studied in EPEC strains. NleA (also EspI) is translocated into 
host cells, where it localizes to the Golgi apparatus (Gruenheid et al. 2004) and is also 
linked to disruption of intestinal tight junctions between epithelial cells and EPEC. This 
mechanism seems to be related to its inhibition of host cell protein trafficking through 
COPII-dependent pathways (Thanabalasuriar et al. 2011).  
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NleB was first identified as a secreted effector of Citrobacter rodentium and is 
conserved across all A/E pathogens (Deng et al. 2004). It was shown that NleB 
suppressed IκB degradation and NF-κB activation in response to TNF but not IL-1β 
stimulation (Newton et al. 2010). Gao et al. (2014) revealed that NleB has a conserved 
GlcNAc-transferase activity. They proposed the binding of NleB to host Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and subsequent O-GlcNAc modification leading 
to hindered TNF-receptor associated factor 2 (TRAF2)-mediated NF-κB activation. This 
observation is concurrent with the observations of Newton et al. (2010) that showed 
blocking of TNF-induced Inhibitor of κB (IκB) degradation and p65 nuclear translocation 
by NleB. Deletion of the nleB gene did not have a significant effect on the adherence of 
HEp-2 cells. However, in an in vivo model, it strongly reduced the ability of STEC 
O26:H11 to colonize the bovine intestinal tract (Misyurina et al. 2010).    
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Figure 1.5: Different EPEC/EHEC effectors (shown in red) inhibit NF-κB activation by targeting components of 
the signaling cascade or preventing nuclear translocation of NF-κB complex components. Tir enhances the 
association of inhibitory SHP1 and SHP2 with TRAF6. NleE methylates TAB2/3, inhibiting TAK1 activation. 
NleB glycosylates GAPDH, preventing its activation of TRAF2. NleH1 inhibits the nuclear translocation of the 
NF-κB complex subunit, RPS3. NleH2 promotes RPS3 nuclear translocation. NleC proteolytically cleaves the p65 
subunit of NF-κB. NleC also cleaves p300, an acetyltransferase that promotes p65 activity. From Santos & Finlay 
(2015). 
 
NleC is a 37 kDa non-LEE encoded effector with proteolytic properties, targeting 
NF-κB Rel proteins for degradation, which was first identified as an effector by the LEE-
encoded T3SS of C. rodentium. EHEC and EPEC NleC share 100% amino acid sequence 
similarity and are 95% similar to NleC of C. rodentium. NleC degrades the p65 subunit of 
NF-κB using zinc metalloprotease motifs. [Baruch, 2011] There is no consensus 
regarding the exact cleavage site of p65, as two independent research groups identified 
the site within the N-terminal Rel homology domain of p65, but Baruch et al. indicated 
the site between residue C38 and E39, whereas Yen at al. (2010) put the site between 
residue P10 and A11. Nevertheless, since the Rel homology domain of p65 proteins is 
required for binding, dimerization, and nuclear translocation, cleavage by NleC unables 
p65 to bind target genes and to activate transcription of inflammatory cytokines.   
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NleC and NleD are Zn2+-dependent endopeptidases that specifically clip and 
inactivate RelA (p65) and c-Jun N-terminal Kinases (JNK), respectively, thus blocking 
NF-κB and Activator Protein-1 (AP-1) activation. It was shown that NleC and NleD co-
operate and complement other EPEC effectors in accomplishing maximal inhibition of 
IL-8 secretion. This is a another example of pathogenic E. coli using multiple effectors to 
manipulate systematically the host inflammatory response signalling network (Baruch et 
al. 2011). A study of Yen et al. (2010) has shown that also NleE is necessary for 
inhibition of NF-κB activation as the cooperative function of NleE and NleC disrupts the 
NF-κB pathway and accounts for most of the immune suppression caused by 
EHEC/EPEC. A study in human dendritic cells and Peyer’s patch dendritic cells showed 
that NleE can inhibit nuclear translocation of activated NF-κB and expression of 
proinflammatory cytokines as IL-8, IL-6 and TNF. These dendritic cells are highly 
present in the follicle-associated epithelium lining the gut-associated lymphoid tissue 
from the luminal contents of the intestinal tract. It is plausible that enteric pathogens such 
as EHEC, EPEC, and Shigella sp. have evolved to a mechanism which allows them to 
evade immune detection at this epithelium, promoting survival of the pathogen in the gut 
(Vossenkämper et al. 2010).  
 
The highly conserved NleF binds to caspase-4, -8, and -9 and directly inhibits the 
catalytic activity of the caspases in vitro and in cell lysate and prevents apoptosis in HeLa 
and Caco-2 cells. Evasion of apoptosis helps pathogenic E. coli and other pathogens to 
take over the host cell by counteracting the cell's ability to self-destruct upon infection 
(Blasche et al. 2013). Furthermore, NleF induces the nuclear translocation of NF-κB p65 
and the expression of IL-8 following ectopic expression and during early EPEC infection 
(Pallett et al. 2014).  
 
NleH1 and NleH2, sharing 84% amino acid identity contribute to suppression of 
NF-κB activation by binding ribosomal protein S3 (RPS3), a non-Rel NF-κB subunit. The 
N-terminal region in NleH1 reduces the nuclear abundance of RPS3, by inhibition of 
IKKβ-mediated phosphorylation of RPS3 at the S209 residue, with no effect on other 
NF-κB signalling factors. NleH2 does not inhibit RPS3 nuclear translocation, but 
increases the expression of an AP-1- dependent luciferase reporter; hence it may affect a 
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different pathway (Gao et al. 2009). Infection studies in C57BL/6 mice showed that this 
effector might play a role in the persistence of the bacteria since nleH mutants were  
cleared more rapidly than the wild-type strain (Hemrajani et al. 2008). However, it was 
shown that neither NleH1 nor NleH2 inhibits the NF-κB activity to the same extent as 
NleE and NleC in vitro (Newton et al. 2010). Only limited data about NleI is available, 
but NleI was shown to ease the secretion of other effector molecules, like NleA, F and H 
(Li et al. 2006).  
2.7 E. coli O157:H7 infection 
Cattle are the main natural reservoir of EHEC, but other ruminant species such as 
sheep, goats, and even deer may also act as reservoirs (Ferens & Hovde 2011). Other 
animals like birds, swine, dogs and horses can be categorized as spillover hosts, meaning 
that they are susceptible to colonization and may transmit disease, but once they are no 
longer exposed to a source of EHEC, they do not maintain colonization. A third host 
category are dead-end hosts, which are incapable of transmitting EHEC naturally to 
other animals. They can only transmit EHEC when consumed. Examples of dead-end 
hosts are finfish and shellfish (Persad & LeJeune 2014). Below we focus on the main 
reservoir of EHEC, cattle, as well as the most important modes of transmission towards 
human and the effect of an infection in humans.    
2.7.1 EHEC in cattle 
Cattle are regarded as the main natural reservoir of STEC and EHEC, showing no 
clinical symptoms upon infection. Some serogroups such as E. coli O5, O26, and O118 
are sometimes linked with diarrhea in young calves (Mainil 1999). Cattle carry a distinct 
pattern of Gb3 receptor isoform mixtures in the bovine kidney. This, together with the 
general absence of receptors on vasculature, could contribute to the apparent resistance of 
cattle to systemic effects of Stxs. Expression of Gb3 on the bovine intestinal epithelium, 
together with previously described effects, may affect STEC colonisation in its reservoir 
hosts and promote the distribution to humans (Hoey et al. 2002). Recently, the 
prevalence of STEC was studied in twelve Belgian cattle herds of which some animals 
were diagnosed as STEC-positive at slaughter. Of these 12 herds, nine were confirmed to 
be culture positive for STEC at farm level, showing a within-herd prevalence of 
approximately 18.4% (Joris 2012). In three of these herds, a longitudinal study was 
performed to analyze the persistance and dissemination of STEC. In 43.5 % of the 
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positive animals, fecal samples were intermittent positive. In 8.7% of the cases, the 
animals were shedding chronically over a period of at least six to 12 weeks. Furthermore, 
it was shown that positive animals can shed different strains at different sample points 
(Joris et al. 2013b). Other studies showed that positive animals became culture negative 
within two to three months after the first testing (Rahn et al. 1997).  
Serum antibodies against O157 lipopolysaccharide (LPS) and Stx1, and -2 
frequently occur in bovine samples and in colostrum upon experimental infection 
(Hoffman et al. 2006). However, these responses are inadequate to clear infections, as 
they persist over longer periods of time (Stevens et al. 2002c) or do not protect from re-
infections. Nevertheless, serum antibodies against EspA and EspB might be a useful tool 
for screening herds, but not individuals, for O157, O26, and O103 infections (Joris et al. 
2013b). E. coli O157:H7 prefers the terminal rectum up to the recto-anal junction (RAJ) 
as primary site for colonization in cattle. This site is characterized by a high density of 
lymphoid follicles, which could be an important gate towards modulation of the immune 
system (Naylor et al. 2003). 
The shedding of STEC tends to be higher in warmer months, with a peak 
prevalence in summer and early fall and a drastic decrease in prevalence during the 
winter months (Hancock et al. 2001). This seasonal effect might be linked to an increased 
proliferation of the bacteria during warm weather (Hancock et al. 1994), but also the 
changing day length and corresponding physiological responses within the animal might 
explain this seasonal patterns (Edrington et al. 2006).   
2.7.2 Transmission routes of EHEC to humans 
Four principal routes of transmission of EHEC to humans are described: (1) 
foodborne transmission; (2) waterborne transmission; (3) person-to-person transmission; 
and (4) direct contact with animals. 
Most EHEC outbreaks are associated with foodborne transmissions, as 
inadequately cooked or baked meat, un- or unsufficiently pasteurized dairy products or 
outbreaks linked with fermented sausages and apple juice have been reported (Torso et 
al. 2015; Buvens et al. 2011; Holck et al. 2011; Cody et al. 1999). Worldwide trends 
towards healthier lifestyle and the ever busier consumer life styles have greatly increased 
the consumption of ready-to-eat-no-need-to-wash fresh fruits and vegetables. 
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Unfortunately, fresh produce can become contaminated pre-harvest via fertilizers such as 
ruminant manure or post-harvest during processing of foods (Feng 2015). 
Also water plays an important role in spreading of EHEC since surface waters can 
become contaminated through draining from pastures or through cow manure-fertilized 
soil. This source of contamination allows EHEC to spread easily in the environment. A 
large outbreak in Canada was linked to contamination of the drinking water supply by 
rainwater run-off contaminated with cattle feces (Hrudey et al. 2003). Also EHEC 
infections due to contaminated swimming water were reported (Samadpour et al. 2002). 
Recently, several pathogenic strains were identified in water and fish from pay-to-fish 
ponds in Brazil. This clearly links proper management of these environments with the 
risk of foodborne transmissions (Ribeiro et al. 2016).        
Person-to-person transmission has been reported in institutional settings such as 
day-care centres, geriatric homes and hospitals, but also among family members 
(O’Donnell et al. 2002; Reiss et al. 2006). Since the infectious dose is low (1 to 100 cells) 
this transmission can easily occur via the fecal-oral route, when hygiene after toilet visits 
is poor (Welinder-Olsson & Kaijser 2005). 
Several EHEC outbreaks have been associated with petting zoos and farms 
resulting from direct contact with the infected animals followed by inadequate hand 
washing (Heuvelink et al. 2002; Ihekweazu et al. 2012). Also domestic pets like cats and 
dogs can be a natural reservoir (Rumi et al. 2012; Morato et al. 2009). In Germany, a 2-
year old girl with bloody diarrhea was found to excrete EHEC for three months. Stool 
samples of her cat yielded the identical EHEC strain (Busch et al. 2007).     
2.7.3 EHEC in humans 
After ingestion, EHEC passes through the acidic stomach to colonize the gut by 
adhering to the epithelial cells of the colon, inducing A/E lesions (Lewis et al. 2015). 
These lesions are characterized by destruction of the microvilli and rearanggement of the 
cytoskeleton to form pedestals, as described previously in section 2.4. After colonization 
in the colon, EHEC releases its Stxs, causing microvascular endothial injuries. 
Subsequently, it is believed that Stx1 passes the epithelial barrier through a transcellular 
route, while Stx2 uses a paracellular pathway (Hurley et al. 1999). Furthermore, Stxs 
may also enter the bloodstream by binding and damaging intestinal epithelial cells and 
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subsequently endothelial cells, causing HC. This is probably an additional way to cross 
the epithelial barrier (Tarr et al. 2005). In the circulation, the toxins bind to PMN 
leukocytes and are delivered to endothelial kidney cells (Brigotti et al. 2008). 
Subsequently, the toxins are released close to endothelial glomerular cells, mesangial and 
tubular epithelial cells of the kidney and vascular endothelium of the brain. These cells 
are characterized by a high presence of the Gb3 receptor. Injuries to the vascular 
endothelium of brain and kidney leads to increased permeability and loss of fluids and 
erythrocytes, and to thrombosis of small blood vessels (Proulx et al. 2001). The 
occludation of blood vessels damages erythrocytes, which are removed via the 
reticuloendothial system leading to hemolytic anemia. Furthermore, HUS is also 
featured by thrombocytopenia, which might be related to a direct effect of the toxins on 
platelets or might be related to a toxin-induced endothelial cell injury, exposing the 
subendothelium. This injury may release prothrombotic factors leading to platelet 
aggregation, which leads to ischemic damage (Corrigan & Boineau 2001; Proulx et al. 
2001). 
The clinical outcome of an EHEC infection can range from a symptom-free 
infection through watery diarrhea, to severe HC and HUS. Characteristically, patients 
suffer the first three days from watery diarrhea, frequently associated with abdominal 
cramps, occasionally with nausea and vomiting. In 90% of the cases the diarrhea 
becomes hemorrhagic within one to three days, starting with a normal platelet count, 
creatinine concentration and packed-cell volume with no erythrocyte fragmentation (Tarr 
et al. 2005). Spontaneous recovery after one week occurs in most of the cases. However, 
the infection can evolve into life-threatening HUS, characterized by acute renal failure, 
microangiopathic hemolytic anemia, and thrombocytopenia. Children and elderly have a 
higher risk of developing HUS (Dundas & Todd 2000). The average mortality rate 
associated with HUS is 3-17 %, but can increase for elderly people up to 87 % (Griffin & 
Tauxe 1991). Sometimes not only the kidney and gastrointestinal tract, but also other 
organs are affected in HUS. The central nervous system was affected in 25 % of the cases 
and leads to irritability, learning disabilities, lethargy and seizures. More sporadic cases 
have been linked with cerebral oedema and coma (Amirlak & Amirlak 2006; Elliott & 
Robins-Browne 2005). In 10 % of the cases, insulin-dependent diabetes mellitus and 
increase of pancreatic enzymes indicate involvement of the pancreas (Andreoli & 
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Bergstein 1982). Also a small rate (<1%) have been associated with heart failure and 
infarction, lung oedema and muscle and skin problems (Siegler 1994).   
2.8 Immune responses against EHEC 
2.8.1 Immune response and subsequent modulation of host immune system to 
promote EHEC survival 
During intestinal colonization EHEC encounters chemical barriers (e.g. mucins and 
enzymes in saliva, acidity in the stomach, bile secretion in the small intestine, and 
antimicrobial proteins throughout the intestine), mechanical barriers (mucus layer) and 
biological barriers (intestinal microflora) (House et al. 2009; Barnett Foster 2013). When 
the bacteria have bypassed these barriers, the host immune system is required for control 
and elimination of pathogens. As a first line of defence, the innate immune system will 
protect against invading pathogens by activation of pathogen recognition receptors 
(PRRs) which recognize pathogen-associated molecular patterns (PAMPs), such as LPS, 
flagellin, and peptidoglycan (Akira et al. 2006). This recognition results in production of 
proinflammatory cytokines which stimulate the innate immune response, leading to the 
development of a more specific and long-term adaptive response to a certain pathogen, 
mediated by B- and T-cells (O’Neill et al. 2013). 
 
It is unclear to which extent antibodies against E. coli O157:H7, produced by the 
adaptive immune system, are protective against infections since antibodies found in cattle 
are not capable of preventing re-infections (Joris et al. 2013a; Kieckens et al. 2015). On 
the other hand in humans, antibodies against common EHEC and EPEC antigens may 
have a protective effect as they might be the reason for the low prevalence of EHEC 
infections in areas where EPEC is endemic (Martinez et al. 1999).  
 
The primary site of infection of EHEC and EPEC is the epithelium lining the 
mucosa of the gastrointestinal tract (Robins-Browne & Hartland 2002). These epithelial 
cells play a crucial role in homeostatis of the digestive system and coordinate the 
expression and upregulation of antimicrobial cytokines with a proinflammatory and 
chemoattractant function, in response to infection. These cytokines include TNF, IL-1, 
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IL-8, macrophage inflammatory protein 1-alfa (MIP1-α) and, monocyte chemoattractant 
protein-1 (MCP-1) (Kagnoff & Eckmann 1997).  
 
Different studies have shown that bacterial flagellin and LPS are important factors 
affecting proinflammatory cytokine production upon infection (Schüller et al. 2009; 
Miyamoto et al. 2006; Griener et al. 2011).  
Acute inflammation mediates the influx of polymorphonuclear (PMN) leukocytes, 
mainly neutrophils. These cells are the first leukocytes which are recruited to the site of 
infection and can kill an invading pathogen by phagocytosis, degranulation or release of 
neutrophil extracellular traps. Chemoattractive factors, like IL-8 which can be induced by 
EHEC and EPEC, cause transmigration of neutrophils from the blood into the lamina 
propria (Hurley et al. 2001). Different infection studies in gnotobiotic piglets show that 
EHEC and EPEC induce inflammatory cell infiltration in the lamina propria and 
transmigration of inflammatory cells across the intestinal epithelium into the intestinal 
lumen (Tzipori et al. 1985; Tzipori et al. 1989). Also patients infected with EHEC show 
significantly increased numbers of leukocytes in their feces (Slutsker et al. 1997). These 
studies indicate the importance of neutrophilic migration and subsequent inflammation 
during EHEC and EPEC infections. 
 
Dahan et al. (2002) have shown in intestinal epithelial cells that the IL-8 production 
during EHEC or EPEC infection is dependent on a transcription factor in the IL-8 
promotor region, AP-1. This transcription factor is activated by MAPK, which are 
conserved host proteins playing a pivotal role in different cell responses, including 
regulation of cytokine expression, cytoskeletal reorganization, and stress responses 
(Davis 1993). IL-8 gene expression in the host is initiated by activation of the key 
transcriptional regulator of the innate immune system, NF-κB (Mukaida et al. 1990). This 
transcription factor controls gene expression during inflammation and is activated by 
various stimuli such as pathogens, stress signals and proinflammatory cytokines like TNF 
and IL-1β (Figure 1.6) (Li & Verma 2002). When a ligand is recognized by the T-cell 
receptor, signalling events will be triggered that result in the activation of the IκB kinase 
(IKK) complex, consisting of IKKβ (IKK2), IKKα (IKK1), and IKKϒ (NEMO). 
Activated IKK in turn phosphorylates the inhibitory protein of NF-κB (IκB), followed by 
subsequent ubiquitination (inactivation by attaching ubiquitin) and degradation of IκB by 
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the host proteasome (Perkins 2007). In a resting cell IκB is bound to p50/p65 dimers, 
which are released upon proteosomal degradation of IκB and transported through the 
nuclear pore complex into the nucleus, where they can influence the expression of 
multiple cytokine genes, including IL-8 (Li & Verma 2002). Upon infection, EHEC is 
capable of producing different factors that have the potential of upregulating 
inflammatory cytokine production by intestinal epithelial cells, as a result of activation of 
MAPK and NF-κB signalling.  
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Figure 1.6: Activation of the dormant NF-κB pathway triggered by stimulus-dependent signaling network. The 
canonical NF-κB pathway (left) induced by signals including antigens, TLR ligands and cytokines such as TNF 
uses a wide variety of signaling adaptors to engage and activate the IKKβ subunit of the IKK complex. IKKβ 
phosphorylation of classical IκB proteins bound to NF-κB dimers such as p50-p65 results in ubiquitination (Ub) of 
IκB and proteasome-induced degradation. This allows NF-κB to enter the nucleus where it binds specific DNA 
sequences (κB sites) involved in controlling the transcription of genes encoding functions as diverse as 
inflammation, cell survival and cell division. The noncanonical pathway (right) engaged by members of the TNF-
like family of cytokines requires NIK to activate IKKα, which then phosphorylates p100, triggering its 
proteosomal processing needed for the activation of p52-RelB dimers. Among its functions, this specific NF-κB 
heterodimer controls gene expression crucial for lymphoid organogenesis. From Gerondakis et al. (2014). 
 
EHEC produce Stxs which induce ribotoxic stress responses and apoptosis. Next to 
receptor mediated uptake of Stx, also endocytosis by macropinocytosis has been 
described (Malyukova et al. 2009).Increased permeability of the mucosal barrier might 
allow paracellular Stx transport from the lumen. Once Stx is internalised in epithelial 
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cells it induces apoptosis, (Smith, 2003) which initiates an inflammatory response and 
influx of leukocytes. The copious neutrophil migration can enhance Stx translocation 
from the lumen via enterocytes in vitro (Hurley et al. 2001).  
 
Stx alone was also shown to be capable of inducing IL-8 production, related to 
induction of MAP kinase (MAPK) pathways, JNK and stress-activated protein kinase, 
and p38, in the intestinal epithelial cells (Smith et al. 2003). Stx-induced increases in 
cytokine synthesis could be important in augmenting the host mucosal inflammatory 
response to EHEC infection (Thorpe et al. 1999). Stx could also induce the expression of 
TNF-α and IL-6 in murine peritoneal macrophages (Tesh et al. 1994). Next to affecting 
the innate response, Hoffman et al. (2006) demonstrated that Stxs are also capable of 
modulating the adaptive immune response by delaying the antigen-specific cellular 
immune response in cattle.  
 
Epithelial cell MAPK and NF-κB pathways (Firgure 1.6) leading to IL-8 secretion 
were also activated to a significant extent by isolated EHEC H7 flagellin, which was 
active when added to either the apical or basolateral surface of polarized human 
intestinal epithelial cells (Berin et al. 2002). In vitro, it was shown that the most potent 
activation of inflammation of EHEC/EPEC occurs by Toll like receptor 5 (TLR5) 
recognition of flagellin, and not Stx signalling through the Gb3 receptor (Miyamoto et al. 
2006; Berin et al. 2002). Furthermore, some EHEC strains have shown preference for 
TLR5 of the follicle-associated epithelium in the gastro-intestinal tract (Schüller et al. 
2009). Also Toll-like receptor 4 (TLR4), which binds bacterial LPS, induces the host 
response resulting in the secretion of proinflammatory cytokines. (Bridger et al. 2010).  
 
Another E. coli O157:H7 factor capable of inducing an inflammatory response in 
vitro is the type IV pilus, hemorrhagic coli pilus (HCP). Significant increases in the 
production of IL-8 and TNF, but not IL-2, IL-6, and IL-10, have been observed at the 
basolateral surface of polarized T84 and HT-29 cells, and in non-polarized HeLa cells 
during infection with HCP-expressing EHEC strains. These strains were able to induce 
p38 phosphorylation, and activate ERK1/2 and JNK within three hours after EHEC 
infection (Ledesma et al. 2010).  
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2.8.2 Host immune responses: cattle 
Unlike humans, cattle can secrete E. coli O157:H7 over longer periods of time, 
although they develop immune responses, without showing clinical signs (Hoffman et al. 
2006; Kieckens et al. 2015). The development of immune responses has been a matter of 
debate for several years, as not all studies showed commensurate results. A study of 
Johnson et al. (1996) demonstrated that oral inoculation of cattle can induce sustained 
increases in serum antibodies against O157 LPS and Stx1, but not Stx2 (Johnson et al. 
1996). These findings were contradicted by a study of Hoffman et al. (2006), who 
evidenced that cattle can develop humoral responses against Stx2 and bacterial O157 
LPS, but it was shown that only inoculation with Stx2- and not Stx2+ O157 strains 
resulted in significant cellular responses. This suggests that Stx-producing E. coli O157:H7 
can suppress the development of specific cellular immune responses (Hoffman et al. 
2006). Another study showed that Stx1 directly affects all main bovine lymphocyte 
subpopulations by blocking lymphoblast transformation and proliferation in CD8+ T-cell 
and CD21+ B-cell populations, resulting in a dramatically reduced number of viable 
Gb3/CD77+ blast cells. This effect is not cytokine-mediated (Menge et al. 2003). A study 
of Corbishley et al. (2014) observed strain-dependent differences in the kinetics of cellular 
immune responses against O157:H7. The T-helper cells isolated from the terminal rectum 
showed an increased expression of interferon-γ (IFN-γ) and T-bet, whereas the CD4+ T-
cells, NK- cells and CD8+ and γδT-cells had an increase in proliferation marker Ki67. 
Next to systemic responses, strong mucosal IgA responses in the bovine terminal rectal 
mucosa were found after experimental oral inoculation of calves. These responses were 
directed against multiple antigens including T3SS proteins, O157 LPS, H7 flagellin and 
OmpC (Nart et al. 2008). Mathematic modelling of mucosal innate immune responses 
has suggested that 5-9 days post inoculation, the innate immune response nullifies the 
bacterial replication on the rectal epithelium by either reducing the attachment or 
increasing the detachment from this epithelium (Tildesley et al. 2012).       
2.8.3 Host immune responses: humans 
The systemic antibody responses of patients towards EHEC infections have been 
well investigated, as they might be an important diagnostic marker. Karmali et al. (1983) 
were the first to suggest that sera from patients suffering from HUS mount an antibody 
response to Stx, as this serum was able to neutralise Stx. However, later on it was shown 
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that it was also the case for sera of healthy controls (Barrett et al. 1991). Caprioli et al. 
(1994) described that the neutralizing activity was not an effect of the immunoglobulin 
fraction, but was caused by other serum components. Serological enzyme-linked 
immunosorbent assay’s (ELISA’s) using the detection of antibodies specific for Stx 
showed that patients suffering from an EHEC infection, but not all, as well as control 
individuals can demonstrate a high prevalence of antibodies to Stx (Lingwood et al. 
1987; Barrett et al. 1991). 
 Also serum responses against LPS have been repeatedly reported in patients with 
HC and HUS (Bitzan et al. 1991; Flores et al. 1997; Jenkins & Chart 1999; Tanaka et al. 
2000). IgM and IgA antibodies against LPS were detected in breast milk of an E. coli 
O157-infected pregnant woman (Tanaka et al. 2000) and in saliva of children with HUS 
(Ludwig et al. 2002). A minority of the HUS patients showed serum responses against 
enterohaemolysin and H7 flagella (Jenkins & Chart 1999). The responses against LPS 
might be used for serodiagnosis, but are not protective as recurrent infections with HUS 
have been described (Siegler et al. 1993). 
Next to responses against Stx and LPS, antibodies against intimin, Tir, EspA and 
EspB have been detected in human sera (Jenkins et al. 2000; Li et al. 2000; Karpman et 
al. 2002). Li et al. (2000) determined that the responses against the previously mentioned 
antigens were strongly elevated in patients with HUS, from day 8 after hospitalization 
onwards. The response against Tir was highest, and maintained high until day 60. 
However, Karpman et al. (2002) discovered that the response against EspB has a higher 
diagnostic value, as this response was more significantly associated with an acute 
response. An important drawback of these responses as diagnostic marker is their 
presence in healthy control patients due to similarities of EHEC and EPEC antigens 
(Jenkins et al. 2000; Karpman et al. 2002).   
Two studies have tried to estimate the risk factors in HUS patients on cytokine 
level. A study in children with HUS showed that high IL-8 and low IL-10 are risk factors 
for developing HUS (Westerholt et al. 2000). In contrast, Murata et al. (1998) showed 
that increases in IL-6, IL-8, IL-10, TNF-α, and granulocyte colony-stimulating factor 
levels augmented the risk of HUS development. This differences might be due to 
differences in the host immune response between an uncomplicated E. coli O157:H7 
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infection and HUS, and is likely an inter-person variability rather than an O157-specific 
immune response (Proulx et al. 1998).  
2.9 Strategies to reduce E. coli O157:H7 colonization in ruminants 
As we have previously discussed in 2.7.2, transmission routes of E. coli O157:H7 to 
humans can be verydiverse. Most outbreaks are linked to foodborne infections and since 
ruminants are the most important reservoir for E. coli O157:H7, we will focus on 
strategies to reduce the colonization in these species that will lead to reduction of the 
prevalence and magnitude of fecal E. coli O157 excretion by live cattle (pre-harvest). Pre-
harvest intervention methods can be grouped into 3 categories: (1) exposure reduction 
strategies, (2) exclusion strategies, and (3) direct anti-pathogen strategies (LeJeune & 
Wetzel 2007). 
2.9.1 Reduction of exposure 
Exposure reduction involves environmental management targeted at reducing 
bovine exposure to E. coli O157 through biosecurity and environmental niche 
management such as feed and drinking water hygiene, reduced exposure to insects or 
wildlife, and improved cleanliness of the bedding or pen floor (LeJeune & Wetzel 2007). 
The occurrence of the pathogen tended to be higher on hides of dirty looking animals 
(Nastasijevic et al. 2008). Transfer of bacteria from one animal to another often occurs 
during transport to slaughterhouses, which leads to contamination of more animals but 
also to contamination of the transport vehicle (Arthur et al.2007b, Guerini, et al. 2007; 
Cuesta Alonso et al. 2007). Swabbing of different areas of the hide of cattle on the 
slaughterline revealed the occurrence of the pathogen: hooves (11.3%), brisket (8.4%), 
rump (7.0%), neck (4.2) and flank (2.8%). The presence of E. coli O157 on cattle hides is a 
major meat safety risk because, in modern industrial abattoirs where a spillage from guts 
onto the meat during evisceration occurs only rarely, the key source of microbial 
contamination of bovine carcass meat is the hide (Nastasijevic et al. 2008). Hide-to-meat 
microbial cross-contamination during cattle dressing can be via direct contact or via 
equipment (Tutenel et al. 2003). Good slaughtering practices like cleaning knives and 
washing hands in between carcasses may prevent contamination, but are time consuming 
and not always well established. Decontamination measures on carcasses like washing or 
the use of organic acids are implemented but not always effective (Bosilevac et al. 2006; 
Arthur et al. 2007a; Penney et al. 2007; Laury et al. 2009). One study highlighted the 
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importance of correct feed management as the feed itself can be contaminated with E. coli 
O157:H7 (Lynn et al. 1998). 
2.9.2 Exclusion strategies 
 In the category of exclusion strategies, we group dietary modifications such as 
selection of specific feed components and feeding of probiotics and vaccination in or on 
exposed animals.  
Strategies related to feed management aim at modifying the gastrointestinal flora of 
ruminants to prevent colonization by or to clear E. coli O157:H7 from the gut. They are 
typically fed high-energy grain diets to increase weight gain and efficiency of feed 
conversion. Different studies confirmed that the type of feed (grain vs. hay) influences 
prevalence and shedding in cattle. Barley grain has been positively associated with E. coli 
O157 shedding in both observational and experimental studies (Dargatz et al. 1997; 
Buchko et al. 2000; Berg et al. 2004). Specifically, Berg et al. (2004) reported that cattle 
shed a higher concentration of E. coli O157 and had higher fecal pH when fed a barley 
grain diet compared with cattle fed a corn-based diet. The specific mechanism responsible 
for increased E. coli O157 shedding in barley-fed cattle is unknown, but barley has a lower 
starch content than other traditional cereal grains (Huntington 1997), and is more rapidly 
and completely digested in the rumen (Orskov 1986; Theurer 1986) which results in less 
undigested starch for secondary fermentation in the large intestine. This results in an 
increased pH and decreased volatile fatty acids concentrations in the hindgut and might 
influence the E. coli O157 shedding (Jacob et al. 2009). Dietary changes or withholding 
feed could induce excretion of E. coli O157 in culture negative sheep (Kudva et al. 1995). 
Also diet switches from grass to alfalfa could reduce the shedding of E. coli O157:H7 in 
sheep. Kudva et al. (1997) hypothesized that a high fiber, low nutrient grass diet 
decreases volatile fatty acids and increases pH in the sheep gut and is therefore more 
favourable for E. coli O157:H7 then a low fiber, high nutrient alfalfa diet.  
Probiotics are live, non-pathogenic micro-organisms that confer a health benefit to 
the host and have been used in cattle industry for over 20 years to enhance animal health 
and production (Vande Walle 2010). More recently they have been investigated as a 
means to reduce foodborne pathogens in animals. Lactobacillus strains showed promising 
results in reducing intestinal colonization and fecal shedding of E. coli O157 in cattle 
(Ohya et al. 2000) and sheep (Lema et al. 2001). Other studies confirmed the potential of 
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probiotics in reducing EHEC shedding in weaned calves (Tkalcic et al. 2003) and 
harvest-ready feedlot cattle (Younts-Dahl et al. 2005). More recently, also combined 
probiotic products have been tested in cattle (Stanford et al. 2014). The beneficial effect of 
Lactobacillus strains might be due to the production of lactic acid (Ogawa et al. 2001), the 
increase of volatile fatty acid concentrations in feces (Ohya et al. 2000), or the reduction 
of biofilm formation (Kim et al. 2009).     
Different vaccination strategies have been tested as a means to control E. coli 
O157:H7 infection in cattle. Most experimental vaccines are based upon T3SS proteins or 
H7 antigens and show limited and variable effects. Econiche (developed by Bioniche Life 
Sciences Inc., Belleville, Ontario, Canada) received full licensing approval from the 
Canadian Food Inspection Agency in October 2008 and was the first commercially 
available E. coli O157 vaccine for use in cattle. Unfortunately, this vaccine is 
insufficiently capable of limiting the duration of infection and shedding in cattle, even 
after three vaccine doses. In 2015, Bioniche sold his animal health branch to the French 
Vetoquinol and they ceased the production of Econiche, making the product no longer 
available on the market. Another vaccine strategy is based upon the bacterial needs for 
iron as a nutrient: a siderophore receptor and porin-protein (SRP) based vaccine 
formulation disrupts the iron transport system, causing bacterial cell death and has 
shown to be effective in two cattle feedlot settings (Fox et al. 2009; Thomson et al. 2009). 
This vaccine received a conditional licence for the U.S. market (Epitopix LCC, Willmar, 
Minnesota, U.S.) in 2009, so the efficacy still has to be demonstrated with additional 
experiments.  
2.9.3 Direct anti-pathogen strategies 
Direct anti-pathogen strategies include treatment with sodium chlorate and 
bacteriophages, in addition to washing of animals before slaughter. Sodium chlorate can 
kill E. coli O157 but pure cultures gave rise to chlorate-resistance (Callaway et al. 2001). 
Another study suggested that it is unlikely that chlorate treatment will result in a 
dissemination of antibiotic resistance, but further research is needed to confirm these 
results (Callaway et al. 2004). Bacteriophages are viruses that infect bacteria, inject their 
DNA and make use of the biosynthetic machinery of the bacterial host to produce 
daughter phages, which are released via host lysis in order to repeat the process in other 
bacteria (Callaway et al. 2008). They have shown to help the removal of E. coli O157:H7 
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from hard surfaces, fruits, vegetables and ground beef up to 100 % (Abuladze et al. 2008). 
Although bacteriophages seem very effective, in vivo studies in ruminants show very 
variable results and until today no satisfactory bacteriophage therapy has been reported 
to eliminate E. coli O157:H7 in ruminants. This might be due to the very high specificity 
of a bacteriophage for a bacterial strain.      
Many of the methods mentioned in this topic are promising, but it is expected that 
interventions should be applied on different levels in the agro-food processing chain, from 
farms to slaughterhouses, in food industry and distribution and even to the consumer’s  
kitchen. Here, general food safety and hygiene measures for kitchen apply as meat should 
be always well baked or cooked. Furthermore, the use of untreated dairy products might 
be avoided, while vegetables should be well washed before eating. 
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3. Lactoferrin 
3.1 Introduction 
In 1939, lactoferrin (LF) was first described as an unknown “red fraction” in cow’s 
milk (Sorensen & Sorensen 1939). Over 20 years later, this red protein was defined as a 
transferrin-like glycoprotein in both human and bovine milk (Groves 1960; Montreuil et 
al. 1960). The foundations of research for the human variant were put in the late 1970’s , 
when the antimicrobial (Arnold et al. 1977) and immunomodulatory (Broxmeyer et al. 
1978) properties were discovered. In the early 1980’s, the structure was elucidated (Spik 
et al. 1982). The possible applications, but also the limited availability of the human 
variant moved the focus of researchers towards the bovine form. Furthermore, the 
problems with multiple antimicrobial resistant pathogens and the antibiotics-ban as 
growth-promoter in Europe, has increased the interest in the protein as well as its 
availability. Several companies brought human (hLF) and bovine lactoferrin (bLF) on the 
market as food additive. Since the bovine form is more available and cheaper than the 
human form, it is more affordable for big scale operations in animal industry as well as in 
human clinical trials even in developing countries. In this section, an overview is given 
on the current knowledge of LF, as well as the possible applications against microbial 
infections.   
3.2 Structure of LF 
LF is a 78 kDa iron binding glycoprotein that belongs to the transferrin family of 
non-haem proteins. The amino acid sequence of hLF shows 60% identity with human 
transferrin (Metz-Boutigue et al. 1984). The three-dimensional structure of LF reveals a 
single polypeptide chain consisting of an N- and a C-lobe linked by a short α-helix. Each 
lobe has the same folding and can bind one ferric atom, which is coordinated by four 
protein ligands: two tyrosines, one histidine, and one aspartate (Anderson et al. 1987). 
Binding of iron requires a cooperative interaction of both lobes, resulting in an iron-
saturated (holo-) and a non-saturated (apo-) form. The iron-saturated LF becomes more 
“closed” with more resistance against proteolysis whereas the non-saturated form is more 
“open” and flexible (Baker & Baker 2004) (Figure 1.7). LF displays an unique iron 
binding structure in the two domains of each lobe that can bind to one Fe3+ and one CO3
2- 
ion. This carbonate ion may play a role in the pH dependent release of iron under low 
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pH conditions (Baker & Baker 2005; MacGillivray et al. 1998). Improving the passage of 
LF in the gastric tract, its resistance to trypsin and trypsin-like enzymes is important. 
However, in the stomach, pepsin is capable of cutting LF into smaller peptides (e.g. 
lactoferricin), which has a stronger antibacterial effect than the native protein (Tomita et 
al. 1991). 
 
Figure 1.7: Iron binding by LF changes the conformation of LF from the open non-saturated (apo-) form to a more 
closed iron-saturated conformation (holo-) form  (Adapted from:  Berg et al. 2002). 
3.3 Natural occurrence of LF 
LF is found in exocrine secretions of the digestive, respiratory and reproductive 
system, suggesting a role in the non-specific defence against invading pathogens. An 
overview of these mucosal secretions and their corresponding LF abundance is given in 
Table 1.2. The highest concentrations are found in colostrum and milk, making it the 
second most abundant protein after caseins. Human colostrum contains the highest LF 
concentration, followed by natural human milk (Masson & Heremans 1971). The 
concentration of LF is lower in bovine colostrum and milk and depends on the lactation 
stage, but this milk is available in huge amounts (Cheng et al. 2008). The concentration 
of LF in blood is low in a healthy situation (1 µg/ml) but can rise up to 200 µg/ml in case 
of inflammation (Masson & Heremans 1971). This can be explained by the considerable 
apo-LF                                                                         holo-LF
     
     
     
     
Chapter I 
46 
 
amounts of LF found in secondary neutrophil granules. Upon microbial infection, 
neutrophils are rapidly recruited to the site of inflammation, where they play an 
important role in the innate immune response against bacterial infections (Bennett & 
Kokocinski 1978).  
Table 1.2: Occurence of LF in biological fluids (adapted from: Steijns & van Hooijdonk (2000)) 
Biological fluid Amounts reported 
Human colostral breast milk > 7 mg/ml 
Human mature breast milk > 1- 2 mg/ml 
Human tear fluid > 2.2 µg/ml 
Human seminal plasma > 0.4- 1.9 mg/ml 
Human synovial fluid > 10 -80 µg/ml 
Human saliva > 7- 10 µg/ml 
Human blood > 1- 200 µg/ml 
Cow’s colostral whey > 1.5 mg/ml 
Cow’s milk > 20- 200 µg/ml 
 
3.4 Biological functions and applications of LF 
Several biological functions have been awarded to LF and a lot of research is still 
ongoing. Until now, it is clear that LF plays a role in iron homeostasis (Frazer et al. 
2011), cellular growth and differentiation (Bi et al. 1997), host defence against microbial 
infection (Yekta et al. 2010), protection against viral infections (Wakabayashi et al. 
2014), anti-inflammatory activities (Actor et al. 2009) and cancer protection (Zhang et al. 
2014). Here, we will focus on the antibacterial effect and its mechanisms of action.  
The antibacterial effect of LF has been described in vitro and in vivo for Gram-
positive and Gram-negative bacteria, and influences different levels: it (1) affects iron-
uptake; (2) disrupts LPS in the bacterial cell membrane; (3) lyses secreted bacterial 
proteins; and (4) interacts with bacterial secretion systems.    
To maintain iron homeostasis within the cell, bacteria have evolved various types 
of iron acquisition systems. Ferric iron (Fe3+) is the dominant species in an oxygenated 
environment, while ferrous iron (Fe2+) is more abundant under anaerobic conditions or at 
low pH (Lau et al. 2015). LF is an iron-chelator, and can decrease bacterial growth by 
taking up the ferric iron from the bacterial environment, thereby limiting its use by 
bacteria at the site of infection. Since LF can bind the ferric atoms with a very high 
affinity and body secretions and neutrophil granules are mostly iron-free, it can easily 
Literature Review 
47 
 
sequester iron and maintain an environment refractory to microbial growth (Aisen & 
Leibman 1972; Levay & Viljoen 1995; Ward et al. 2005). Next to iron deprivation, LF 
can also disrupt bacterial LPS which results in an increased membrane permeability and 
bacterial death (Ellison et al. 1988). A third mechanism used by LF is blocking EPEC-
mediated actin polymerization in HEp2 cells and blocking EPEC-induced hemolysis, 
caused by LF-mediated degradation of secreted proteins necessary for bacterial contact 
and pore formation, particularly EspB (Ochoa et al. 2003). A fourth mechanism was 
described by Beeckman et al. (2007) as avian transferrin (ovotransferrin) was capable of 
inhibiting bacterial irreversible attachment and cell entry by affecting the T3SS of 
Chlamydia psittaci in chicken macrophages.     
3.5 Modulation of the immune system by LF 
LF was shown to modulate the immune system in two directions: firstly, it can 
have immunostimulating effects, when the immune response is downregulated as a result 
of infection; secondly, LF can have immune suppressive effects leading to attenuation of 
exorbitant immune responses.  
LF is an essential element of innate immunity, as it is released from neutrophils 
within hours after infection. As LF recognizes unique microbial molecules called PAMPs 
- LPS from the gram-negative cell wall and bacterial unmethylated CpG DNA- it might 
act as a competitor for these receptors or as a partner molecule, depending on the 
physiological status of the organism. These immunomodulatory properties are explained 
by the ability of LF to interact with proteoglycans and receptors on the surface of 
mammalian cells of the innate (natural killer (NK) cells, neutrophils, macrophages, 
basophils, neutrophils and mast cells) and adaptive (lymphocytes and antigen-presenting 
cells (APC’s)) immune systems. Through these interactions, LF is able to modulate the 
migration, maturation and functions of immune cells, and thus to influence both adaptive 
and innate immune responses (Legrand & Mazurier 2010). The immunomodulation of 
LF has been extensively studied in in vitro and in vivo experiments.  
LF inhibits LPS signalling by acting as a competitor with serum LPS-binding 
protein (LBP) and prevents the transfer of LPS to mCD14 bound on the surface of 
neutrophils (Elass-Rochard et al. 1998). This results in the inhibition of LPS-induced 
activation and release of proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, as 
described by Miyazawa et al. (1991); Crouch et al. (1992); Mattsby-Baltzer et al. (1996); 
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and Haversen et al. (2002). LF can also interact indirectly with soluble sCD14 inhibiting 
the secretion of IL-8 by endothelium (Elass et al. 2002) and interferes with the expression 
of adhesion molecules on the endothelium which is necessary for recruitment of immune 
cells to the site of infection (Baveye et al. 2000). The binding with soluble as well as 
membrane-bound CD14 results in an anti-inflammatory role in the immune system.   
It has been shown that LF can modulate the recruitment of immune cells under 
different circumstances. LF is able to decrease leukocyte infiltration (Yamauchi et al. 
2006), diminish recruitment of eosinophils (Kruzel et al. 2006), lessens migration of 
Langerhans cells (Griffiths et al. 2001), modulates fibroblast motility (Oh et al. 2001) and 
reduces the neutrophil migration (Dial et al. 2005). The precise mechanisms are not 
completely understood, but everything seems to result in an attenuation of the immune 
response.    
LF can modulate the phagocytic capacities of cells. However, the mechanism 
behind is still under debate. Phagocytosis by PMN’s is enhanced by the interaction of 
complement activation products, as complement factor C3. It remains unclear whether 
this LF activity is related to complement activation since LF was shown either to inhibit 
(Kijlstra & Jeurissen 1982) or to activate (Rainard 1993) the classical and alternate 
pathways of complement. More recent research shows that the lactoferricin (LFcin) 
domain inhibits only the classical complement (Samuelsen et al. 2004). But direct LF 
binding to PMN’s and opsonin-like activity could also be involved (Miyauchi et al. 
1998). 
Next to affecting the innate immune response, LF also intervenes in adaptive 
immunity. This connection between innate and adaptive is made by degranulation of LF 
from neutrophils at inflammation sites. There, LF can promote the activation, 
maturation and migration of APC’s (de la Rosa et al. 2008; Spadaro et al. 2008).  
Studies in mice have shown that orally administered LF can influence mucosal and 
systemic immune responses, as LF can modulate the maturation, differentiation and 
activation of lymphocytes and promote the antigen-presentation to these cells. It was 
demonstrated that orally administered bLF strongly elevates the number of CD3+ and 
CD4+ T-cells (Sfeir et al. 2004) and could even reconstitute a T-cell mediated immune 
response in immunosuppressed mice (Artym et al. 2003a). LF supports the proliferation 
and differentiation of Th-cells into the Th1 or the Th2 phenotype, depending on the 
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host’s immune status by affecting the Th1/Th2 cytokine balance. Fischer et al. (2006) 
have demonstrated the ability of LF to support the proliferation. Thus, LF can cause a 
Th1 polarization in diseases in which the ability to control infection relies on a strong 
Th1 response, e.g. an upregulation of Th1 in LF transgenic mice could be associated with 
clearance of Streptococcus aureus (Guillén et al. 2002). However, LF may also reduce the 
Th1 component to limit excessive inflammatory responses. Besides its effects on cellular 
immunity, LF can also support the humoral immune response. An increased 
differentiation of splenic B-cells by LF was described by Zimecki et al. (1995). 
Furthermore, LF was able to restore the humoral immune response in 
immunocompromised mice (Artym et al. 2003b). Lastly, LF’s binding to CpG-containing 
oligonucleotides was shown to inhibit their immunostimulatory effects on B-cells 
(Britigan et al. 2001).  
3.6 Effect of LF on E. coli O157:H7 
In 1998, Shin et al. were the first to report the antibacterial activity of bLF and its 
peptides, its pepsin hydrolysate bLFH and the active peptide lactoferricin B (LFcinB), 
against clinical E. coli O157:H7 isolates. They showed that LFcinB was the most potent 
of the three peptides and induced a 4-fold increase of Stx1 and a 4-fold decrease of Stx2 
in the supernatant when 5.107 CFU/ml were used. If the bacteria were diluted to 106 
CFU/ml, both Stx1 and 2 dropped below the detection limit. Therefore, it was suggested 
that high concentrations LFcinB can influence the levels of the extracellular Stxs by 
interactions with the cell surface and/ or through suppression of bacterial growth (Shin et 
al. 1998). However, the mechanisms explaining the different effect on Stx1 and Stx2 
remain unclear. The effect of LF on the bacterial cell membrane was confirmed as bLfH 
can cause a collapse of the membrane integrity by pore formation in the inner membrane, 
leading to the death of the cell (Murdock et al. 2010). 
These findings aroused interest for application of LF in food industry and LF and 
its derivates were confirmed to reduce E. coli O157:H7 in ground beef (Venkitanarayanan 
et al. 1999) and in UHT milk (Murdock & Matthews 2002). The use of ActivinTM 
(activated LF; patented process) was tested in a spray formulation to reduce E. coli 
O157:H7 from beef tissues, and was found to be as effective as the readily established 
decontamination strategies (Tittor 2003). Furthermore, the applicability of LF in food 
containing NaCl (Al-Nabulsi & Holley 2006) and in dry sausage production (Al-Nabulsi 
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& Holley 2007) was confirmed. Next to consumer-ready food applications, the effect of 
orally administered LF was also confirmed in live hosts. Yekta et al. (2010) described the 
prevention of persistent colonization of E. coli O157:H7 in experimentally infected sheep. 
The in vivo mechanism of action is not completely elucidated, but Blease et al. (2009) 
suggested the binding of LF and E. coli O157:H7 by intelectins. Intelectins are lectins 
with potential roles in innate immunity, capable of binding bacteria and also function as 
intestinal receptors for LF. Humans have two intelectins, termed intelectins -1 and -2.  
Intelectin-1 has been described under different names such as intelectin and intestinal 
lactoferrin receptor. Intelectin-2 is also known as endothelial lectin HL-2 and is expressed 
only in the small intestine. Human intelectin-1 is found in a range of tissues, including 
the small intestine, where it is expressed by Paneth cells, goblet cells and enterocytes.  
This expression pattern suggests a role for the intelectins as host defence molecules in the 
small intestine. Also in cattle two intelectins have been described, which seems to have a 
similar distribution pattern. They both showed only weak expression in jejunum, but 
were clearly expressed in abomasum and rectum, and bovine intelectin-2 was 
significantly more expressed in terminal than proximal rectum. Blease et al. (2009) did 
not find indications for a possible binding of E. coli O157:H7 to the bovine intelectins. 
Yekta et al. (2010) showed that both bLF and hLF can inhibit bacterial growth and 
attachment to Caco-2 cells, and that the inhibition of attachment was at least partly due 
to the proteolytic effect of LF on the T3SS proteins. hLF seemed to be more effective, 
probably due to a more efficient binding of bLF to intelectins (Shin et al. 2008) present on 
human enterocytes, leading to more uptake and removal of bLF compared to hLF.  
Several variables play a role in the efficiency of LF to reduce or inhibit E. coli 
O157:H7 growth. Griffiths et al. (2003) discovered that the iron saturation status of the 
used LF is an important factor to predict its efficiency, as the vast majority of saturated 
LF could not significantly reduce the E. coli O157:H7 growth. Shimazaki et al. (2000) 
reported that divalent cations protect bacteria from LF by inducing changes in its tertiary 
structure yielding a tetrameric form of LF with reduced bio-functionality and 
simultaneously generating bacterial cell membranes with increased stability. Next to iron 
saturation and the difference in amounts of cations in the media used, also the purity of 
the used lactoferrin and the susceptibility of different strains play a role in the outcome of 
the studies (Al-Nabulsi & Holley 2006).  
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Enterohemorrhagic Escherichia coli O157:H7 (EHEC) is a food-borne pathogen, 
which causes human illness ranging from self-limited watery or bloody diarrhea and 
hemorrhagic colitis to acute renal failure and haemolytic uremic syndrome (HUS).  
 
The main reservoirs for E. coli O157:H7 are ruminants, mostly cattle. Many studies 
have investigated the colonization of E. coli O157:H7 in cattle. Infection and re-infection 
appears within the same animal and the infection can persist for long time within cattle 
herds. Therefore, it is hypothesized that an E. coli O157:H7 infection suppresses the 
immune system in cattle, leading to a reduced and non-protective immune response. The 
occurrence of serum antibodies against antigenic parts of the bacteria, as well as E. coli 
O157:H7 specific B- and T-cell responses have been described. However, little is known 
about immune-related gene transcription in cattle upon infection (i) at the site of 
colonization near the terminal rectum, and (ii) at the gateway to the gut immune system, 
being the ileal Peyer’s patches. The most important colonization site of E. coli O157:H7 
in cattle is the epithelium of the recto-anal junction, located above the gut-associated 
lymphoid tissue. Recently, the PhD thesis of Maryam Atef Yekta (2011) and Joanna 
Rybarczyk (2016) showed promising results of using bovine lactoferrin (bLF), a natural 
occurring antibacterial and immunomodulating protein, against E. coli O157:H7 
colonization in sheep and cattle.  
Furthermore, the current treatment of EHEC-related diseases in human is limited to 
supportive care, as antibiotic treatment is contra-indicated because it might increase the 
frequency of HUS occurrence due to the release of bacterial Stx. Administration of bLF 
proved to be effective in clearing E. coli O157:H7 from the bovine intestine, suggesting 
that bLF might also be beneficial for future application in EHEC infected humans.  
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These aspects were addressed and the objectives of this PhD thesis were:   
1) Investigating the occurrence of E. coli O157:H7 infection induced immuno-
suppression in cattle (Chapter III). 
2) Evaluating the use of bLF as antibacterial agent against EHEC infection in cattle 
(Chapter IV). 
3) Determining the release of the pro-inflammatory cytokines IL-6 and TNF-α and 
the chemokine CXCL8 by rectal epithelial cells and tissue explants upon E. coli 
O157:H7 infection in presence or absence of bLF (Chapter V). 
4) Exploring the feasibility of using bLF in EHEC infected humans by analyzing the 
release and biological activity of Shiga toxins upon treatment of different E. coli 
O157:H7 strains with bLF (Chapter VI).  
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Potential immunosuppressive effects of Escherichia coli 
O157:H7 experimental infection on the bovine host 
  
 
 
 
 
 
Kieckens E., Rybarczyk J., Li R.W., Vanrompay D., Cox E.(2016). Potential immunosuppressive effects of 
Escherichia coli O157:H7 experimental infection on the bovine host. (Manuscript submitted) 
  
 
 
Immune suppression of the bovine host 
57 
 
3.1 Abstract  
 
Background: Enterohemorrhagic Escherichia coli (EHEC), like E. coli O157:H7 are 
frequently detected in bovine fecal samples at slaughter. Cattle do not show clinical 
symptoms upon infection, but for humans the consequences can be severe after 
consuming contaminated beef. The immune response against EHEC in cattle cannot 
always clear the infection as persistent colonization and shedding in infected animals 
over a period of months often occurs. In previous infection trials using the E. coli 
O157:H7 (Stx-; NCTC12900) strain, we observed a primary immune response after 
infection which was unable to protect cattle from re-infection. Furthermore, the duration 
of the primary infection was mostly shorter (<14 days, n=32) compared to the duration 
of the secondary infection (>28 days, n=21). These results may reflect a suppression of 
certain immune pathways, making cattle more prone to persistent colonization after re-
infection. To test this, RNA-Sequencing (RNA-Seq) was used for transcriptome analysis 
of recto-anal junction tissue and ileal Peyer’s patches in nine Holstein-Friesian calves in 
response to a primary and secondary Escherichia coli O157:H7 (Stx-) infection. Non-
infected calves served as controls.  
 
Results: In tissues of the recto-anal junction, only 15 genes were found to be 
significantly affected by a first infection compared to 1159 genes in the ileal Peyer’s 
patches. Re-infection significantly changed the expression of 10 and 17 genes in the recto-
anal junction tissue and the Peyer’s patches, respectively. After a primary as well as after 
re-infection, a significant downregulation of 69 immunostimulatory genes and a 
significant upregulation of seven immune suppressing genes were observed. 
 
Conclusions: Although the recto-anal junction is a major site of colonization by E. 
coli O157:H7 (Stx-), this area does not seem to be modulated upon infection to the same 
extent as ileal Peyer’s patches as the changes in gene expression were remarkably higher 
in the ileal Peyer’s patches than in the recto-anal junction during a primary but not a 
secondary infection. We can conclude that the main effect on the transcriptome was 
immunosuppression by E. coli O157:H7 (Stx-) due to an upregulation of 7 out of 12 genes 
with immune suppressive effects or a downregulation of 69 out of 94 genes with 
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immunostimulatory effects . These data might indicate that a primary infection promotes 
a re-infection with EHEC by suppressing the immune function. 
 
3.2 Introduction 
 
Enterohemorrhagic Escherichia coli (EHEC), such as E. coli O157:H7, are frequently 
detected in fecal cattle samples at slaughter (6.3% in Belgium, n = 1281) (Tutenel et al. 
2002). Cattle are the main natural reservoir, do not show clinical signs upon infection 
and can remain asymptomatic carriers for very long periods. If humans become infected 
by consuming contaminated food, mainly inadequately cooked beef products, the 
consequences can be severe (Caprioli et al. 2005). After ingestion and subsequent 
colonization of the human colon, EHEC releases verotoxins causing microvascular 
endothelial injuries, which might lead to bloody or non-bloody diarrhea, hemorrhagic 
colitis and the haemolytic uremic syndrome (Vilte et al. 2011; Stevens et al. 2002c).   
Recently, the prevalence of EHEC was determined in Belgian cattle herds of which 
some animals were diagnosed as EHEC-positive at slaughter,  showing a within-herd 
prevalence of approximately 18.4% (Joris 2012). Longitudinal follow-up of herds 
demonstrated that  fecal samples of some animals were intermittently positive, while 
other animals seemed to have a chronic excretion over a period of at least six to 12 
weeks. Furthermore, the shedding patterns showed that positive animals can shed 
different strains at different sample points (Joris et al. 2013b). Other studies showed that 
positive animals became culture negative within two to three months after the first testing 
(Rahn et al. 1997). The immune response of the animals against the EHEC strains, which 
has been investigated in few studies, might explain these excretion patterns. One study 
demonstrated that antibodies against the O157 lipopolysaccharide (LPS) and Shiga toxin-
1 and -2 (Stx1, Stx2) frequently occur in bovine sera and colostrum upon experimental 
infection (Hoffman et al. 2006), but this response could not clear the infection, as infected 
animals secreted bacteria over a period of months (Stevens et al. 2002c). Another study 
on two farms demonstrated that fecal excretion was not always correlated with E. coli 
secreted protein A (EspA), intimin and, translocated intimin receptor (Tir) specific serum 
antibody responses. In contrast, 87.5 % of the animals showed a serum antibody response 
against Escherichia coli secreted protein B (EspB) at the same time as their fecal samples 
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were positive for EHEC O157, O26 or, O111, or 6 weeks after a positive fecal sample. 
These antibodies persisted, even when shedding had ceased, until the animals were 
slaughtered, which was 2 to 8 months later, whereas EspA-specific antibodies 
disappeared within two months. These results indicate that farm animals, which develop 
an immune response after infection, can become re-infected by different EHEC strains as 
evidenced by intermittent excretion. In accordance, in our lab we observed in several 
infection experiments that a primary infection could elicit an antibody response, but this 
primary immune response was unable to protect against an experimental re-infection 
with the same strain (unpublished results). On the contrary, whereas the primary infection 
led to fecal shedding during less than two weeks (< 14 days, n=32), a re-infection resulted 
in excretion for more than four weeks (>28 days, n=21) (Table 3.1).  
 
Table 3.1: Duration of infection after primary or re-infection with E. coli O157:H7 (Stx-) NCTC12900 
strain (unpublished results).  
Duration of infection Primary infection (n=32) Re-infection (n=26) 
0-7 days 9 0 
7-14 days 23 5 
14-21 days 0 4 
21-28 days 0 3 
> 28 days 0 14 
 
These results may reflect suppression of certain pathways of the immune system by 
the primary infection, making cattle more prone to persistent colonization by a 
subsequent infection. In 2003, Naylor et al. (2003) described the preference of E. coli 
O157:H7 for the terminal rectum up to the recto-anal junction (RAJ) as primary site for 
colonization. This site is characterized by a high density of lymphoid follicles. This 
predilection for epithelium above mucosa-associated tissue could be important for 
modulating the immune system. Indeed, E. coli O157 is capable of suppressing cell-
mediated immune responses in cattle by targeting lymphocytes via their Shiga toxins 
(Menge et al. 2003; Hoffman et al. 2006), but enterocytes do not have receptors for these 
toxins, suggesting that close contact with the immune system might be necessary. 
Furthermore, other bacterial factors might modulate the immune system . The H7 
flagellin, bacterial LPS and type IV pilus have been shown to induce proinflammatory 
responses upon EHEC infection. On the contrary, it has been observed that EHEC as 
well as EPEC strains could suppress NF-κB and MAPK activation as well as IκB 
degradation (Hauf & Chakraborty 2003) and could inhibit the production of 
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proinflammatory cytokines IL-8 andIL-6, early in the infection by different LEE- and 
non-LEE encoded effectors (Tir, NleB, NleC, NleD, NleE, NleH1, and NleH2) (Stevens 
& Frankel 2015).  Clearance of E. coli O157:H7 is associated with an upregulation of Th-
1 associated transcripts within the rectal mucosa, the principle site of colonization 
(Naylor et al. 2003; Corbishley et al. 2014), suggesting that a cellular component of the 
adaptive immune response may be important in E. coli O157:H7 control.  
In this study we wanted to obtain insights in genes involved in an 
immunosuppressive effect of an E. coli O157:H7 Stx negative strain. In our experimental 
infections prolonged excretion was observed after a second infection with this strain. 
Transcriptome analysis of the ileal Peyer’s patches and the RAJ from calves was 
performed using RNA-seq technology. Samples were obtained from animals that were 
infected either once or twice or were  never in contact with E. coli O157:H7.  
3.3 Materials and methods 
3.3.1 Bacterial strain 
 
           The E. coli O157:H7 strain NCTC 12900, a well-characterized Shiga-toxin negative 
EHEC strain of human origin (Dibb-Fuller et al. 2001) was used for experimental 
infections in calves. We used this verotoxin negative strain for biosafety reasons. Bacteria 
were grown overnight in Luria Bertani broth (LB, Becton Dickinson, Erembodegem, 
Belgium) with aeration (200 rpm) at 37oC, harvested by centrifugation (11 337 x g, 5 
min), re-suspended in sterile phosphate-buffered saline (PBS, pH 7.4) to a concentration 
of 1010 CFU/10 ml and subsequently used for experimental infections. 
 
3.3.2 Experimental infection of calves and sample collection 
 
Nine 5-week-old Holstein-Friesian calves were randomly assigned to three groups 
(primary infection, re-infection, and uninfected control; n =3), each reared in separate 
boxes in isolation units with free access to hay and water (Figure 3.1). These animals 
were screened to be seronegative for intimin, EspA and EspB, as well negative for fecal 
shedding of E. coli O157:H7. Starting from 8 days of age onwards, the milk diet of the 
calves was increased and then slowly decreased and completed by a grain-based pellets 
diet, until the end of the experiment without completely removing milk from the diet.  
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Figure 3.1: Experimental setup. 
Six animals were inoculated at the age of six weeks with 1010 CFU during two 
consecutive days as previously described by Kieckens et al. (2015). Two weeks after 
infection, three animals were euthanized (Infection Group, IG). The remaining three 
infected animals were re-infected and euthanized two weeks later at ten weeks of age (Re-
infection Group, RG). At that time, the three uninfected control animals (Control Group, 
C) of the same breed and age, were also euthanized. Euthanasia was carried out by 
captive bolt and samples from the ileal Peyers’ patches and the RAJ were collected for 
RNA isolation to analyze the transcriptome profiles by RNA-Seq. Hereto, tissue samples 
of 1 cm² were cut and rinsed in sterile cold PBS (4°C) and immediately frozen in liquid 
nitrogen and stored at -80°C until RNA purification. All experimental and animal 
management procedures were undertaken in accordance to the requirements of the 
animal care and ethics committee of the Faculty of Veterinary Medicine, Ghent 
University, Belgium  (EC2011/082). 
3.3.3 Excretion of E. coli O157:H7 
 
Fecal samples were analyzed immediately after sampling, as described by Vande 
Walle et al. (2011). Briefly, ten gram of faeces was homogenized in 90 ml sterile modified 
tryptone soy broth (Oxoid Ltd., Basingstoke, United Kingdom) supplemented with 20 
mg/liter novobiocin (Sigma Aldrich, St. Louis, MO, USA). Enumeration of E. coli O157 
was performed by plating 10-fold serial dilutions onto MacConkey agar supplemented 
with sorbitol, cefixime, tellurite, and nalidixic acid (NalCT-SMAC) (Merck, Darmstadt, 
Germany) and incubating the plates at 37°C for 18 h. The remaining broth was enriched 
for 6 h at 42°C and subjected to immunomagnetic separation (IMS) using Dynabeads 
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O157 (Invitrogen, Merelbeke, Belgium), according to the manufacturer’s instructions. 
Finally, 100 µl was plated onto NalCT-SMAC agar and incubated for 18 h at 37°C. 
Selected sorbitol-negative colonies were confirmed by the O157-specific latex 
agglutination assay (Oxoid Ltd., Basingstoke, United Kingdom). 
3.3.4 RNA extraction and sequencing using RNA-seq 
 
Total RNA was extracted from the tissues using the Qiagen RNeasy mini kit 
(Qiagen, Hilden, Germany) as described by the manufacturer. Briefly, the samples were 
grind to a fine powder under liquid nitrogen using a mortar and pestle and homogenized. 
Then, the lysate was further processed as instructed by Qiagen. The RNA purity was 
verified using NanoDrop Technology (Thermo Fisher Scientific, Massachusetts, USA) 
and the RNA concentration was measured. High-quality RNA (260/280 nm ratio ~ 2.0; 
RNA Rin# > 8.0) was processed using an Illumina TruSeq RNA sample prep kit 
following manufacturer’s instruction (Illumina, San Diego, CA, USA). Individual RNA-
Seq libraries were pooled based on their respective sample-specific 6-bp adaptors and 
sequenced at 50 bp/sequence read using an Illumina HiSeq2000 sequencer.  
3.3.5 Data analysis and bioinformatics 
 
The mean number of raw reads generated per sample in the study was 
18,910,480.56 + 5,610,677.59 (mean + SD; n =18). SolexaQA was used for trimming 
and filtering using default parameters. The resultant reads with < 40 bp in length were 
discarded. After performing trimming and filtering, the final number of reads for the 
genome alignment was 16,042,336.72 + 5,046,779.84 (mean + SD).  
The resultant quality reads were aligned to the bovine reference genome (UMD 3.1) 
using TopHat2 (v2.0.6) (Trapnell et al. 2009) using the following parameters: mismatches 
allowed: 2 bp; and max insertions: 3 bp and max deletions: 3 bp (using bowtie2 v2.0.2 
with INDEL allowed). The SAM output files from the TopHat alignment, along with the 
GTF file from ENSEMBL bovine genebuild v67.0, were used in the Cuffdiff program in 
the Cufflink package (v2.0.2) to test for differential gene expression. Mapped reads were 
normalized based on the upper-quartile normalization method. Cuffdiff models the 
variance in fragment counts across replicates using the negative binomial distribution 
(Anders & Huber 2010).  
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Results were considered significant for p <0.05. Differentially expressed genes 
identified in the transcriptome were further analyzed using GeneOntology (GO) analysis 
(https://github.com/tanghaibao/goatools). A Fisher‘s exact test was used for 
enrichment of certain GO terms. A multiple correction control (permutation to control 
false discovery rate, FDR) was implemented to set up the threshold to obtain the list of 
significantly over-represented GO-terms as previously described (Li & Schroeder 2012). 
Ingenuity Pathway Analysis (IPA pathways) and Path designer was used to 
visualize connections between differentially expressed genes.  
The fold change was reported in the result section for every gene in brackets.  
3.4 Results 
3.4.1 Excretion of  E. coli O157:H7(Stx-) 
Average excretion patterns of the infected animals per group are shown in Figure 
3.2. All animals were negative before infection and the highest peak of bacteria in faeces 
was detected at day 4 post infection. Within 14 days after the primary infection, all 
animals of the primary infection group became negative. The second infection gave rise 
to a lower level of bacterial shedding and the animals were still positive at the timepoint 
of euthanasia.  
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Figure 3.2: Average faecal excretion of infected animals. Error bars indicate standard deviations. Arrows on the x-axis 
indicate the timepoint of first and second infection.  
 
3.4.2 Transcriptome analysis of gut tissues 
 
A total of 21,046 genes were detected at least once in one of the nine RAJ samples 
or in one of the nine ileal Peyer’s patches samples. The number of genes expressed per 
sample was 18,753.22 + 276.94 (Mean + SD). The number of genes with mean hits > 5.0 
was 16,788 whereas the core transcriptome of the RAJ and the ileal Peyer’s patches 
consisted of 16,948 and 17,197 genes, respectively. This core transcriptome incorporates 
genes represented by at least one sequence hit in each of the samples tested. 
 We used the transcript abundance classification as described by Li et al. (2012). 
Assuming 300,000 mRNA molecules per cell, approximately 70.68% of genes transcribed 
in the RAJ and 70.55% of genes transcribed in the ileal Peyer’s patches can be classified 
into “very rare” with a relative abundance of ≤15 molecules per cell (Table 3.2), followed 
by “rare” (16-99 molecules per cell) at 16.18% and 17.29%, respectively. “Not expressed” 
genes (0 molecules per cell) were calculated as 11.17% and 10.18%, whereas “moderately 
abundant” genes (100-500 molecules per cell) accounted for 1.74% and 1.78%. 
“Abundant” genes accounted for only 0.23% and 0.21% part of the transcriptome.      
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Table 3.2: Transcript abundance in the recto-anal junction and Ileal Peyer’s patches. 
Transcript category Recto-anal junction Ileal Peyer’s patches 
Not expressed 
Very rare 
Rare 
Moderately abundant 
Abundant 
11.17% 
70.68% 
16.18% 
1.74% 
0.23% 
10.18% 
70.55% 
17.29% 
1.78% 
0.21% 
 
3.4.3 Genes significantly influenced by E. coli O157:H7 experimental infections 
 
In the RAJ, the primary site of E. coli O157:H7 colonization in cattle, fifteen genes 
were found to be significantly affected by a primary infection with E. coli O157:H7 (Stx-) 
whereas ten genes were affected after re-infection compared to the uninfected control 
group (false discovery rate, FDR < 0.1). Only one gene (FABP2) appeared to be 
significantly impacted by both primary infection and re-infection with E. coli O157:H7 
(Stx-) (Figure 3.3). Three out of fifteen genes that were significantly affected during the 
primary infection could be linked to an immune function (KLRJ1, MARCO, CCL20); one 
was upregulated and two downregulated (Table 3.3). In the ileal Peyer’s patches 1159 
genes were significantly influenced by a primary infection compared to the control group 
and only seventeen genes were significantly affected by the re-infection compared to the 
same control, indicating a larger effect on the transcriptome during primary infection 
compared to a re-infection. Seven genes were significantly different regulated after a 
primary as well as after a re-infection (Figure 3.4). The function of 103 out of 1159 genes 
that were differently regulated during the primary infection could be traced back to the 
immune system.  
 
Table 3.3: Overview of numbers of up- and downregulated genes in respect to their effect on the 
immune system. 
                                            Immune stimulating effect Immune suppressive effect 
  # upregulated # downregulated  # upregulated # downregulated 
Recto-anal 
junction 
 / 2  1 / 
Ileum + PP  25 67  6 5 
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Figure 3.3: Venn diagram of differentially expressed genes in the recto-anal junction. Upregulated genes 
are indicated in green, while downregulated genes are indicated in red.  
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Figure 3.4: Venn diagram of differentially expressed genes in ileal Peyer’s patches. Upregulated genes 
are indicated in green, while downregulated genes are indicated in red. 
 
3.4.4 Gene ontology (GO) analysis 
 
A total of 15 genes were significantly affected by a primary infection with E. coli 
O157:H7 (Stx-) in the RAJ at a cutoff FDR <10%. Enrichment with Bonferroni corrected 
P value = 0.0115 reveals three genes possessing scavenger receptor activity (GO:0005044) 
and three genes having cargo receptor activity (GO:0038024). In the Peyer’s patches 
ileum, 1159 genes were significantly affected by a primary E. coli O157:H7 (Stx-)infection. 
After enrichment, we could identify 997 genes linked to a molecular function 
(GO:0003674), 882 genes to biological processes (GO:0008150), 673 genes were linked to 
a cellular process (GO:0009987) and 561 genes to a single-organism process 
(GO:0044699). Also GO-terms for metabolic process (GO:0008152), single-organism 
cellular process (GO:0044763), catalytic activity (GO:0003824), response to stimulus 
(GO:0050896), cellular response to stimulus (GO:0051716), nitrogen compound 
metabolic process (GO:0006807), single-organism metabolic process (GO:0044710), 
hydrolase activity (GO:0016787), small molecule metabolic process (GO:0044281), and 
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response to stress (GO:0006950 ) were found for 492, 488, 405, 329, 247, 230, 223, 204, 
145 and 123 genes, respectively, out of 1159 genes that were significantly impacted. GO-
terms for <100 genes were not reported in this manuscript.   
3.4.5 Regulatory gene networks 
 
The IPA software was used to further examine the RNA-Seq dataset. Uploading 
the dataset for the RAJ after a primary infection, the database could assign two 
relationships between the significantly regulated genes, whereas for the re-infection four 
relationships could be detected in both cases linked to antimicrobial responses. When the 
data for ileal Peyer’s patches was uploaded, IPA could identify three different networks 
that might play a role in E. coli O157:H7 (Stx-) infection, related to antimicrobial response 
(28 relationships) (Figure 3.5), inflammatory response (69 relationships) (Figure 3.6) and 
infectious disease (166 relationships) (Figure 3.7).   
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Figure 3.5: Regulatory network related to antimicrobial response impacted in the ileal Peyer’s patches 
of calves after a primary infection with E. coli O157:H7 (Stx-). Up- and downregulation is represented 
by green and red colours, respectively. 
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Figure 3.6: Regulatory network related to inflammatory response impacted in the ileal Peyer’s patches 
of calves after a primary infection with E. coli O157:H7 (Stx-). Up- and downregulation is represented 
by green and red colours, respectively. 
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Figure 3.7: Regulatory network related to infectious disease impacted in the ileal Peyer’s patches of 
calves after a primary infection with E. coli O157:H7 (Stx-). Up- and downregulation is represented by 
green and red colours, respectively. 
 
3.4.6 Possible effect of E. coli O157:H7 experimental infection on the function of immune 
cells 
  
In order to gain insight in the impact of the differential mRNA expression, the data 
were arranged according to their effect on different immune cells in the specific tissues: 
lymphocytes (3.4.5.1), natural killer cells (3.4.5.2), monocytes and macrophages 
(3.4.5.3), dendritic cells (3.4.5.4), granulocytes (3.4.5.5). Only genes with the highest fold 
changes per cell type are reported, whereas the tables give an overview of the fold 
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changes (log2) >2 in both RAJ and ileal Peyer’s patches. The gene expression results for 
RAJ and ileal Peyer’s patches after primary infection are represented in Table 3.4 and 
3.5, respectively.  
Table 3.4: Gene expression results for recto-anal junction samples with Fold change (log2) >2. 
Gene name* Gene function Fold change (log2) Reference 
KLRJ1 
+(Ly49) 
Natural killer cell receptor binding host 
MHC I as a mechanism of self/health 
recognition. Binding of the ligand results in 
an inhibitory signal to prevent killing of the 
target cell. 
--3.90 Storset et al. (2003) 
MARCO- Innate immune defense. Can bind Gram-
negative bacteria to stimulate clearing of the 
pathogen.  
4.88 (Elomaa et al. 
1998) 
CCL20- Strongly chemotactic for lymphocytes and 
weakly for neutrophils. 
3.73 (Mohammed et al. 
2007) 
(*: + = upregulated; - = downregulated). 
 
Table 3.5: Gene expression results for Ileal Peyer’s patches samples with Fold change (log2) >2. 
Gene Name* Gene function Fold change (log2) Reference 
ENPP7+ Might have an inflammatory effect, as it 
could degrade and inactivate platelet-
activating factor (PAF). 
-9.93 (Wu et al. 2006)  
PDIA2+ Helps to load antigenic peptides into 
MHC I molecules and is therefore 
important in antigen recognition and 
clearing. 
-4.41 (LeBrasseur 2006)  
BT.36112+ (KIR) Killer cell immunoglobulin 
receptor suppresses the cytotoxic activity 
of NK cells.  
--2.93 (Vilches & Parham 
2002) 
MGC137099+ Is preferentially expressed on Th2 cells 
and is  together with SEMA4A a 
stimulatory molecule for T-cell 
activation. 
-2.54 (European 
Bioinformatics 
Institute 2015)  
PRLR+ Cytokine receptor and important in the 
JAK-STAT, JAK-RUSH, Ras-Raf-
MAPK and PI-3K pathways. 
-2.47 (Bouchard et al. 
1999), (Lee et al. 
1999), (Amaral et 
al. 2004) 
LY6G6E+ Possible role of Ly-6 family members in 
T-cell activation, differentiation, and 
maturation (mouse studies) 
-2.42 (Mallya et al. 2006)  
BTRAPPIN-5+ Multifunctional host-defense peptide 
with anti-proteolytic, anti-inflammatory 
and anti-microbial activities. 
-2.25 (Kato et al. 2010)  
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Gene Name* Gene function Fold change (log2) Reference 
SUSD2+ Contributes to evasion of immune 
responses by induction of apoptosis in 
activated T-cells 
-2.25 (Watson et al. 
2011)  
KLRJ1+ (see Table 3 on RAJ) -2.05 (Storset et al. 2003) 
FCRLA- Leading to inflammatory responses and 
antibody-mediated cellular cytotoxicity. 
7.21 (Inozume et al. 
2007)  
CXCL13- Chemokine B-lymphocyte 
chemoattractant. 
6.64 (Legler et al. 1998) 
DEFB5- Bovine neutrophil β-defensins exert 
broad spectrum of antimicrobial activities 
against several species that cause mastitis 
as S. aureus, E. coli, K. pneumoniae, and P. 
aeruginosa 
6.45 (Alnakip et al. 
2014)  
BT.53744- Development and differentiation of B-
cells into plasma cells. 
6.01 (International 
Molecular 
Exchange 
Consortium 2015) 
TNFRSF13C- Mature B-cell survival. 5.99 (Thompson et al. 
2001)  
CD79B- Initiation of the signal transduction 
cascade activated by the B-cell antigen 
receptor complex which will lead to 
antigen presentation. 
5.81 (Luisiri et al. 1996), 
(Tseng et al. 1997), 
(Pelanda et al. 
2002) 
SRCRB4D- Regulation of innate and adaptive 
immune responses. 
5.45 (Online Mendelian 
Inheritance in Man 
2004) 
CD180- Controls B-cell recognition and signaling 
of LPS. 
4.60 (NCBI Reference 
Sequence Database 
2008) 
FCRL1- Functions in B-cell activation and 
differentiation. 
4.43 (Gauld et al. 2002),  
(Harwood & 
Batista 2010) 
CLEC4E- Induces secretion of inflammatory 
cytokines after binding of ligands (such as 
damaged cells, funghi and 
microbacteria).  
4.40 (Miyake et al. 
2010)  
CXCR5- Chemokine plays an essential role in B-
cell migration. 
4.00 (Sáez de Guinoa et 
al. 2011) 
CD19- Acts as a B-cell coreceptor in conjunction 
with CD21 and CD81. 
3.84 (van Zelm et al. 
2006) 
P2RY8- Regulator of the immune response. 3.81 (Amisten et al. 
2007)  
LTA- Mediates a large variety of inflammatory, 
immunostimulatory and antiviral 
responses. 
3.712 (NCBI Reference 
Sequence Database 
2012) 
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Gene Name* Gene function Fold change (log2) Reference 
CXCR4- Receptor for SDF-1, has potent 
chemotactic activity for lymphocytes. 
3.67 (Tamamis & 
Floudas 2014) 
TLR10- Role in pathogen recognition and 
activation of innate immunity. 
3.64 (Lee et al. 2014)  
SPP1- Chemotactic for many cell types 
including macrophages, dendritic cells, 
and T cells; it enhances B lymphocyte 
immunoglobulin production and 
proliferation. In inflammatory situations 
it stimulates both pro- and anti-
inflammatory processes. 
3.50 (Wang & Denhardt 
2008)  
BANK1- Is expressed during development of B-
lineage cells. 
3.34 (Dymecki et al. 
1992) 
FCRL3- Regulator of the immune system. 3.32 (Swainson et al. 
2010) 
LTB- LTs are important for innate and 
adaptive immune responses by 
controlling the expression of several 
adhesion molecules, other cytokines and 
chemokines 
3.03 (Creus et al. 2012) 
DOK3- Negative regulator of JNK signaling in B-
cells. 
3.03 (Robson et al. 
2004) 
KLRF1- Activating lectin-like receptor expressed 
on NK-cells and stimulates their 
cytotoxicity and cytokine release. 
3.00 (Kuttruff et al. 
2009) 
FCER2- Transportation in antibody feedback 
regulation 
2.85 (Kijimoto-Ochiai 
2002) 
FCAMR- is expressed constitutively on the 
majority of B-lymphocytes and 
macrophages; FCAMR functions as a 
receptor for the Fc fragment of IgA and 
IgM and binds IgA and IgM with high 
affinity and mediates their endocytosis 
2.82 (Shibuya et al. 
2000), (McDonald 
et al. 2002) 
CCL19- Antimicrobial gene; may play a role in 
normal lymphocyte recirculation and 
homing. It also plays an important role in 
trafficking of T cells in thymus, and in T 
cell and B cell migration to secondary 
lymphoid organs 
2.54 (National Center 
for Biotechnology 
Information Gene 
2014)  
TNFSF8- Involved in cell differentiation, apoptosis 
and immune response 
2.43 (Wu et al. 2011)  
SOCS1- Negative regulator of cytokine signaling. 2.334 (Krebs & Hilton 
2001) 
TIMD4- Enhances the engulfment of apoptotic 
cells: involved in regulating T-cell 
proliferation and lymphotoxin signaling.  
2.30 (UniProt 2015) 
SIT1- Negatively regulates T-cell receptor 
mediated signaling in T-cells. 
2.28 (Marie-Cardine et 
al. 1999)  
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Gene Name* Gene function Fold change (log2) Reference 
BDKRB1- Receptor binding leads to increase in the 
cytosolic calcium ion concentration, 
resulting in chronic and acute 
inflammatory responses. 
2.26 (Talbot et al. 2012), 
(Enquist et al. 
2014) 
AKAP5- Is expressed in T-lymphocytes and may 
function to inhibit IL-2; IL-2 is part of the 
body’s natural responses to microbial 
infections. 
2.21 (Schillace et al. 
2002) 
PGLYRP2- Recognizes peptidoglycan, a component 
of bacterial cell walls.  
2.20 (Dziarski & Gupta 
2010) 
CD37- T-cell and B-cell interactions. 2.13 (Knobeloch et al. 
2000)  
(*: + = upregulated; - = downregulated). 
 
3.4.6.1 Lymphocytes 
 
In the RAJ, a significant downregulation of Chemokine C-C motif ligand 20 (CCL20)  
(fold change (log2) = 3,74) was observed, which is strongly chemotactic for immature 
dendritic cells, and B- and T-lymphocytes (Mohammed et al. 2007).  
Furthermore, in the ileal Peyer’s patches, Sushi domain containing 2 (SUSD2) was 
significantly upregulated (fold change (log2) = -2,25). SUSD2 can interact with Galectin-1 
which is known to contribute to the evasion of immune responses of tumors and 
infectious organisms by inducing apoptosis of activated T cells (Watson et al. 2011). The 
activation of T-lymphocytes might be inhibited by the significant downregulation of the 
expression of T cell immunoglobulin and mucin domain 4 (TIMD4) (fold change (log2) 
=2.30), responsible for regulation of Th1 responses (Meyers et al. 2005). C-X-C motif 
ligand 13 chemokine (CXCL13), strongly expressed in the follicles of the spleen, lymph 
nodes, and Peyer's patches promoting the migration of B-lymphocytes in the lymph 
nodes (Sáez de Guinoa et al. 2011) was significantly downregulated in the ileum (fold 
change (log2) =6.64). Interleukin 17 receptor E-like (IL17REL), a member of the Interleukin 17 
(IL17) cytokine receptor family that functions as a receptor for the proinflammatory 
cytokine responding to invading extracellular pathogens (Wu et al. 2011) was found to be 
significantly downregulated (fold change (log2) =1.18) upon E. coli O157:H7 infection. A 
significant downregulation of prothymosin alpha (PTMA), a tumor necrosis factor receptor 
(RELT), Interleukin-21 receptor (IL21R), a guanine nucleotide exchange factor (VAV1) with 
log2(fold change) = 1.29, 1.39, 1.48, 1.52 respectively, and many more immune response 
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stimulating genes linked with lymphocyte responses were seen in the ileal Peyer’s 
patches. 
3.4.6.2 Natural Killer cells 
 
Effector functions of NK cells are controlled by a balance of inhibitory and 
stimulatory signals. In the RAJ, a strong significant upregulation of killer cell lectin-like 
receptor (KLRJ1) was observed (fold change(log2) = -3.90). KLRJ1 is probably important 
for the NK cell recognition of target cells, which are certain tumor cells, virally infected 
cells and host MHC class I cells as a mechanism of self/health recognition. An 
upregulation of KLRJ1 would imply an upregulation of the inhibitory signal, causing 
more survival of the target cells (Storset et al. 2003). In the ileal Peyer’s patches, a 
significant upregulation of protein disulfide isomerase (PDIA2) (fold change (log2) =  -4.41), 
killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail 1 (KIR2DS1) (fold 
change (log2) = -1.89), killer cell immunoglobulin-like receptor, two domains, long cytoplasmic 
tail 5A (KIR2DL5A) (fold change (log2) = -1.48) and killer cell lectin-like receptor subfamily C, 
member 1-like (KLRC1) (fold change (log2) =  -1.36) was observed. In contrast, a significant 
downregulation of IL21R (log2(fold change) = 1.44) important for the proliferation and 
differentiation of B-, T- and NK-cells, leukocyte-associated immunoglobulin-like receptor 1 
(LAIR1) (fold change (log2) = 0.52) an inhibitory receptor found on NK cells, T cells, and 
B cells regulating the immune response to prevent lysis of cells recognized as self (Poggi 
& Zocchi 2014), hematopoietic cell signal transducer (HCST) (fold change (log2) = 1.35) 
playing a role in cell survival and proliferation by activation of NK and T cell responses 
(André et al. 2004; Karimi et al. 2005) and killer cell lectin-like receptor subfamily F, member 1 
(KLRF1) (fold change (log2) = 3.43) stimulating the cytotoxicity and cytokine release of 
NK cells (Kuttruff et al. 2009), was observed.  
3.4.6.3 Monocytes and macrophages 
 
In the RAJ, macrophage receptor with collagenous structure (MARCO) was significantly 
downregulated (fold change (log2) = 4.88). This is a receptor which is part of the innate 
antimicrobial immune system binding both Gram-negative and Gram-positive bacteria 
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via an extracellular, C-terminal, scavenger receptor cysteine-rich (SRCR) domain 
(Elomaa et al. 1998).  
At the ileal Peyer’s patches significant upregulation was seen of ectonucleotide 
pyrophosphatase/phosphodiesterase 7 (ENPP7), PDIA2, carboxypeptidase M (CPM) important 
for monocyte to macrophage differentiation (Rehli et al. 2002), the inflammatory 
purinergic receptor ligand-gated ion channel, 7 (P2RX7) and egf-like module containing, mucin-
like, hormone receptor-like 4 pseudogene (EMR4P), a member of the EGF-TM7 receptor gene 
family which is thought to be important for adhesion and migration of macrophages 
(McKnight & Gordon 1998) with (fold changes (log2) of -9.93, -4.41, -0.78, -0.64, and -
0.14, respectively. These genes result in stimulation of the immune system on level of 
monocytes and macrophages. On the other hand, macrophage migration inhibitory factor 
(MIF) which is important for the acute immune response (Rex et al. 2014) was 
significantly downregulated as well as chemokine C-C motif receptor 1 (CCR1) playing a role 
in recruitment of leukocytes to the effector site (Anderson et al. 2010) (fold change (log2) 
= 1.17 and 1.46, respectively). Furthermore, sialic acid binding Ig-like lectin 10 (SIGLEC10) 
which is a negative regulator of immune signaling by functioning as an inhibitory 
receptor (Whitney et al. 2001) and B cell linker (BLNK), an adaptor molecule linked to the 
pathway activated by B-cell antigen receptor signals (NaserEddin et al. 2015), were 
significantly downregulated, with (fold changes (log2) of 6.53 and 1.94, respectively.   
3.4.6.4 Dendritic cells (DC’s) 
 
No differential mRNA expression of genes indicating an effect on DC’s was seen in 
the RAJ. In samples from the ileal Peyer’s patches, a significant upregulation of PDIA2, 
toll-like receptor adaptor molecule 1 (TICAM1) (fold change (log2)= -4.41) and EMR4P was 
observed, whereas SIGLEC10 and MIF were significantly downregulated.  
3.4.5.5 Granulocytes 
 
In the RAJ, there was no differential regulation observed that could have a direct 
influence on granulocytes. However, in the ileal Peyer’s patches, a significant 
upregulation of ENPP7, PDIA2, chemokine C-C motif ligand 24 (CCL24) (fold change (log2) 
= -1.93), which is chemotactic for eosinophils and neutrophils (White et al. 1997) and of 
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EMR4P was detected. While a significant downregulation of neutrophil cytosolic factor 1 
(NCF1) (fold change (log2) = 1.71), neutrophil cytosolic factor 2 (NCF2) (fold change (log2) 
=1.70) and neutrophil cytosolic factor 4 (NCF4) (fold change (log2) = 1.22) important for the 
formation of the neutrophil phagosome leading to phagocytosis of bacteria (Nordenfelt & 
Tapper 2001), CCR1, hemopoietic cell kinase (HCK) (fold change (log2) = 1.70) playing a 
role in the neutrophil migration and degranulation (Quintrell et al. 1987), SIGLEC10 and 
vascular cell adhesion molecule 1 (VCAM1) (fold change (log2) = 2.79) mediating the 
adhesion of lymphocytes, monocytes, eosinophils, and basophils to vascular endothelium 
(Hwang et al. 1997), was noticed.  
3.5 Discussion 
 
It is well known that some pathogens have developed mechanisms to prolong their 
persistence in a host and can modulate the host immune response in different ways in 
order to increase their survival in the host (Janeway et al. 2005). This might be done by 
passive evasion of the immune surveillance for instance by altering expressed antigens, as 
Streptococcus pneumonia does. Another way to survive is actively modulating and 
interfering with networks that are part of the immune defence. This is done when EHEC 
and EPEC inject modulatory proteins into the host cell using T3SS (Schmid-Hempel 
2009; Croxen & Finlay 2010). Furthermore, the suppression of immune responses via 
TLR4 by uropathogenic E. coli (UPEC) leads to a decrease of IL-6 and IL-8 release 
(Hunstad & Justice 2010). To our knowledge, this is the first RNA-Seq study highlighting 
the effect of a primary infection and a re-infection with E. coli O157:H7 in cattle, leading 
to a better understanding of the transient and sometimes recurrent pattern of EHEC 
infections. We could identify an important difference in regulation of the transcriptome 
after an initial contact with the bacteria: the ileal Peyer’s patches were more influenced 
by the infection compared to the RAJ, which is part of the primary site for colonization 
in cattle (Naylor et al. 2003). In this study we were able to show suppression of immunity 
on different levels of the innate and adaptive immune response, indicating that E. coli 
O157:H7 can modulate this response in a wide variety of ways. This discussion focuses 
on genes that were significantly affected in our study and which were previously linked 
with bacterial infections in other studies.     
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Our data suggests that an infection with E. coli O157:H7 is capable of modulating 
the immune response causing dramatic decreases in CCL20. A similar trend was observed 
in a bacterial infection with Mycoplasma gallisepticum in chicken, where a downregulation 
in mRNA expression of CCL20 as well as of IL-1, IL-8 and IL-12p40 genes was seen. 
These results indicate the importance of lymphocyte and monocyte chemotactic factors 
in development of disease, but also the fast occurrence of modulations of the host 
immune responses by bacteria (Mohammed et al. 2007).  
Granulysin delivers granzymes into bacteria to kill diverse bacterial strains. In Escherichia 
coli, granzymes cleave electron transport chain complex I and oxidative stress defense 
proteins, generating reactive oxygen species (ROS) that rapidly kill bacteria (Walch et al. 
2014). An upregulation of granulysin is part of the adaptive immune response against 
bacterial infections.  
A study of St John et al. (2009) demonstrated downregulation of CXCL13 and 
CCL21 during an infection of draining lymph nodes by Salmonella typhimurium. The 
pathogen disrupts the lymph node architecture and cellular trafficking, which enhances 
its virulence and could serve as a mechanism of immune suppression used by pathogens 
that primarily target lymphoid tissue (St John & Abraham 2009). In our study, we could 
observe a significant downregulation of CXCL13 but not of CCL21 altough the bacterium 
is in close contact to lymphoid dense tissue in the RAJ and the ileum.  
We observed a downregulation of IL17REL, a gene which is important for a fast 
inflammatory response. The cells of the innate immune system are the first line of defense 
against pathogen and their cytokines govern the differentiation of T- helper cells. Their 
pattern-recognition receptors, which are not specific for any particular epitope, allow 
them to respond to a wide variety of microbial invaders by producing cytokines that 
activate T-cells of the adaptive immune system. T-helper 17 cells produce IL17 and this is 
particularly important for immunity at epithelial and mucosal surfaces, as indicated by 
the pattern of expression of their chemokine receptors and effector cytokines. Several 
pathogens, like gram-positive Propionibacterium acnes and Gram-negative Citrobacter 
rodentium, induce mainly Th17 responses (Miossec et al. 2009). Furthermore, Luo et al.( 
2015) have shown that F4 fimbriae of ETEC can elicit an IL-17 response in piglets, 
suggesting a role in protection of the host against ETEC infection.  
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A downregulation of IL21R might play a role in the persistence of colonization 
during the primary EHEC-infection and re-infection of the host, since the IL-21-IL-21R 
pathway is important in the development of immune responses, as abnormal signaling 
through the IL-21R/γc/JAK3/STAT3 pathway leads to defective humoral immune 
responses to both T-dependent and T-independent antigens and impairs the 
establishment of long-lasting B-cell memory (Desjardins & Mazer 2013). A bacterial 
infection can elicit IgM memory B-cells which requires T cell dependent and IL-21R 
signaling. The study of Yates et al. (2013) demonstrates that T cell-dependent IgM 
memory B cells can be elicited at high frequency and can play an important role in 
maintaining long-term immunity during bacterial infection.  
In the RAJ, we could observe the downregulation of MARCO, a receptor that can 
bind Gram-negative bacteria and is only found on macrophages of the marginal zone of 
the spleen and lymph nodes (Elomaa et al. 1998). Pinheiro da Silva et al. (2007) have 
shown that E. coli are capable of hijacking inhibitory ITAMs leading to a decrease in 
MARCO-mediated phagocytosis (Pinheiro da Silva et al. 2008). This observation is 
indicating a decrease in antibacterial protection of the host at the primary site of EHEC 
infection. 
A limitation of our study is that most information from gene function databases is 
derived from studies that are not performed in cattle but in human and mice, therefore 
we have to take into consideration species-specific differences which we unfortunately 
cannot control. This study is important since it is the first study using the highly-accurate 
and sensitive RNA-Seq technique to study the effect of EHEC on the cattle immune 
responses. These insights are crucial to better understand EHEC colonization and 
shedding within herds and our data could contribute to effective measures to control 
EHEC colonization in ruminants, thereby reducing zoonotic food-borne infections in 
humans. 
3.7 Conclusions 
 
We can conclude that the main effect on the transcriptome was immune 
suppression by E. coli O157:H7 due to an upregulation of 7 out of 12 genes with immune 
suppressive effects or a downregulation of 69 out of 94 genes with immunostimulatory 
effects (Table 3.3). Furthermore, the changes in gene expression were remarkably higher 
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in the ileal Peyer’s patches (1159 genes) than in the RAJ (15 genes) during a primary 
infection. This effect was less obvious after the re-infection (17 and 10 genes, 
respectively). The data might indicate that a primary infection promotes a re-infection 
with EHEC by suppressing the immune function. 
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4.1 Abstract 
Enterohemorrhagic Escherichia coli (EHEC) strains, of which E. coli O157:H7 is the 
best-studied serotype, are an important group of foodborne pathogens causing severe 
illness in humans worldwide. The main reservoirs for EHEC are ruminants, mostly 
cattle, which harbor the bacteria in their intestinal tracts without showing clinical 
symptoms. Many studies have shown that EHEC uses a wide range of factors to suppress 
host immune responses thereby promoting persistent infection. In this study, we used 
bovine lactoferrin (bLF), a naturally occurring immunomodulating and bactericidal 
protein, as a possible stimulator of the systemic host immune response against E. coli 
O157:H7 infection in cattle. Nine 3-month-old Holstein-Friesian calves were 
experimentally infected with E. coli O157:H7 (Stx-; strain NCTC12900). Three animals 
received a daily rectal spray treatment with bLF, three animals received an oral 
treatment, and three animals served as a control group. Blood samples were collected 
weekly and fecal samples twice weekly to monitor antibody responses and fecal 
excretion, respectively. All groups developed serum responses, but no clear differences 
could be observed between the groups although animals in the rectal group ceased 
shedding within 26 days of the experimental treatment and remained negative, whereas 
no beneficial effect of bLF on bacterial shedding was observed in the oral group. Animals 
of the oral and control group remained positive until the time of euthanasia (day 61). The 
results indicate that the use of bLF as a rectal treatment can be a useful strategy to 
preclude further transmission of EHEC infections from cattle to humans. The mechanism 
behind this effect might be, at least partly, due to stimulation of the local immune 
responses by bLF, as no systemic effect was observed. 
4.2. Introduction 
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a foodborne pathogen 
which causes human illness ranging from self-limited watery or bloody diarrhea and 
hemorrhagic colitis to acute renal failure and hemolytic uremic syndrome (Sheng et al. 
2006). Infection in humans is typically acquired through the ingestion of contaminated 
food or water, direct contact with infected animals, or person-to-person transmission. 
The main reservoirs for E. coli O157:H7 are ruminants, mostly cattle, which, in contrast 
to humans, harbor the bacteria in the gastrointestinal tract without showing apparent 
illness (Hancock et al. 1997; Chapman et al. 1993). The persistence of E. coli O157:H7 
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and the duration of shedding in naturally and experimentally infected cattle are highly 
variable and vary from days to months (Hancock et al. 1997; Shere et al. 2002; Cobbaut 
et al. 2009). Mechanisms leading to persistence of E. coli O157:H7 in ruminants are not 
fully understood, impeding the search for a successful approach to combat E. coli 
O157:H7 zoonotic transfer (Yekta 2011). Nevertheless, many studies have shown the 
importance of effector molecules produced by EHEC, which influence the host immune 
response in order to promote persistent colonization (reviewed in Chapter I, section 2.6).  
The current treatment of EHEC-related diseases in humans is limited to supportive 
care, as antibiotic treatment is contraindicated because it might increase the frequency of 
hemolytic uremic syndrome occurrence due to the release of bacterial Shiga toxins (Grif 
et al. 1998). Different strategies to reduce the EHEC carriage rates in ruminants, 
including vaccination (Rabinovitz et al. 2012), probiotic treatment (Ohya et al. 2000), 
bacteriophages (Sheng et al. 2006), and modification of diet (Callaway et al. 2011), have 
been tested. Unfortunately, these strategies show only limited results. Currently, no 
methods that can substantially reduce EHEC carriage rates in ruminants are available. 
Thus, innovative strategies which could effectively reduce E. coli O157:H7 carriage in 
ruminants are urgently required for diminishing the risk to public health.  
Emerging multiple-antimicrobial-resistant pathogens and the full ban on in-feed 
antibiotics in Europe have increased research on natural antimicrobial proteins such as 
transferrins. Lactoferrin, a member of the transferrin protein family, is an iron-binding 
glycoprotein that is found in many exocrine secretions, including milk, tears, saliva, and 
serum. Lactoferrin exhibits antibacterial activity against Gram-negative and Gram-
positive bacteria in a variety of ways. First, it sequesters iron, which is an essential 
growth factor for microorganisms (Otto et al. 1992). Second, lactoferrin is capable of 
destabilizing the outer membranes of Gram-negative bacteria, which results in the release 
of bacterial lipopolysaccharides (LPS) from the bacterial membrane (Ellison et al. 1988). 
Another important feature of lactoferrin is its immune-modulating effect (reviewed in 
Chapter I, Section 3.5). It can influence both innate and adaptive immune responses and 
seems to activate immune responses when suppressed or attenuate responses when too 
high. In this study, we investigated if bovine lactoferrin (bLF) can stimulate the systemic 
immune response upon E. coli O157:H7 colonization in cattle.       
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Several studies have identified the epithelium of the recto-anal junction, located 
above the gut-associated lymphoid tissue, as the major colonization site of EHEC in 
cattle (Naylor et al. 2003; Grauke et al. 2002). The present study evaluated the curative 
effect of orally or rectally administered bLF in an experimental E. coli O157:H7 infection 
model in calves, which we established in our laboratory (unpublished results, 2013). Three 
major questions were addressed. (i) Can orally administered bLF sufficiently reach the 
predilection site for E. coli O157:H7, the rectal mucosa, to stimulate the immune response 
and contribute to clearance of E. coli O157:H7 colonization? (ii) Does rectal 
administration of bLF result in stimulation of immune responses which lead to E. coli 
O157:H7 clearance? (iii) Does bLF treatment influence the systemic antibody response 
against E. coli O157:H7 virulence proteins, and might these responses be used in the 
future to monitor the infection status of a cattle herd? 
4.3. Materials and methods 
4.3.1. EHEC strain 
 
E. coli O157:H7 strain NCTC12900, a well-characterized Shiga toxin-negative 
EHEC strain of human origin with nalidixic acid resistance (Dibb-Fuller et al. 2001), was 
used for experimental infections in calves. We used this Shiga toxin-negative strain for 
biosafety reasons. Bacteria were grown overnight in Luria-Bertani broth (LB) with 
aeration (200 rpm) at 37°C, harvested by centrifugation (11,337 x g, 5 min), resuspended 
in sterile phosphate-buffered saline (PBS), to a concentration of 1010 CFU/10 ml, and 
subsequently used for experimental infections. 
4.3.2. Bovine lactoferrin 
 
bLF with 92% purity and 16% iron saturation (manufacturer [Ingredia Nutritional, 
France] information), derived from bovine milk, was used in this study. Using a bovine 
Ig enzyme-linked immunosorbent assay (ELISA), the absence of bovine antibodies (AbD 
Serotec) in the bLF was confirmed. 
4.3.3. Experimental infection of calves and sampling 
 
 Nine three-month-old calves (Holstein-Friesian; Hindryckx N.V., Ichtegem) were 
randomly assigned to three groups (oral, rectal, and control) of three animals, each reared 
in a separate pen. The calves were fed grain-based pellets and were allowed free access to 
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hay and water. All animals were screened to be seronegative for intimin, EspA, and EspB 
and the feces of these animals were free of E. coli O157:H7 as demonstrated by direct 
plating and isolation (the procedure is described below). Experimental procedures and 
animal management procedures were undertaken in accordance with the requirements of 
the animal care and ethics committee of the Faculty of Veterinary Medicine, Ghent 
University, Belgium (EC2012/170).  
 
The experimental infection was carried out one week after arrival of the animals. 
First, using a nursing bottle, calves were given 300 ml of a 10% NaHCO3 solution in 
order to close the esophageal groove and to allow the bacterial inoculum to drain directly 
into the abomasum. Each animal was infected with 1010 CFU E. coli O157:H7 (Stx-) for 
two consecutive days (days 0 and 1 of the experiment) and re-infected on days 7 and 8. 
Treatment with bLF started on day 11 and continued until day 61 for the oral and control 
groups and until day 43 for the rectal group. The oral group received bLF orally (1.5 g 
twice a day) suspended in a volume of 10 ml sodium bicarbonate buffer (10%). The rectal 
group was treated with bLF powder, which was dispersed by air blast onto the rectum 
(300 mg per day) using a 20-cm-long polyvinyl chloride tube (diameter, 1 cm). The 
control group received only the bicarbonate buffer orally. 
 
Serum samples (taken from the jugular vein) were collected to detect intimin-, 
EspA-, EspB- and -specific antibody titers before the primary infection on day 0, before 
re-infection on day 7, and subsequently on a weekly basis for the duration of the 
experiment. In all groups, fecal excretion of E. coli O157:H7 was monitored twice a week 
from day 1 onwards until E. coli O157:H7 was no longer present in the feces. Animals in 
the rectal group were euthanized at day 43, while animals in the oral and the control 
groups were euthanized at day 61. At euthanasia, tissues and contents of the jejunum, 
ileum, cecum, colon, and rectum were sampled for enumeration of the inoculated strain.  
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4.3.4. Serum antibody response against virulence factors of E. coli O157:H7 
Blood samples were processed directly after collection. Briefly, sera were heat 
inactivated (30 min at 56°C) and kaolin treated. Polysorb 96-well plates (Polysorb 
Immuno Plates; Nunc, Roskilde, Denmark) were coated (200 ng/well) with recombinant 
intimin, EspA, or EspB in phosphate buffered saline (PBS) and incubated overnight at 
4°C. Nonspecific binding sites were blocked for 1 h at 37°C by adding PBS plus 0.2% 
Tween 80. After washing with PBS plus 0.2% Tween 20, the plates were incubated with 
2-fold dilution series of serum in PBS plus 0.05% Tween 20, followed by washing and 
incubating (1 h at 37°C) with affinity chromatography-purified horseradish peroxidise 
(HRP)-conjugated sheep anti-cattle IgA and IgG antibodies (AbD Serotec, United 
Kingdom). After a final washing step, 2,2’-azino-di-(3-ethylbenzthiazoline sulfonate) 
diammonium salt (ABTS) (Roche Diagnostics, Vilvoorde, Belgium) was added. The 
optical density at 405 nm (OD405) was measured. Positive- and negative-control sera were 
kindly provided by the Laboratory of Veterinary Public Health and Food Safety 
(Merelbeke) (Joris 2012). The cut-off value was determined as mean of the value for the 
negative-control sera + three times the standard deviation (SD). For the calculation of the 
titers, the maximum dilution that exceeded the cut-off value was used. This values were 
subsequently log2 transformed. 
4.3.5. Excretion and intestinal presence of E. coli O157:H7(Stx-) 
Fecal samples were analyzed immediately after sampling, as described by Vande 
Walle et al. (2011). Briefly, 10 g of feces was homogenized in 90 ml sterile modified 
tryptone soy broth (mTSB, Oxoid Ltd., Hanst, United Kingdom) supplemented with 20 
mg/liter novobiocin (Sigma Aldrich, St. Louis, MO, USA). Enumeration of E. coli O157 
(Stx-) was performed by plating 10-fold serial dilutions onto MacConkey agar 
supplemented with sorbitol, cefixime, tellurite, and nalidixic acid (NalCT-SMAC) 
(Merck, Darmstadt, Germany) and incubating the plates at 37°C for 18 h. The remaining 
broth was enriched for 6 h at 42°C and subjected to immunomagnetic separation (IMS) 
using Dynabeads (Invitrogen, Merelbeke, Belgium), according to the manufacturer’s 
instructions. Finally, 100 µl was plated onto NalCT-SMAC agar and incubated for 18 h 
at 37°C. Selected sorbitol-negative colonies were confirmed by the O157-specific latex 
agglutination assay (Oxoid Ltd., Basingstoke, United Kingdom). 
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At euthanasia, 10 g of content from the jejunum, ileum, cecum, colon, and rectum 
and 10 g of tissues (washed with sterile PBS) from the jejunum with and without Peyer’s 
patches (PP), ileum with and without PP, cecum, colon, and recto-anal junction were 
tested for the presence of E. coli O157:H7 by direct plate counts, as described for the fecal 
samples. 
4.3.6. Statistical analysis 
Statistical analysis was performed based on the linear fixed-effects model with 
treatment as the categorical fixed effect and the area under a curve (AUC) as the response 
variable. The data represent mean + standard deviation. A P-value of <0.025 (Bonferroni 
adjusted) was considered statistically significant. Colony counts were log10 transformed 
for data analysis. If E. coli O157:H7 could not be detected by direct plating but only by 
enrichment, a concentration of 10 CFU/g was assigned to the sample (Vande Walle et al. 
2011). 
4.4. Results 
4.4.1 Serum antibody responses against virulence factors of E. coli O157:H7 
IgG responses against intimin, EspB, and EspA are presented in Figure 4.1 and IgA 
responses in Figure 4.2. The responses in all 3 groups showed some similarities, such as 
(i) the occurrence of low IgG titers against all 3 virulence factors, (ii) the appearance of 
an IgG response against EspB at 14 days post-primary infection (dppi) until 38 to 43 
dppi, (iii) an EspB-specific IgA response which peaked at 14 dppi, and (iv) an intimin-
specific IgA response which peaked 33 dppi. The EspA-specific antibody responses were 
different between groups. EspA-specific IgG was lowest and shortest in duration in the 
control group (21 dppi), slightly higher en clearly longer in the rectal group (7, 14, 21, 
and 33 dppi), and the oral group (14, 21, 27, 33 dppi), with in the latter group a second 
increase 61 dppi. The opposite was seen for the EspA-specific IgA response, which 
longest in duration in the control group (21, 27, and 33 dppi) and very short in the rectal 
group (21 dppi) to absent in the oral group. The intimin-specific IgG response resembled 
the EspB response in the control group and the oral group but not in the rectal group, 
where intimin specific IgG was detected at 14 dppi only, whereas the intimin-specific IgA 
response was most pronounced in the rectal group and lower and of shorter duration in 
both other groups. Another important difference was the reappearance of an IgG 
response against all three type III secretion system (TTSS) proteins at the end of the 
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experiment (61 dppi) in the oral group and not in control group, as if a re-infection 
occurred in the oral group. Animals of the rectal group were already euthanized at this 
timepoint. Furthermore, EspB-specific IgA appeared and disappeared 3 times in the oral 
group during the observation period but was absent at the end of the experiment. 
Comparing the rectal group with both other groups showed a tendency for a less 
pronounced intimin-specific IgG response and an enhanced intimin-specific IgA 
response, even though not significant. 
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Figure 4.1: Mean IgG titers (log2) for the 3 treatment groups. Letters indicate a significant difference 
between groups for a designated time point; (a) significant differences in intimin responses compared to 
the oral group, (b) significant differences in EspB responses to the oral group; (c) significant differences 
in EspA responses to the oral group (c) and to the rectal group (d). Arrows indicate the time points of 
oral inoculation with bacteria. 
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Figure 4.2: Mean IgA titers (log2) for the 3 treatment groups. Letters indicate a significant difference 
between groups for a designated time point; (a) significant differences in EspB responses compared to 
the oral group, (b) significant differences in EspA responses to the oral group. Arrows indicate the time 
points of oral inoculation with bacteria. 
 
4.4.2. Excretion of E. coli O157:H7 
 
 For all 3 animals, fecal shedding heavily fluctuated between 101 and 105.5 CFU E. 
coli O157:H7/g feces when positive from day 1 until euthanasia at day 61 (Figure 4.3). 
The feces of animals 1, 2, and 3 were E. coli O157:H7 negative on 4 (25%), 1 (6.2%), and 
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5 (31%) of 16 sampling time points, respectively. Only 1 of 3 (33%) animals (animal 3) 
ceased shedding at day 50 and remained negative the end of the experiment (day 61).  
 
Figure 4.3: Excretion of E. coli O157:H7 in calves. Results are represented as real values of CFU/g 
feces for individual animals in the control group on a logarithmic scale. A value of 1E+00 corresponds 
to negative sampling after enrichment and IMS. The vertical dashed line at day 11 indicates the start of 
the treatment. The arrows indicate the starts of the first and second infections.  
 
Also in the oral group, fecal E. coli excretion fluctuated heavily between 101 and 104, 
101 and 103.5, and 101 and 105 CFU E. coli O157:H7/g feces, for animal 1, 2 and 3, 
respectively, when positive (Figure 4.4). Also here one animal (animal 1) ceased 
shedding, but already from day 33 onwards. For animal 2, feces were negative on 4 of 16 
(25%) sampling time points. On the other hand, the feces of animal 3 remained E. coli 
O157:H7 positive from day 1 until day 61.  
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Figure 4.4: Excretion of E. coli O157:H7 in calves. Results are represented as real values of CFU/g 
feces for individual animals in the oral group on a logarithmic scale. A value of 1E+00 corresponds to 
negative sampling after enrichment and IMS. The vertical dashed line at day 11 indicates the start of 
the treatment. The arrows indicate the starts of the first and second infections. 
 
Rectal administration of bLF gave a completely different result (Figure 4.). As in 
the oral and control groups, at day 1 large amounts of E. coli O157:H7 were found in all 3 
animals in the rectal group (104.5,105, and 104 CFU, respectively). Hereafter, E. coli 
O157:H7 shedding constantly declined afterwards, resulting in 2 of 3 (66%) negative 
animals (animal 1 and 3) by day 19. The third animal (animal 2) became negative by day 
33. Importantly, once negative, E. coli O157:H7 could not be isolated again in the feces of 
these animals.  
 
Figure 4.5: Excretion of E. coli O157:H7 in calves. Results are represented as real values of CFU/g 
feces for individual animals in the rectal group on a logarithmic scale. A value of 1E+00 corresponds to 
negative sampling after enrichment and IMS. The vertical dashed line at day 11 indicates the start of 
the treatment. The arrows indicate the starts of the first and second infections. 
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The treatment groups did not have a significantly lower mean E. coli O157:H7 
CFU/g feces (AUC) than the control group (Figure 4.6). However, the P-value for the 
comparison between the rectal and the control groups equaled 0.0414, slightly below the 
Bonferroni-adjusted significance level of 0.05. 
 
 
Figure 4.6: Results are presented as the mean real values of CFU/g feces + SD on a logarithmic scale. 
A value of 1E+00 corresponds to negative sampling after enrichment and IMS. The vertical dashed line 
at day 11 indicates the start of the treatment. The arrows indicate the starts of the first and second 
infections. 
 
4.4.3. Presence of E. coli O157:H7(Stx-) in intestinal tissues at euthanasia  
E. coli O157:H7 (Stx-) could not be isolated from the intestinal tissues or contents of 
animals in the rectal group (Table 4.1). On the other hand, the bacteria could be isolated 
from the intestinal contents of 2 of 3 (66%) animals in the oral and control groups. In the 
control group, it was found in contents of the small intestine and rectum of 1 of 3 (33%) 
and 2 of 3 (66%) animals, respectively, with the largest amount in the ileum (6 x 102). 
Large intestinal contents were negative. For the oral group, E. coli O17:H7 (Stx-) was 
found in contents of the large intestine and rectum of 1 of 3 (33%) and 2 of 3 (66%) 
animals, respectively. The largest amount of E. coli O157:H7 (Stx-) was found in the 
rectum (3 x 102). Small intestinal contents were negative.  
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At euthanasia, E. coli O157:H7 (Stx-) was never found in tissues of the jejunum and 
colon and was absent in all intestinal tissue suspensions of animals in the rectal group 
(Table 4.2). The bacteria were present in recto-anal tissue suspensions of 1 of 3 (33%) 
animals of the oral and of the control group and in tissue suspensions of ileum without 
PP of 2 of 3 (66%) animals in the control group. 
Table 4.1. Number of E. coli O157:H7 CFU/g of intestinal content at euthanasia on day 43 (rectal 
group) or day 61 (oral and control groups) 
 
  E. coli O157:H7 (Stx-) CFU in intestinal contents of 
Group Animal N° jejunum ileum caecum colon rectum 
Oral 
1 <10 <10 <10 <10 1 x 101 
2 <10 <10 <10 <10 <10 
3 <10 <10 2 x 103 1,1 x 103 3 x 102 
Rectal 
1 <10 <10 <10 <10 <10 
2 <10 <10 <10 <10 <10 
3 <10 <10 <10 <10 <10 
Control 
 
1 <10 <10 <10 <10 1 x 101 
2 <10 <10 <10 <10 <10 
3 1 x 102 6 x 102 <10 <10 1 x 102 
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Table 4.2. Number of E. coli O157:H7 (Stx-) CFU/g of tissue at euthanasia on day 43 (rectal group) or 
day 61 (oral and control group) 
 E. coli O157:H7 CFU in tissue suspensions ofa 
Group Animal N° ileum-PP Recto-anal junction 
Oral 
1 4 x 102 <10 
2 <10 <10 
3 3 x 102 1 x 102 
Rectal 
1 <10 <10 
2 <10 <10 
3 <10 <10 
 
Control 
 
1 <10 <10 
2 <10 1 x 102 
3 <10 <10 
a The number of CFU in tissue was determined by direct plating. Jejunum with Peyer’s 
patches (PP), jejunum without PP, ileum with PP, and colon were negative in all 
groups. 
4.5 Discussion 
 
 Bullen et al. (1972) first demonstrated the in vivo effects of lactoferrin by using milk 
against enteropathogenic E. coli in the small intestines of guinea pigs. They found that the 
bacteriostatic effect of milk was mainly due to lactoferrin. Later, Wada et al. (1999) 
showed that the administration of bLF to Helicobacter pylori-infected mice resulted in a 
marked decrease of bacterial colonization and attachment to the gastric epithelium. More 
recently, we demonstrated clearance of E. coli O157:H7 (Stx-) excretion from the intestine 
of sheep by oral administration of bLF (Yekta et al. 2011).The mechanisms behind this 
clearance are far from elucidated, but it might be expected that both immunomodulating 
and antibacterial effects contribute to the clearance. Since cattle are the main reservoir of 
E. coli O157:H7, we investigated in the present study the effects of rectal and oral 
administration of bLF on systemic antibody production and on fecal shedding and 
intestinal clearance of E. coli O157:H7 (Stx-) in experimentally infected calves. As in our 
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previous sheep experiment, bLF was administered orally in a 10% bicarbonate buffer. 
This buffer closes the esophageal groove, allowing bLF to pass the rumen, reticulum, and 
omasum and be directly transported to the abomasum (Rosenberger et al. 1979). 
Delivering bLF directly to the abomasum could prevent it from being consumed by 
ruminal bacteria and enhance its degradation by pepsin in the abomasum. Pepsin can cut 
bLF into different peptides, of which one peptide, lactoferricin, is believed to be involved 
in many lactoferrin functions. It has been shown that lactoferricin can be a more potent 
antibacterial compound than the native protein (Gifford et al. 2005; Bellamy et al. 1992), 
but the immunomodulating effects of lactoferricin are not well described. 
In the present study, we could not observe clear differences in production of 
systemic antibodies against E. coli O157:H7 proteins EspA, EspB or intimin for the 
different groups. The IgG responses against EspB were comparable between control, 
rectal and oral groups indicating bLF had not effect on EspB in this trial. IgG responses 
against EspA were present in both bLF groups but not in the control group, suggesting 
that bLF enhanced antibody responses against this molecule. Furthermore, bLF 
accelerated the appearance of an intimin-specific IgA response upon re-infection with one 
week. This indicates that bLF can, to a certain extent, modulate systemic immune 
responses. However, a distinct effect on these responses was not detected, suggesting that 
the real immunomodulating effect might be found in local responses. A study from 
Rybarczyk et al. (2015) revealed that rectal administration of bLF induced EspA- and 
EspB-specific IgA responses in rectal mucosal tissue. These mucosal antibodies were only 
detected in animals which received bLF treatment and can therefore be linked to the 
immunomodulating effect of bLF. Furthermore, these local antibodies may contribute to 
the clearance of E. coli O157:H7 (Stx-) from the rectum, together with the antibacterial 
effect of bLF. Whereas in a previous study, oral bLF treatment of sheep reduced the 
amount and duration of E. coli O157 (Stx-) fecal shedding, such an effect was not seen in 
the orally treated calves in this study. An explanation for this difference could be the 
different tissue tropisms of E. coli O157:H7 in sheep and calves. In calves, the terminal 
rectal mucosa, which is rich in lymphoid follicles, has been identified as the major site of 
E. coli O157:H7 colonization (Naylor et al. 2003; Naylor et al. 2005). In sheep, the 
bacteria seem to colonize the entire intestinal tract (Vande Walle, Yekta, et al. 2011; 
Yekta et al. 2011; La Ragione et al. 2009), even though slightly higher numbers could be 
seen in the ileum and large intestine (Aktan et al. 2007) or at the recto-anal junction 
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(Yekta 2011; Vande Walle et al. 2011). It is likely that the antimicrobial activity of orally 
administered bLF decreases from cranial to caudal in the gut so that an effect can be seen 
on E. coli O157:H7 colonization in the orally inoculated sheep, with a more equal 
colonization throughout the gut, compared to calves, in which the bacterium has a 
predilection for the recto-anal junction. This is supported by the following observation 
that only rectally administrated and not orally administrated bLF could clear the 
infection from calves, whereas orally administrated bLF could clear the infection in 
sheep. To our knowledge, a total clearance of EHEC in cattle using a rectal treatment 
had not yet been described. Naylor et al. (2007) and Rozema et al. (2009) reported 
different strategies for rectal treatment that could reduce but not clear the bacterial 
colonization.  
Although antibody responses were detected in the three groups of animals, we do 
not believe that they play a major role in the clearance of bacteria, since a study by Joris 
et al. (2012) showed that responses against EspA, intimin, and Tir did not always occur 
during infection with EHEC. When responses against EspB occurred, the feces were 
positive for EHEC and the response lasted for several months. Therefore, responses 
against EspB might be used in the future as an indication of the EHEC-positive status of 
animals. Nevertheless, interpretation of these serum responses should be performed 
carefully, as we saw in this experiment that responses against EspB can disappear 
although animals are still shedding. Furthermore, we could not observe a clear effect of 
bLF on the antibody responses against EspA, EspB, and intimin. In a study by Yekta et 
al. (2011) with oral bLF treatment in sheep, there was no observed effect of bLF on the 
intimin responses. The EspA and EspB responses were significantly augmented by the 
high bLF dose. This result was not seen in our experiment with calves, although the same 
dose of bLF was used in our oral treatment group.  
Although we were able to use only a limited number of laboratory animals, the 
results of this preliminary study are promising since we observed a complete clearance of 
EHEC after rectal administration of lactoferrin. Future investigations should address the 
limitations of this study related to sample size and could therefore be performed on the 
farm level. 
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4.6 Conclusions 
To our knowledge, this is the first study demonstrating a reduction of E. coli 
O157:H7 (Stx-) shedding by rectal administration of bLF. Moreover, the administration 
of this antimicrobial protein resulted in the clearance of rectal colonization. However, 
when bLF was administered orally, no clearance could be observed. This could indicate 
that orally administered bLF might not reach the recto-anal junction in a sufficient way. 
Although the results on bacterial shedding were encouraging, this could not be linked to 
the influence of bLF on the systemic immune response. This suggests that bLF could 
have local effects on the immune system which affect the clearance of the bacteria, which 
could explain the increase in intimin-specific IgA, observed following rectal treatment 
with bLF. Results also demonstrate that bLF might be an interesting tool to reduce the 
number of E. coli O157:H7-excreting cattle, thereby reducing the exposure of humans to 
this zoonotic pathogen. However, field experiments for further validation of this new 
strategy have to be performed. 
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5.1 Abstract 
Escherichia coli O157:H7 is prevalent in cattle worldwide, but mechanisms leading to 
persistent colonization, are still far from elucidated. Results in earlier studies indicate a 
downregulation of immunity by Type III secretion system (T3SS) effector proteins and 
Shiga toxins (Stx) (Chapter I and Chapter III). In previous studies, we demonstrated that 
bovine lactoferrin (bLF) can clear an E. coli O157:H7 infection in experimentally infected 
cattle (Kieckens et al. 2015), and that bLF seems to enhance a rectal mucosal IgA 
response (Rybarczyk et al. 2015). In this study, we analysed the release of 
proinflammatory cytokines upon E. coli O157:H7 infection by (i) bovine rectal epithelial 
cells and upon infection by (ii) explants of the recto-anal junction (RAJ), the most 
important colonization site in cattle, and by (iii) explants of ileal Peyer’s patches (I+PP), 
shown to play a role in suppression of the immune response upon colonization. 
Furthermore, we analysed the effect of Shiga toxin 2 (Stx2) and bLF on this 
proinflammatory cytokine response. Our data in rectal epithelial cells show that 
incubation with E. coli O157:H7 strains reduces both IL-6 and IL-8 levels and increases 
TNF-α levels. These effects were even more pronounced when cells were pretreated with 
Stx2. bLF was able to restore the IL-6 but not the IL-8 levels and induced the release of 
supplementary TNF-α. Inoculation of tissue explants with E. coli O157:H7 (Stx-) induced 
the secretion of IL-6 and IL-8 in the RAJ and of IL-8 in the I+PP, while reducing only 
IL-6 in the I+PP. No significant effects of pretreatment with Stx2 could be observed. bLF 
could again restore IL-6, but overstimulated IL-8 secretion. TNF-α was slightly decreased 
by E. coli O157:H7 (Stx-) in RAJ and increased in I+PP explants.   
 
5.2 Introduction 
The prevalence of E. coli O157:H7 in cattle varies widely, depending on countries, 
regions, farms types (dairy versus beef), and herds. But a recent study in Belgium has 
reported an overall prevalence of 37.8 % cattle farms which are infected, with the highest 
prevalence for dairy cattle farms (61.2%, 30 of 49 farms) (Cobbaut et al. 2009). This 
shows that there is a significant risk for transmission of these bacteria to humans, where 
it can result in severe clinical signs and mortality. Many researchers have studied factors 
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that can influence colonization in cattle, but there are still a number of gaps that need to 
be elucidated to fully understand the mechanisms behind this colonization. Until now, 
there is no explanation why some animals within a herd shed high numbers of E. coli 
O157:H7 over longer time periods whereas others barely get infected and/or shed only 
small amounts of the bacteria. This effect might be linked to differences in immune 
responses and levels of cytokine production between animals.  
Several studies have demonstrated that E. coli O157:H7 can modulate immune 
responses in a variety of ways. Recognition of H7 flagellin by TLR5 and of 
lipopolysaccharide (LPS) by TLR4 initiates proinflammatory responses, which can be 
downregulated by injection of Locus of Enterocyte Effacement (LEE) and non-LEE 
encoded proteins via the bacterial type III secretion system (T3SS). Indeed, Tir, EspB, 
NleB, NleC, NleD, NleE, NleH1 and NleH2, can all intervene in the NF-κB pathway 
decreasing the expression of pro-inflammatory cytokines IL-6, IL-8 and TNF-α (Hauf 
and Chakraborty, 2003; Wan et al. 2011; Vande Walle et al. 2013; Chapter 1). However, 
NleF can enhance the proinflammatory responses. Besides modulation via T3SS effector 
proteins, modulation of the immune system can also occur by Shiga toxins (Stx) 1 and/or 
2 produced by enterohemorrhagic E. coli (EHEC) (Chapter I, section 2.8.1). Stx is capable 
of inducing IL-6, IL-8, and TNF-α production in bovine and murine macrophages and 
human intestinal epithelial cells (Menge et al. 2015; Tesh et al. 1994; Smith et al. 2003).  
The Stx inhibit protein synthesis by acting on the 28S rRNA of the 60S ribosome of 
eukaryotic cells (Endo et al. 1988). This results in cellular apoptosis, which initiates the 
inflammatory response and influx of leukocytes (Smith et al. 2003). Stx2-producing 
EHEC strains are more frequently linked to severe disease in humans than strains 
producing Stx1 or a combination of both (Fuller et al. 2011). Moreover, Stx2+ EHEC are 
shown to suppress cellular immune responses, which might facilitate long-term 
colonization and re-infection (Hoffman et al. 2006).  
In cattle, the recto-anal junction (RAJ) is the predominant colonization site of E. 
coli O157:H7 (Naylor et al. 2003). We hypothesized that the epithelium of the RAJ could 
play a major role in the suppression of the immune system by E. coli O157:H7, but an 
RNA-Seq experiment performed on mRNA extracted from the RAJ and ileal Peyer’s 
patches (I+PP) of animals that were infected and re-infected with a Shiga toxin-negative 
(Stx-)-strain could not confirm this hypothesis (Chapter III). On the contrary, we found a 
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weighty effect on the gene expression in the I+PP, while the RAJ was almost unaffected. 
A limitation of our study using the RNA-Seq technique is that changes in mRNA 
expression were only determined at a specific time point (14 days post infection or re-
infection). Most likely activation or suppression of proinflammatory responses by EHEC 
changes in time, explaining why we could not observe effects on mRNA of these 
cytokines, which are short-lived, using the RNA-Seq method. In the present study tissue 
explants or cell cultures were used and incubated with E. coli O157:H7 in the presence of 
absence of Stx and/or bovine lactoferrin (bLF). Incubation of explants or cells with 
bacteria was performed during six hours, a period long enough to measure 
proinflammatory cytokine responses on protein level. We analysed the cytokine response 
of RAJ explants, but because of the extensive effect on mRNA expression in I+PP 
tissues, also of I+PP explants. As the predilection of EHEC in cattle for the recto-anal 
epithelium was demonstrated (Naylor et al. 2003), we also established bovine primary 
rectal epithelial cell cultures, which were used to analyze their role in proinflammatory 
responses of E. coli O157:H7 as well as to determine the effect of Stx2 on their interaction 
with E. coli O157:H7. Since there are indications that Stx2 might facilitate colonization of 
E. coli O157:H7, Stx2 pretreatment of rectal epithelial cells was included.  
Previous studies in our group showed that bLF was capable of clearing E. coli 
O157:H7 from the rectal mucosa when administered topically (Chapter IV). This was 
accompanied with the induction of mucosal IgA responses (Rybarczyk et al. 2015). Since 
IL-6 is known to enhance IgA secretion, we analyzed the effect of bLF on the 
proinflammatory cytokine responses of tissues explants and cell cultures (Mowat 2003). 
5.2 Materials and methods 
5.2.1 Cell culture of bovine rectal epithelial cells 
 
Rectal specimens were obtained from freshly slaughtered cattle (18-24 months old) 
of different breeds from a local slaughterhouse (Flanders Meat Group, Zele, Belgium). 
The rectal tissues were  rinsed with cold phosphate buffered saline (PBS, pH 7.2, 4°C) 
supplemented with 100 U/ml penicillin (Sigma-Aldrich, Diegem, Belgium), 100 µg/ml 
streptomycin (Sigma-Aldrich) and 25 µg/ml gentamicin (Thermo Fisher Scientific). 
Further, the rectal specimens were placed in ice-cold Hanks' balanced salt solution 
(HBSS; Thermo Fisher Scientific) supplemented with 100 U/ml penicillin (Sigma-
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Aldrich), 100 µg/ml streptomycin (Sigma-Aldrich), 2.5 µg/ml amphotericin B (Sigma-
Aldrich) and 25 µg/ml gentamicin (Thermo Fisher Scientific) and transported on ice to 
the laboratory. 
Rectal crypts were isolated from rectal specimens as described (Bridger et al. 2010; 
Kaushik et al. 2008; Sheng et al. 2011), with minor modifications. Briefly, mucosal tissue 
was separated from the lamina propria by scraping with a sterile glass slide, homogenized 
by a razor blade and centrifuged (5 min, 130 x g, 4oC) in HBSS (4oC) three times to 
remove the upper mucus containing layer. The remaining pellet was used for enzymatic 
digestion (60 min, 100 rpm, 37oC) carried out in a solution containing Dulbecco's 
modified Eagle medium (DMEM, Thermo Fisher Scientific), 1% (v/v) heat-inactivated 
fetal calf serum (FCS), 100U/ml penicillin (Sigma-Aldrich), 100 µg/ml streptomycin 
(Sigma-Aldrich), 2.5 µg/ml amphotericin B (Sigma-Aldrich), 25 µg/ml gentamicin 
(Thermo Fisher Scientific) and 100 U/ml collagenase (Sigma-Aldrich). To disintegrate 
crypt clots, the suspension was passed through a 0.9 x 50 mm needle (Beckton 
Dickinson, Erembodegem, Belgium), whereafter it was centrifuged 5 times (5 min, 50 x 
g, 4oC) with DMEM containing 2% sorbitol (w/v) to enrich the crypts and separate them 
from the most bacteria and single cells including fibroblasts. Rectal crypts formed a pellet 
while the supernatant containing single cells and debris was discarded after each 
centrifugation step. At the end the crypts were washed with HBSS (3 min, 65 x g , 4°C) 
with 100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin B and 25 
µg/ml gentamicin. 
Isolated crypts were seeded at a density of 200-250 crypts per well into 24-well 
culture plates pre-coated with rat tail collagen (5 µg/cm2; Sigma-Aldrich) and cultivated 
in 37oC, and 5% CO2, in complete culture medium containing DMEM supplemented with 
100 U/ml penicillin, 100 µg/ml streptomycin, 25 µg/ml gentamicin, 2.5 µg/ml 
amphotericin B, 10 ng/ml epidermal growth factor (Sigma-Aldrich), and 10 µg/ ml 
bovine insulin (Sigma-Aldrich). For the first 24 h, 10% FCS was added to enhance the 
attachment of the crypts. After that only 1% of FCS was used to reduce the amount of 
fibroblasts. The growth of fibroblasts was additionally inhibited by light trypsinization 
(0.025% Trypsin-EDTA for 2-3 min at 37°C, every 2 days). The epithelial nature of the 
culture was confirmed by detecting cytokeratin by immunofluorescence staining with the 
anti-pan cytokeratin antibody, clone C11 (C2931; Sigma-Aldrich) as described by Hoey 
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et al. 2003 and Kaushik et al. 2008. A monoclonal anti-vimentin antibody (clone V9) 
(V6389; Sigma-Aldrich) was used to detect fibroblasts in the cell culture.  
5.2.2 Generation of bovine intestinal tissue explants  
Three Holstein-Friesian calves (+12 months old), seronegative for EspA, EspB and 
intimin, were euthanized and tissues from the ileal Peyer’s patches and the RAJ were 
isolated. The tissues were cut in pieces of 1 cm² and washed using ice-cold sterile PBS 
(2°C, pH 7.4). Subsequently, the pieces were immersed with cold Roswell Park Memorial 
Institute (RPMI) 1640 Medium (Thermo Fisher Scientific) during 30 minutes. Then, the 
tissues were placed with the mucosal side up on biopsy foam pads (Leica Biosystems, 
Nussloch GmbH, Germany) in 6-well tissue culture plates (Sigma-Aldrich) with 5 ml 
RPMI 1640 medium per well and incubated at 37°C, 5% CO2.  
5.2.3 Inocula: E. coli O157:H7 strains, bovine lactoferrin and purified Stx2 
Two bovine EHEC field isolates, strain 147 (O157:H7, Stx2+) and strain 220 
(O157:H7, Stx1+/Stx2+), and one E. coli isolate of human origin (strain NCTC12900; 
O157:H7, Stx-; Dibb-Fuller et al. 2001) were used. The bacteria were grown overnight in 
Luria-Bertani (LB) broth with aeration (200 rpm) at 37°C, harvested by centrifugation 
(11,337 x g, 5 min, 4°C), and re-suspended in DMEM.  
Bovine lactoferrin (bLF) with 92% purity and 16% iron saturation (Ingredia 
Nutritional, Arras, France) derived from bovine milk, was used. Purified Stx2 was 
obtained from Toxin Technology Inc (Sarasota, USA) with a purity of 50 %. 
5.2.4 Incubation of primary rectal epithelial cell cultures or tissue explants with 
Stx2, EHEC and/or bLF 
Rectal epithelial cells were pre-treated with 10 ng/ml of purified Stx2 or 0.05 
mg/ml of bLF, during 24 hours. The next day, all medium was replaced by the 
corresponding medium with or without one of the three bacterial strains (106 CFU/ml 
medium), eventually supplemented with Stx2 (only for the Stx- strain) and bLF 
(triplicates of each condition). After six hours of incubation (37°C; 5% CO2) the 
supernatant was collected and stored at -20°C for further analysis.  
Six explants of the RAJ and Ileal Peyer’s patches in RPMI 1640 medium were 
cultured during six hours with 106 CFU/well of strain NCTC12900 (Stx-), 106 CFU/well 
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of strain NCTC12900 (Stx-) + 0.05 mg/ml bLF, 106 CFU/well of strain NCTC12900 
(Stx-) + 5 ng/ml Stx2, 0.05 mg/ml bLF, or 5 ng/ml Stx2 only. Explants of both tissues 
incubated in RPMI 1640 medium served as controls. After six hours of incubation (37°C; 
5% CO2) the supernatant was collected and stored at -20°C until further analysis with 
cytokine-specific ELISA’s.  
5.2.5 Cytokine analysis 
The IL-6, IL-8 and TNF-α concentrations in supernatants were determined by 
ELISA using either the Bovine IL-6 sandwich ELISA Reagent Kit (detection range 80-
5000 pg/ml; ESS0029; Thermo Scientific), the Bovine IL-8 competitive ELISA kit 
(detection range 50-2000 pg/ml; MBS701879; MyBiosource, San Diego, USA) or the 
Bovine TNF-α sandwich ELISA kit was obtained from RayBio (detection range 125-
8000 pg/ml ELB-TNFa; RayBiotech Inc, Norcross, USA) without modifications to the 
manufacturer’s protocol. The cytokines were chosen because TNF-α and IL-6 together 
with IL-1 are essential in the acute phase response, initiating the innate immune 
response, while chemokine IL-8 causes influx of immune cells at the site of infection, 
which is important for a subsequent adaptive immune response. Standards and 
supernatant of samples from three animals were tested as technical duplicates. A 
standard curve was generated by plotting the average absorbance obtained for each 
standard concentration on the Y-axis vs. the corresponding cytokine concentration on the 
X-axis.  
5.2.5 Statistical analysis 
GraphPad Prism was used for statistical analysis and graphic design of figures. Data from 
cytokine ELISA’s for rectal epithelial cells were analyzed using Tukey’s multiple 
comparisons test to identify statistic significant differences (p<0.05) between conditions 
for each E. coli strain. The data for tissue explants were analyzed using Tukey’s multiple 
comparisons comparing the different conditions per tissue type.  
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5.3 Results 
5.3.1 Cytokine release by rectal epithelial cells 
Following optimization of the primary bovine rectal epithelial cells cultures (Figure 
5.1), the cultures were used as an in vitro model for studying the interaction of Stx2, bLF 
and E. coli O157:H7 strains with bovine primary epithelial cells. 
 
Figure 5.1: Microscopic pictures of the RAJ. From left to right: (A) Rectal crypts (SEM); (B) Enzymatic digestion 
of rectal crypts (LM); (C) Monolayer of rectal epithelial cells after digestion with collagenase (LM). 
 
We determined the cytokine concentrations in the supernatants using IL-6, IL-8 
and TNF-α specific ELISAs (Figure 5.2).  
Incubation with E. coli O157:H7 strains reduced the IL-6 secretion in the 
supernatants compared to control cells (which were set at 100%), while pretreatment and 
supplementation with bLF increased IL-6 levels above the control cells. Only pretreating 
the cells with bLF partially restored the IL-6 concentration. Pretreating the cells with 
Stx2 on the contrary decreased the IL-6 secretion when subsequently inoculated with 
bacterial strains, which also produced Stx. Supplementing the Stx- strain with Stx2 after a 
pretreatment with Stx2 diminished the IL-6 levels below the detection limit.  
Only the E. coli O157:H7 Stx1+Stx2+-strain clearly reduced IL-8 levels and 
pretreatment with Stx2 could not aggravate this reduction. An increase in IL-8 was 
observed when the Stx2+-strain was pretreated with Stx2. Furthermore, bLF was unable 
to restore IL-8 concentrations and even reduced it to the lowest levels. The IL-8 levels for 
the Stx- strain were comparable in all Stx2 and bLF groups. 
TNF-α levels were increased by the Stx- strain and after pretreatment with Stx2 and 
bLF for all strains. Inoculation with Stx+ strains decreased the TNF-α level to below 
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detection levels as treatment with bLF did. The effects of the Stx- strain with and without 
pretreatment with Stx2 on TNF-α were comparable to the Stx+ strains.  
In conclusion, incubation with Stx+ strains could reduce IL-6 and TNF-α 
concentrations, whereas for IL-8 this was only the case for the double Stx + strain. 
Pretreatment with Stx2 increased the effect on IL-6 but reduced the effects on IL-8 and 
even reverted the effect on TNF-α. Effects of bLF seem to be independent of the strains 
used. Pretreatment of cells with bLF reduced the decrease in IL-6, but not in IL-8, 
whereas it enhanced TNF-α production induced by the Stx+ strains. However, adding 
bLF also to the bacterial strains, restored IL-6 completely, had no additional effect on IL-
8 and reduced TNF-α below the detection limit. The effect of bLF on IL-6 might be 
consistent with the local mucosal IgA response following rectal bLF treatment of calves 
rectally colonized with O157:H7 E. coli (Rybarczyk et al. 2015). 
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Figure 5.2: Cytokines secreted in supernatant of rectal epithelial cells after incubation with Stx2 or bLF. Stx2 
inhibited the release of IL-6 and IL-8, while bLF partly restored the release of IL-6 and TNF-α. Data are presented 
as % values relative to the cytokine concentration in untreated cultures (set at 100%). Conditions decribed before / 
indicate pretreatment and after / treatment together with inoculation of the strain. Missing values are caused by 
concentrations below the detection limit of the ELISA. Error bars indicate standard deviations. ND indicates 
conditions that were not determined (only tested for the E. coli O157:H7 (Stx-) strain). Significant differences were 
indicated with *(*: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001) 
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5.3.2 Cytokine release by bovine intestinal explants 
 
Although EHEC directly interact with mucosal epithelial cells, immune cells in 
close proximity to the epithelum might also influence the innate immune response. 
Therefore we assessed the effect of a Stx- E. coli strain, Stx2 and bLF on tissue culture 
explants. Six bovine intestinal explants of I+PP and the RAJ were cultured during six 
hours in the presence of E. coli O157:H7 (Stx-), E. coli O157:H7 (Stx-) + Stx2, E. coli 
O157:H7 (Stx-) + bLF, bLF, and Stx2. The IL-6, IL-8 and TNF-α production was 
determined by cytokine-specific ELISA’s (Figure 5.3).  
In contrast to the rectal epithelial cell culture, where all three cytokines were 
reduced by adding Stx2 to the Stx- E. coli strain, the cytokine levels did not change in 
culture supernatant of RAJ. Furthermore, adding bLF to the Stx- E. coli strain only had a 
minor effect. Whereas the bacteria non-significantly increased IL-6 and non-significantly 
reduced TNF-α, bLF seemed to normalize the concentration of both cytokines to basal 
levels (= 100%; control tissues incubated in cell medium). However, for IL-8 the opposite 
was observed. The infection slightly increased the IL-8 levels, but bLF increased IL-8 
levels almost two-fold. The effects of bLF treatment are opposite to what was observed 
for rectal epithelial cells, suggesting an effect of immune cells in the complex tissue 
environment of explants.  
For the I+PP explants, no effects were seen on levels of IL-8 and TNF-α, whereas 
IL-6 was reduced by infection with the Stx- E. coli strain in the presence or absence of 
Stx2. Adding bLF to the Stx- E. coli strain slightly increased the concentration. 
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Figure 5.3: Release of IL-6, IL-8 and TNF-α from RAJ (n=6) and ileal Peyer’s patches (I+PP) explants (n=6). The 
IL-6 and IL-8 concentration in RAJ and IL-8 concentration in I+PP was increased, but IL-6 decreased in the I+PP 
as a consequence of the E. coli O157:H7 (Stx-) infection. bLF restored IL-6, but overstimulated IL-8 secretion. The 
TNF-α level was lowered in the RAJ but slightly increased in the I+PP upon E. coli O157:H7 (Stx-) infection. Data 
are presented as % values relative to cytokine concentrations in supernatant of untreated explants (set at 100%). Error 
bars indicate standard deviations. Significant differences between conditions per tissue type were not found.   
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5.4 Discussion 
Our data demonstrate that the immune system of calves infected with E. coli 
O157:H7 can be suppressed after a first infection (Chapter III) and that bLF could have a 
positive effect by enhancing the protective immunity of animals against E. coli O157:H7 
colonization (Rybarczyk 2016). To gain more insight in the possible mechanisms of bLF 
and the effect on the epithelium and more complex tissues, we performed in vitro 
experiments using primary rectal epithelial cells and tissue explants.  
Human colon epithelial cells are to be programmed to provide a set of signals for 
the activation of the mucosal inflammatory response in the earliest phases after microbial 
invasion, by upregulation of IL-8 and TNF-α as a response to infection with 
enteroinvasive E. coli (Jung et al., 1995). This raised the question if this could be 
confirmed for bovine rectal epithelial cells and EHEC. Therefore, we investigated the 
cytokine release of bovine primary rectal epithelial cells. We focused on the release of IL-
6, IL-8 and TNF-α because these cytokines are known to play key roles in the early phase 
of the immune defence against bacterial pathogens. Hereafter, we investigated the 
cytokine release of tissue explants of the RAJ and I+PP to complement our data from the 
RNA-Seq experiment. These tissue explants form a complex environment in which 
mucosal epithelial cells interact with lymphocytes and antigen presenting cells.  
IL-6 is produced by various cell types as T-cells, B-cells, dendritic cells, 
macrophages and monocytes (Mihara et al. 2012) and is one of the most important 
cytokines produced in the intestinal mucosa during inflammation because of its 
proinflammatory and anti-inflammatory effects (Pritts et al. 2002) by decreasing the effect 
of TNF-α and inducing epithelium repair (Kuhn et al. 2014; Scheller et al. 2014). IL-6, 
together with IL-1 are essential in the acute phase response, initiating the innate immune 
response (Striz et al. 2014). IL-6 is required for antibody production by B-cells and is 
involved in proliferation and differentiation of helper T-cells. IL-6 also promotes IL-4 
induced TH2 differentiation and inhibits IL-12 induced TH1 differentiation and is involved 
in TH17 induction (Mihara et al. 2012). It is important for inducing production of IgA by 
B-cells (Macpherson et al. 2008), and is known to enhance IgA secretion (Mowat 2003). 
bLF might modulate the host immunity by affecting this IL-6 release. Only in RAJ tissue 
explants, we detected an increase in IL-6 upon bacterial exposure, which indicates the 
protective effect of IL-6 against pathogenic threats. In contrast, rectal epithelial cells and 
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I+PP explants showed a reduction in IL-6 concentration. The opposite effect on IL-6 
concentration between RAJ explants and rectal epithelium indicates that immune cells, 
which are only present in the complex explants, play a role. The effect in the I+PP is 
parallel to our data from Chapter III, showing a suppression of proinflammatory immune 
responses. The increase of IL-6 in RAJ explants effect was less pronounced when bLF 
was added to the bacteria, suggesting an attenuation of the immune response by bLF. 
This is congruent with a study in the human monocytic cell line THP-1 in which bLF 
suppresses the release of IL-6, as a reaction on the addition of bacterial LPS to the cell 
medium (Mattsby-Baltzer et al. 1996). This effect of bLF is due to a decreased LPS-
induced binding of NF-κB to the TNF-α promoter, which reduces the IL-6 level 
(Haversen et al., 2002). Also in I+PP explants, bLF seemed to revert IL-6 secretion 
towards baseline levels suggesting a normalization of the immune response. A similar 
phenomenon was described in a study demonstrating the effect of bLF on immune cells. 
Treatment with bLF resulted in an expression of IL-6, IL-1, IL-18 and TNF-α that was 
restored to the baseline (Elass et al. 2002; Legrand & Mazurier 2010). We observed that if 
bLF was added to E. coli O157:H7 or used as a pretreatment, the effect of the bacteria 
was less pronounced. This could be due to the immunomodulating effect but also to the 
bactericidal effect of bLF.  
IL-8 is a chemokine that causes influx of immune cells, mainly neutrophils but also 
T-cells, at the site of infection which is important for a subsequent adaptive immune 
response (Palomino & Marti 2015). EHEC can induce in vitro a potent proinflammatory 
response in the intestinal epithelium by secretion of IL-8 (Dahan et al. 2002). This 
secretion is due to the involvement of MAPK, AP-1, and NF-κB signalling pathways. 
Also EAEC can induce IL-8 secretion by intestinal epithelial cells in a rapid way by 
contact with flagellin (Steiner et al., 2000). bLF can counteracted this pathway as it 
inhibits the flagellin-induced activation of the NF-κB pathway (Inubushi et al. 2012). In 
the present study, RAJ tissues showed slightly increased IL-8 levels for all six E. coli 
O157:H7 (Stx-) inoculated tissues, comparable to the results of Dahan et al. (2002) and 
Steiner et al. (2000). Also for ovine I+PP explants induction of IL-8 by E. coli O157:H7 
infection was demonstrated (Atef Yekta 2011). Stx2 and bLF increased IL-8 levels even 
more. That Stx2 can induce IL-8 is not unexpected since studies using a human colonic 
epithelial cell line (Hct-8) showed that the active Stx A-subunit is capable of increasing 
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IL-8 (Thorpe et al. 1999). Less expected was the increase of IL-8 by bLF. This occurred 
when added to RAJ but also to I + PP.  
The proinflammatory role of TNF-α is important in the host immune response to a 
number of microbial pathogens, including viruses, bacteria and parasites. It can be 
induced upon stimulation with bacterial LPS (Pawlaczyk et al. 2008). TNF-α is produced 
by activated monocytes, macrophages, lymphocytes and epithelial cells in response to an 
infection (Gardam et al. 2003; Jung et al. 1995). Aderka et al. (1989) has shown that IL-6 
can inhibit the TNF-α production causing an anti-inflammatory effect on the immune 
system. The inhibitory action of IL-6 on TNF-α production is consistent with a 
predominantly anti-inflammatory role of IL-6 in the intact organism. In rectal epithelial 
cells, we observed an increase in TNF-α whereas a non-significant decrease was observed 
for the RAJ tissue. These opposite results again indicate a possible effect of immune cells 
which are only present in the RAJ tissue. This effect might be the result of partial 
inhibition of TNF-α secretion by a bacterial protein, as has been described for some 
enteropathogenic E. coli or Yersinia enterocolitica strains (Wilson et al. 1998).  
A difficulty of this study is the fact that we could only investigate the cytokine levels 
after six hours of incubation with E. coli O157:H7, as longer incubation times are not 
possible due to bacterial overgrowth in cell and tissue cultures and degradation of 
explants. Analyzing later time points might affect the outcome since kinetics are 
important for cytokine effects. We investigated protein levels in supernatants which 
probably does not change so quickly as mRNA (Chapter III). Nevertheless, an added 
value for these data could be confirmation on mRNA level with PCR for different time 
points, taking into account the short stability of mRNA transcripts.  
During the setup of this study, we were able to establish a good procedure for the 
isolation and maintenance of rectal epithelial cells, which was necessary since no 
permanent cell line of bovine rectal epithelial cells is available. This makes future studies 
about the interaction of cells with bLF more attractive.     
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5.5 Conclusions 
Some of the data in this study are in line with suppression of the immune response 
by E. coli O157:H7 as IL-6 and IL-8 levels were found to be reduced in rectal epithelial 
cells and IL-6 levels in I+PP explants. bLF, a well studied immune-modulator, seems to 
restore the affected IL-6 cytokine levels to normal levels, promoting the natural 
homeostasis of the host. It remains unclear if this bLF effect is due to 
immunomodulation of the cells or bactericidal effects.    
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6.1 Abstract  
 
Prevention of enterohemorrhagic Escherichia coli (EHEC) O157:H7 infections and of 
their severe clinical sequelae in humans remain to be a current challenge. Administration 
of bovine lactoferrin (bLF) proved to be effective in clearing EHEC from the bovine 
intestine, an important EHEC reservoir, suggesting that bLF may also be beneficial in 
human application against EHEC infections. To estimate the biological safety of this 
approach, we analysed the effects of bLF on the main EHEC virulence factor, Shiga 
toxin (Stx). We quantified the release of Stx 1 and 2 from two O157:H7 EHEC strains 
(Stx1+Stx2+ and Stx2+ producing, respectively) cultured in the presence of bLF using 
ELISA assays and assessed cytotoxic effects of bLF on Vero cells and on co-cultures of 
EHEC on Vero cells. Effects of bLF on the stability of Stx2 were investigated using 
Western blotting. ELISA results indicate a bLF concentration-dependent decrease of 
active, cell-free Stx2, but not Stx1 in EHEC cultures. High concentrations (100 and 50 
mg/ml) of bLF resulted in significantly reduced (p<0.05) metabolic activity rates of Vero 
cells, whereas a concentration of 10 mg/ml bLF was considered non-toxic for Vero cells. 
At concentrations of 1 or 0.1 mg/ml, bLF mitigated the verocytotoxicity of EHEC strains 
in a co-culture model up to 48 hours after inoculation. For colonizing bacteria only, 
cytotoxicity could be significantly reduced by 10 and 1 mg/ml bLF during 48 hours. This 
effect of bLF at least partly results from degradation of the Stx2 receptor-binding B-
subunit. 
6.2 Introduction 
 
Because of the potentially severe and long-lasting consequences for affected patients 
and the significant costs for health-care and economy, reduction of enterohemorrhagic 
Escherichia coli (EHEC) in prevalence and numbers at farm level and the mitigation if not 
prevention of EHEC-induced diseases in humans remain to be a current challenge for 
veterinary and human medicine (Elbasha et al. 2000). Every year, several small-scale 
outbreaks of EHEC O157:H7 are reported worldwide, repeatedly resulting in the need to 
hospitalized patients. In 2011, Germany and other European countries experienced an 
unprecedented outbreak caused by a highly virulent E. coli strain, which had acquired the 
capability of Shiga toxin (Stx) production by gene transfer. Subsequent withdrawal of 
food from the market and export bans had a major negative economic impact (Karch et 
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al. 2012). Clinical manifestations of human EHEC infections such as diarrhea, 
hemorrhagic colitis (HC) and, most importantly, the hemolytic uremic syndrome (HUS) 
leading to chronic renal failure or even death of the patient, pose a significant burden for 
the health care system (Sockett et al. 2014). Since the use of antibiotics is contra-
indicated, because of the risk to aggravate the disease due to a higher release of Stx by the 
bacteria, treatment of infected patients is limited to supportive care. Consequently, there 
is an urgent need for curative therapies as well as effective prevention measures (Spacek 
et al. 2004). 
Innovative strategies for effectively reducing EHEC carriage in ruminants would 
diminish the public health risk. Several studies were performed in cattle, the main 
reservoir of EHEC, in order to gain more insight into the prevalence and the colonization 
pattern of the bacteria. EHEC do not cause severe disease in cattle due to the distinct 
tissue distribution pattern of Stx receptors in the kidneys and the absence of receptors on 
blood vessels (Hoey et al. 2002). Shedding by cattle is intermittent, but the infection 
persists on farms in animals and their environment (Wells et al. 1991). A seasonal effect 
with consistently higher detection rates during spring and summer (Chapman et al. 1997) 
makes prevalence studies complex and hampers the development of reduction strategies. 
Different research groups have tried to reduce the environmental contamination by 
reduction of fecal shedding. Vaccination (Dziva et al. 2007; van Diemen et al. 2007; Van 
Donkersgoed et al. 2005), probiotic treatment (Brashears et al. 2003), bacteriophage 
administration (Sheng et al. 2006) and diet modification (Callaway et al. 2011) were of 
only limited success, however. A study using the host-specific iron-binding glycoprotein 
bovine lactoferrin (bLF) in ruminants was the only one showing a complete clearance of 
the bacteria from the host (Kieckens et al. 2015). The superior effect of bLF compared to 
other strategies might be due to the multiple antibacterial activities of the protein. 
Lactoferrin sequesters iron that is an essential growth factor for microorganisms (Otto et 
al. 1992). It disrupts bacterial type III secretion systems (Ochoa and Clearly, 2004) and 
destabilizes the outer membrane of Gram-negative bacteria resulting in the release of 
bacterial lipopolysaccharides (LPS; Ellison et al. 1988). However, this is not followed by 
an increase in proinflammatory cytokine secretion due to the property of bLF to bind 
LPS (Elass-Rochard et al. 1998) and the soluble LPS-receptor CD14 (Haversen et al. 
2002). Since bLF administration proved to be a promising approach to clear EHEC from 
the ruminant gut, it is reasonable to assume that it can also be used to treat EHEC 
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infections in humans or prevent infections in persons at risk of exposure. Of note, bLF 
was already classified as a safe food supplement for human use (EFSA, 2012). However, 
its use in the context of human EHEC infections can only be considered if bLF, a natural 
anti-microbial agent, does not lead to an increased production and release of Stx, a 
phenomenon well known to occur in EHEC-infected patients treated with antibiotics 
(Zhang et al., 2000).  
 
Two main types of Stx are produced by EHEC, namely Stx1 and Stx2. The stx2 
gene is frequently detected in human isolates, while the stx1 gene is more commonly 
found in isolates of animal origin (Boerlin et al. 1999). Epidemiological data suggests that 
Stx2+ strains are more likely to cause severe disease in humans than those producing only 
Stx1 or a combination of both types (Fuller et al. 2011). All Stxs possess an AB5 
molecular configuration in which the enzymatically active A subunit (molecular mass of 
approximately 32 kDa) is non-covalently associated with a pentamer of identical B 
fragments (molecular mass of 7.7 kDa, each), responsible for binding to the cellular 
receptor (Johannes & Römer 2010). The A subunit can be cleaved by bacterial proteases 
(Samuel & Gordon 1994) as well as by the host protease furin into the A2 fragment and 
the catalytically active A1, which then are still held together by a disulfide bond 
(Fagerquist & Sultan 2010).  
To estimate the biological safety of bLF with respect to administration to EHEC-
infected human patients, we analysed the effects of different bLF concentrations on: (1) 
Stx1 and Stx2 release by two EHEC strains of the most common EHEC-serotype 
O157:H7, (2) cytotoxicity of Stx2 for Vero cells, (3) cytotoxicity for Vero cells of treated 
EHEC, (4) cytotoxicity for Vero cells of adherent EHEC bacteria and finally (5) the 
stability of Stx2 taking into account the serine endopeptidase activity of bLF.  
6.3 Methods 
6.3.1 Cell culture.  
 
Vero cells were grown in Minimum Essential Media (MEM; Thermo Fisher 
Scientific, Erembodegem, Belgium) supplemented with 10% FCS, 1% L-glutamine, 1% 
penicillin/streptomycin, and 1% kanamycin. Subsequently, the cells were seeded into 96-
well plates (5x104 cells/well in 100 µl culture medium) and allowed to form a monolayer 
during 24 hours.  
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6.3.2 Bovine lactoferrin.  
 
Bovine lactoferrin (bLF) with 92% purity and 16% iron saturation (Ingredia 
Nutritional, Arras, France), derived from bovine milk, was used in this study.  
6.3.3 Bacterial organisms.  
 
Two bovine EHEC field isolates, strain 147 (O157:H7, Stx2+) and strain 220 
(O157:H7, Stx1+/Stx2+), and one E. coli isolate of human origin (strain NCTC12900; 
O157:H7, Stx-; Dibb-Fuller et al. 2001) were used. The bacteria were grown overnight in 
Luria-Bertani (LB) broth with aeration (200 rpm) at 37°C, harvested by centrifugation 
(11,337 x g, 5 min), and re-suspended in medium to the desired concentration.  
6.3.4 Effect of bLF on Stx release by EHEC strains.  
 
All E. coli O157:H7 strains were grown overnight as described previously and 
subsequently diluted in LB broth to a concentration of 1x106 CFU/ml. The LB broth was 
supplemented with 10, 1, 0.1 or 0 mg/ml bLF and cultures were placed in a shaking 
incubator with aeration (200 rpm, 37°C). Supernatant was collected after 6, 24, 48 and 72 
hours of incubation and was analyzed using the Novitec® Verotoxin sandwich ELISA 
(HISS Diagnostics, Freiburg, Germany) and two in house ELISA assays. The 
commercial ELISA, which cannot distinguish between Stx1 and Stx2, was performed as 
described by the manufacturer. Briefly, diluted samples (1:3 in PBS, pH 7.4) were added 
in duplicate to ELISA plates pre-coated with polyclonal Stx antibodies and incubated (30 
min). After washing, reagent 1, containing a monoclonal anti-Stx antibody cocktail was 
added and the plate was incubated at room temperature (30 min). The plates were 
washed and reagent 2, containing an anti-mouse horseradish peroxidase conjugated 
antibody, was added and the plates were incubated for another 30 min at room 
temperature. After a washing and subsequent rinsing step with distilled water, the 
substrate solution, containing chromogen tetramethylbenzidine (TMB; Life Technologies 
GmbH, Darmstadt, Germany) and peroxide was added. The absorbance was measured 
at 450 nm. The values were presented as Standard% (Std%) values with standard controls 
included in the kit used as standard. The background signal, i.e. the signal generated by 
supernatants of the NCTC12900 strain (Stx-), was always below 2 Std%. Supernatants 
sampled after 6 hours incubation were also tested using two in-house ELISA assays for 
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detection of different Stx1 and Stx2 variants modified from Segura-Alvarez et al. (2003). 
Briefly, microtiter plates were coated overnight at 4°C with hydatid cyst fluid from 
Echinococcus granulosus infected sheep in sodium carbonate buffer (pH 9.5). Thereafter, the 
plates were washed with PBS-Tween (0.05% Tween®20 in PBS, pH 7.4) and non-specific 
binding sites were blocked using blocking buffer containing 1% milk powder in sodium 
carbonate buffer (pH 9.5) for 1 h at 37°C. The plates were washed again with PBS-Tween 
and incubated for 2 hours at 37°C with samples (duplicates, 1:3 diluted in PBS-Tween). 
After washing with PBS-Tween, horseradish peroxidase conjugated antibodies against 
either Stx1 (clone VT109/4-E9b, α-Stx1 B subunit; SIFIN Institut für Immunpräparate & 
Nährmedien GmbH, Berlin, Germany) or Stx2 variants (clone VT135/6-B9, α-Stx2 A 
subunit; SIFIN) were added (1:1000 diluted in PBS-Tween; 1 h, 37°C). Plates were 
washed with PBS-Tween and the TMB chromogen solution was added (15 min). Finally, 
stop solution (0.5 M H2SO4) was added. The optical density was measured at test 
(450 nm) and reference wavelengths (550 nm) and the OD values for all samples 
calculated as difference between test and reference value. The real value was calculated 
as mean OD value of the sample minus mean OD value of blank. Standardization was 
performed using standard controls and values were presented as Std% using recombinant 
Stx1 toxoid (1:675 diluted in PBS-Tween;(Kerner et al. 2015)) and recombinant Stx2e 
toxoid (1:18225 diluted in PBS-Tween; kindly provided by Prof. Dr. R. Bauerfeind, 
Justus-Liebig-University Gießen, Germany) either as positive or as negative control in 
the in-house ELISA assays. 
6.3.5 Bovine lactoferrin cytotoxicity assay.  
 
To check the putative cytotoxic effect of bLF, Vero cells were seeded in 96-well 
plates (Greiner Sigma-Aldrich, Diegem, Belgium) at a concentration of 5.104 cells/well in 
100 µl culture medium and, after overnight incubation at 37°C and 5% CO2, exposed to 
final concentrations of 100, 50, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 and 0 mg/ml of 
bLF in 200 µl culture medium. After 6, 24, 48 and 72 hours cell viability was assessed by 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
measuring mitochondrial activity (Mosmann 1983). Twenty microliter MTT (5 mg/ml, 
Sigma-Aldrich, Diegem, Belgium) in Hanks’ balanced salt solution (Thermo Fisher 
Scientific, Erembodegem, Belgium) was added to each well and after 4 h of incubation at 
37°C and 5% CO2, the MTT solution was removed and 200 µl/well DMSO in ethanol 
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(1/1 v/v) was added. The plates were shaken for 15 min at 450 rpm to dissolve the 
formazan crystals and subsequently analyzed spectrophotometrically at a test wavelength 
of 590 nm (OD1) and a reference wavelength of 635 nm (OD2). Final optical densities 
obtained from formazan formation were presented as OD1 minus OD2. The experiments 
were conducted in triplicates and each experiment was repeated three times. 
6.3.6 Influence of bLF on toxin release by freshly inoculated EHEC bacteria or by EHEC 
bacteria attached to Vero cells. 
 
The influence of bLF on Stx release by freshly inoculated EHEC bacteria was 
examined as follows: Vero cells were seeded in 96-well plates as described above. The 
following day, bLF (10, 1, 0.1 and 0 mg/ml, respectively) was added in 100 µl cell 
medium (without antibiotics) together with the bacteria (106 CFU/well) or partially 
purified Stx2 (5 ng/ml; Toxin Technology Inc, Sarasota, USA). Cells incubated with 
bacteria only served as controls. After 24, 48, and 72 hours, bacteria and cell debris was 
removed by thorough washing with culture medium and the metabolic activity of the 
remaining Vero cells, which is indirectly linked to the Stx release, was measured by MTT 
assay as described above. Data was calculated as percent metabolic activity relative to 
cells incubated in cell culture medium only (values set to 100%) and blank wells (values 
set to 0%). 
Since EHEC colonize the gut and bLF has to prevent cytotoxic effects of colonizing 
bacteria, a similar experimental set up was used to test the influence of bLF on EHEC 
bacteria adhering to Vero cells (Tahamtan et al. 2011). Hereto, the bacterial strains (106 
CFU/well) were allowed to attached for 6 h, after which non-adherent bacteria were 
removed and bLF (10, 1, 0.1 and 0 mg/ml, respectively) was added to different wells. 
Cells incubated with bacteria only served as controls. Again, Stx release was measured 
indirectly by performing an MTT assay at 24, 48, and 72 hours after washing off of 
bacteria and cell debris. Data was calculated as percent metabolic activity as described 
above. All these experiments were conducted in triplicates and each experiment was 
repeated three times.  
6.3.7 Effect of bLF on Stx2.  
 
To determine if bLF cleaves Stx2, SDS-PAGE and Western blotting were used. Ten 
µg/ml of Stx2 were incubated overnight with 1000, 100, 10, 1 or 0 µg/ml bLF in PBS 
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(pH 7.4, 37°C), while gently shaking. Then the samples were heated (5 min, 65°C) or 
treated with 0.01 M β-mercaptoethanol (5 min, 95°C) to reduce disulfide bonds, and then 
run on a 12% SDS-PAGE (45 min, 200 V). Western blotting was performed (350 mA, 90 
min) and blots were developed with monoclonal mouse anti-Stx2 A-subunit antibody 
(1:500; Santa Cruz Biotechnology Inc, Dallas, Texas, USA) or monoclonal mouse anti-
Stx2 B-subunit antibody (1:1000; clone 3C10E10H10, Abcam, Cambridge, UK) and 
rabbit anti-mouse HRP antibody (1:1000; Dako, Heverlee, Belgium). The Pierce ECL 
Western blotting substrate (Thermo Fisher Scientific, Erembodegem, Belgium) was used 
for detection.  
6.3.8 Statistical analysis.  
 
GraphPad Prism was used for statistical analysis and graphic design of figures. 
Data on the influence of bLF on Stx production were analyzed using Tukey’s multiple 
comparisons test to identify statistic significant differences (p<0.05) between groups at 
each time point. Results of the survival rate with different concentrations of bLF were 
analyzed using repeated measures one-way ANOVA for multiple comparisons after 
confirmation of Gaussian distribution. Significant differences between groups (p<0.05) 
were determined using a post hoc test with Bonferroni correction. Data on the metabolic 
activity and colonization effect was analyzed using a two-way ANOVA with multiple 
comparisons. Differences were considered significant if p<0.05.  
6.4 Results 
6.4.1 Bovine LF concentration-dependent decrease of Stx in bacterial culture supernatants.  
 
The amount of Stx in bacterial culture supernatant is the result of production and 
secretion by the bacterial strains, but also Stx destruction and/or binding by bLF might 
occur. The Stx concentrations in supernatants of bacterial cultures after 6, 24, 48 and 72 
hours incubation with 10, 1 and 0.1 mg/ml bLF or without bLF (control) are presented 
in Figure  6.1. Ten mg/ml bLF showed the strongest reduction in released Stx. As early 
as 6 h post inoculation of cultures with strain 147 (Stx2+), presence of 10 mg/ml bLF 
resulted in significant and sustained reduction of Stx concentrations compared to the 
control whereas cultures of strain 220 (Stx1+/Stx2+) only showed this effect beginning 24 
hours post inoculation. One tenth of the bLF concentration (1 mg/ml) exhibited similar 
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effects on strain 147 (Stx2+), but reduced amounts of cell-free Stx in cultures of strain 220 
(Stx1+/Stx2+) at 24 hours only. The effect of 0.1 mg bLF was even less pronounced but 
became significant for strain 147 (Stx2+) at 24 hours. Using ELISA for specific detection 
of Stx1 and Stx2 variants, no Stx could be detected in supernatants of strain NCTC12900 
(Stx-; data not shown). Supernatants of strain 220 (Stx1+/Stx2+) sampled at 6 hours 
contained higher Stx1 concentrations with 10 mg/ml bLF than with lower bLF doses 
suggesting increased release (bacterial lysis) or production of Stx1 (Figure 6.2). However, 
1 and 0.1 mg/ml bLF tended to dose-dependently decrease cell-free Stx1. This effect was 
more pronounced for Stx2 as its concentrations were below the detection limit when 
bacteria were cultured in the presence of 10 and 1 mg/ml bLF. Strain 147 (Stx2+) did not 
show a release of Stx2 into the supernatant when tested by the specific ELISA (data not 
shown). Subsequent PCR tests (performed at the Scientific Institute of Public Health, 
Brussels, Belgium) revealed that strain 147 encodes for the Stx2c variant, which is not 
detected by the monoclonal antibody used here and known to recognize Stx2a but not 
Stx2c, d, and g (N. Deininger, S. Barth and L. Geue, personal communication). 
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Figure 6.1: Standard % values of Stx concentration in supernatant of bacterial broth cultures after 
incubation with different bLF concentrations determined by a commercial Stx-specific ELISA 
(Verotoxin ELISA). Data is presented as percent standard relative to standards included in the kit. Error 
bars indicate standard deviations. Significant differences were indicated with *(*: p ≤ 0.05; **: p ≤ 0.01; 
***: p ≤ 0.001; ****: p ≤ 0.0001). 
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Figure 6.2: Standard % values for Stx1 and 2 concentrations in supernatant of strain 220 (Stx1+/Stx2+) 
cultured for 6 hours in the presence of different concentrations of bLF (results of in-house ELISA 
assays). Data is presented as percent standard relative to rStx1 toxoid and rStx2e toxoid used either as 
positive or and as negative control, respectively. Results are means of technical duplicates after 
standardization.  
 
6.4.2 High concentrations of bLF exert cytotoxicity on Vero cells.  
 
Bovine LF significantly reduced the metabolic activity (%) of Vero cell cultures 
from 48 hours incubation onwards (Figure 6.3; other time points not shown). This was 
dose-dependent as 100 mg/ml reduced the metabolic activity to 41.4%, whereas 50 
mg/ml resulted in 64.6% activity. The reduction was significantly different (p<0.05) from 
control cultures (0 mg/ml bLF) for concentrations of 50 mg/ml bLF and above. The 
highest bLF concentration of lactoferrin considered non-toxic for Vero cell cultures was 
10 mg/ml. 
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Figure 6.3: Mean metabolic activity of Vero cells in cell medium supplemented with different 
concentrations of bLF. Data is presented as percent metabolic activity relative to cells incubated in cell 
culture medium only (values set to 100%) and blank wells (values set to 0%). Results are means of 3 
biological replicates with n=3. Error bars indicate standard deviations. Significant differences compared to 
the control cultures without bLF were indicated with *. 
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6.4.3 Bovine LF can reduce verocytotoxicity of EHEC when co-cultured with Vero cells.  
 
In the first set-up Vero cells were grown to confluence for 24 hours whereafter 
different concentrations of bLF together with the O157:H7 E. coli strains were added. The 
metabolic activity of the Vero cells after different times of incubation with 106 CFU/ml of 
bacteria with or without bLF is presented in Figure 6.4. Although 0.1 mg/ml bLF had 
limited effects on the amount of cell-free Stx in bacterial cultures, it partially protected 
Vero cells co-cultured with each of the EHEC strains from cytotoxic effects. This effect 
was significant for strain 220 (Stx1+Stx2+) after 24 hours of incubation and for strain 147 
(Stx2+) after 48 and 72 hours of incubation. Presence of 1 mg/ml bLF also induced a 
significantly higher metabolic activity at 24 hours of incubation with strain 220 
(Stx1+Stx2+), but not with strain 147 (Stx2+), nor at any other time point. Ten mg/ml 
bLF even seems to increase cytotoxicity for both EHEC strains which was particularly 
evident after 24 hours.  
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Figure 6.4: Metabolic activity of Vero cells following incubation with 10, 1 or 0.1 mg/ml bLF in 
combination with EHEC strain 220 (Stx1+Stx2+) and strain 147 (Stx2+). Data is presented as percent 
metabolic activity relative to cells incubated in cell culture medium only (values set to 100%) and blank 
wells (values set to 0%). Results are means of 3 biological replicates with n=3. Error bars indicate standard 
deviations. The data points in the rectangles are significantly different from the controls. 
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When Vero cells were incubated with purified Stx2, 0.1 mg/ml bLF did not 
mitigate verocytotoxic effects. An increased toxicity was observed for 1 and 10 mg/ml 
bLF although this effect was less pronounced for 10 mg/ml (data not shown).  
Vero cells grown in presence of strain NCTC12900 (Stx-) showed a impaired metabolic 
activity when incubated with the three concentrations of bLF and this was dose 
dependent after 48 and 72 hours of incubation (data not shown).  
 
To mimic potential effects of bLF during intestinal EHEC colonization, an 
experiment was set-up in which bacteria were allowed to adhere for 6 hours to Vero cells, 
whereafter non-adhering bacteria were washed away before bLF was added (Figure 6.5). 
Interestingly, this experimental set-up led to a clear reduction of cytotoxicity by different 
concentrations of bLF until 48 hours of incubation. Especially for strain 220 (Stx1
+
Stx2+) 
a significantly higher metabolic activity was observed at 24 hours for 10, 1 and 0.1 
mg/ml bLF and at 48 hours for 10 and 1 mg/ml bLF. This effect was less pronounced for 
strain 147 (Stx2+). Here, a significantly higher metabolic activity was seen at 48 hours for 
all three bLF concentrations.  
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Figure 6.5: Metabolic activity of Vero cells colonized with the EHEC strains and incubated with 
different concentrations of bLF. Data is presented as percent metabolic activity relative to cells incubated 
in cell culture medium only (values set to 100%) and blank wells (values set to 0%). Results are means of 3 
biological replicates with n=3. Error bars indicate standard deviations. The data points in the rectangles are 
significantly different from the controls. 
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6.4.4 Proteolytic effect of bLF on Stx2.  
 
To investigate if the protease activity of bLF is able to degrade Stx2, we performed 
SDS-PAGE and Western blotting (Figure 6.6). While the A subunit can be detected at a 
molecular weight of almost 31.4 kDa in non-reducing conditions, it mainly presents as a 
27 kDa band under reducing conditions indicating the cleavage of the disulfide bound 
allowing the A1- and A2-fragment to migrate independently with only the A1-fragment 
being visualized by the monoclonal antibody (upper part of the figure). The presence of 
increasing concentrations of bLF led to greater band intensities of the A-subunit under 
both conditions pointing to some stabilizing effect of bLF under these experimental 
conditions. By stark contrast, incubation of Stx2 with bLF at all concentrations applied 
drastically reduced the band intensities for B-subunit detection (lower part of the figure) 
under reducing and even totally abolished B-subunit detection under non-reducing 
conditions. 
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Figure 6.6: Stability of Stx2 in the presence and absence of bLF.  
Partially purified Stx2 was incubated for 16 hours at 37°C and sizes and relative amounts of Stx2 subunits 
were assessed by Western blotting after gel electrophoresis under reducing (left lanes) and non-reducing 
conditions (right lanes). In the upper Western blot (A) detection with anti-Stx2-A subunit-antibody, in the 
lower (B) with anti-Stx2-B subunit-antibody was conducted. Molecular weights (kilodalton) are indicated 
on the right. Lane 1: Stx2 + β-mercaptoethanol; Lane 2: Stx2 + 1 mg/ml bLF + β-mercaptoethanol; Lane 
3: Stx2 + 100 µg/ml bLF + β-mercaptoethanol; Lane 4: Stx2 + 10 µg/ml bLF + β-mercaptoethanol; Lane 
5: Stx2 + 1 µg/ml bLF + β-mercaptoethanol; Lane 6: Stx2; Lane 7: Stx2 + 1 mg/ml bLF; Lane 8: Stx2 + 
100 µg/ml bLF; Lane 9: Stx2 + 10 µg/ml bLF; Lane 10: Stx2 + 1 µg/ml.  
 
6.5 Discussion 
 
To our knowledge, this is the first in vitro study investigating the effect of bLF on 
the release and bioactivity of Stx by EHEC. In the past, other in vitro and clinical studies 
have focused on the release of Stx and outcome of patients when antibiotics were used as 
a treatment. In vitro work indicated that both sub-inhibitory and sub-lethal concentrations 
of antibiotics (polymyxin B, trimethoprime/sulphamethoxazole, ciprofloxacin, cefixime, 
and tetracycline) increase the release of toxins in the supernatant of EHEC O157:H7 
cultures (Karmali et al. 1985; Karch et al. 1986; Tittor 2003; Walterspiel et al. 1992). An 
in vitro study on a common EHEC O157:H7 strain and the O104:H4 German outbreak 
strain (2011) showed that therapeutic concentrations of the antibiotics ciprofloxacin, 
meropenem, fosfomycin, gentamycin, rifampicin, and chloramphenicol did not cause 
release of Stx from the O104:H4 strain but did from the O157:H7 strain (Corogeanu et al. 
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2012). Several clinical studies have evaluated the possible benefit or harm of antibiotics 
on the clinical course of E. coli O157:H7 colitis, mainly by estimating their effect on the 
duration of the illness, diarrhoea and/or bloody diarrhoea, on the risk for development of 
HUS or thrombotic thrombocytopenic purpura and on the death rate. Some studies 
associate the administration of antibiotics with higher risk for HUS as well as with longer 
duration of diarrhoea and/or bloody diarrhoea. Patients treated with 
trimethoprim/sulphamethoxazole tended to have longer duration of diarrhoea and 
bloody diarrhoea and were more likely to develop HUS than patients who did not receive 
an antibiotic, although this negative effect was not seen for ampicillin treatment (Pavia et 
al. 1990; Ostroff et al. 1989). Antibiotics affect the release of Stx, but do not cause 
degradation of the toxin. In this study we provide evidence that the receptor binding 
subunit of Stx2 is degraded by bLF. The effect on the enzymatic activity of the degraded 
toxin has to be investigated, but degradation of the B-subunit is likely to prevent binding 
of the toxin to the cellular receptor and subsequent internalization, both being 
prerequisites for the major cytotoxic effects exhibited by Shiga toxins to occur.  
 
In the present study, we used two Stx ELISA assays to quantify Stx. The 
commercial ELISA is a sandwich ELISA using polyclonal anti-Stx 1 and 2 antibodies to 
capture the antigen in the sample. After capturing the antigen, an anti-Stx antibody 
cocktail is added recognizing the bound antigen. The in-house ELISA can distinguish 
between Stx1 and Stx2. Two O157:H7 EHEC strains showed a bLF dose-dependent 
reduction in Stx release in the supernatant which was significant for 10 mg/ml bLF, the 
highest concentration tested in this part of the study. This might be the result of the 
bacteriostatic effect of bLF on the bacteria. In a previous study 1 mg/ml exerted a similar 
bacteriostatic effect than 10 mg/ml in our study (Atef Yekta et al., 2010). The sensitivity 
for bLF is likely strain dependent and we suggest that other factors are also influenced by 
bLF. This is supported by the results of the in-house ELISA assays for strain 220 
(Stx1+Stx2+). Indeed, 6 hours incubation with 10 mg/ml bLF did not reduce the 
concentration of Stx1 in the culture medium, whereas Stx2 became low to undetectable. 
 
Unfortunately, the in-house ELISA assay was unable to detect Stx2 encoded for in 
strain 147 (Stx2+), because that strain harbours the Stx2 c gene that differs from the 
subtype produced by strain 220 (Stx1+Stx2+), Stx2a. Nevertheless, the results of the 
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commercial Stx-specific ELISA showed similar results for both strains supporting the 
hypothesis that bLF can reduce Stx2 production and release.  
 
To confirm that reduction in the amounts of cell-free toxins translates into 
reduction in cytotoxic effects under conditions similar to EHEC colonization of an 
intestinal mucosa, the effect of bLF had to be tested in a cell culture system which 
allowed for measuring toxicity of Stx. An in vitro Vero cell model was used because of the 
sensitivity of this cell line for Stx (Tahamtan et al. 2011). Incubation of Vero cells with 
different bLF concentrations, suggested that concentrations of 10 mg/ml and less 
retained a stable metabolic activity of the cells. However, once used in combination with 
bacterial inoculation of the Vero cells, the 10 mg/ml bLF was seen to reduce the 
metabolic activity. In contrast, 0.1 mg/ml bLF had a positive effect on metabolic activity 
of cells incubated with toxin producing strains for at least 48 hours, even though it did 
not have a consistent effect on the toxin concentration in bacterial culture supernatants. 
One mg/ml bLF significantly reduced toxin concentrations at 24 hours incubation as 
well as it significantly reduced cytotoxicity, suggesting that a daily administration by a 
bolus using a suitable dose might be a valuable strategy for treatment of infected subjects.  
EHEC deploy a type III secretion system to colonize the intestinal mucosa. Previously 
we demonstrated that bLF can reduce attachment of a non-toxin producing O157:H7 
strain to Caco-2 cells (Yekta et al. 2010). Furthermore, treatment with bLF can 
completely clear rectal colonization with strain NCTC (Stx-) used in the present study in 
calves in vivo (Chapter IV). However, in case of colonization with EHEC, toxins might be 
released in close proximity with the mucosa being unavailable for interaction with bLF.  
 
Since results pointed to an effect of bLF on the bioactivity mainly of Stx2, we 
examined if the protein could cleave the toxin. The presence of increasing concentrations 
of bLF led to greater band intensities for detection of the A-subunit suggesting some 
stabilizing effect of bLF under these experimental conditions. As Stx2 was obtained in a 
partially purified form, making it particularly sensitive to residual protease activities by 
contaminating bacterial products in the solution (C. Menge, personal observation), 
addition of hundred-fold excess of protein by addition of 1000 µg/ml of bLF to 10 µg of 
Stx2 may have prevented unspecific proteolytic cleavage of the A-subunit. The results of 
the respective experiment clearly indicated however, that incubation of Stx2 with bLF 
resulted in an effective removal of the B-subunit that could no longer be detected. 
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Destruction of the receptor binding B subunit by bLF may have protective effects like B-
subunit specific antibodies that efficiently protect cells from the detrimental effects of 
Shiga toxins (Stamm et al. 2002). Destruction of the receptor binding B subunit by bLF 
may have similar effects. Although the effects for Stx1 seem to be less pronounced, it 
would be interesting to also analyze the possible proteolytic effect of bLF on Stx1. 
6.6 Conclusions 
 
The results presented here are of major importance for the application of bLF to 
reduce EHEC-carriage in cattle. Indeed, there is evidence that E. coli O157:H7 Stx can 
actively suppress cellular immune responses in cattle what would enable long-term 
colonization (Hoffman et al. 2006). If further in vivo experiments with cattle can confirm 
a reduction or complete clearance of E. coli O157:H7 at farm level, bLF can be 
systematically applied on infected farms on fattened animals before slaughter. Results are 
also encouraging for considering the use of bLF as treatment of EHEC infections in 
humans. In 2012, bLF has been approved by EFSA to be safe for the use as an ingredient 
for food supplements, infant and follow-on formulae, dietetic food for special medical 
purposes and sports nutrition, and for a variety of foods (Efsa, 2012). The therapeutic 
treatment of infected patients with bLF at non-toxic concentrations which are sufficient 
to limit EHEC growth and Stx production and release, at the same time degrading the B-
subunit of still released Stx2, might be a promising strategy worthwhile further 
investigation.   
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The objective of this thesis was to gain insights in modulation of the local immune 
response by E. coli O157:H7 in cattle and to analyse whether and how bovine lactoferrin 
(bLF) could influence this immune response. For this reason, the setup of this thesis was 
divided in four main goals: (1) understanding factors promoting E. coli O157:H7 
colonization in cattle by studying immune responses; (2) investigating modulation of 
systemic immune responses by bLF and reduction of an E. coli O157:H7 infection in 
cattle with bLF; (3) determining the effect of different E. coli strains and bLF or Shiga 
toxin (Stx) on the release of proinflammatory cytokines; (4) exploring possible effects of 
bLF against Stx-positive EHEC strains.  
First, the effect of an E. coli O157:H7 infection on the bovine host was characterized 
by investigating the gene expression in the recto-anal junction (RAJ) and the ileal Peyer’s 
patches (I+PP) in calves that were infected once or twice with E. coli O157:H7 (Stx-) 
compared to calves that were not infected. 
Many studies have described the persistence of E. coli O157:H7 in ruminants like 
cattle and sheep, in observational and experimental settings (Rahn et al. 1997; Cornick et 
al. 2000; Lim et al. 2007; Aktan et al. 2007; Vande Walle et al. 2011; Joris et al. 2013b). 
Both in vitro and in vivo studies in ruminants and case studies in humans have focused on 
many different aspects of the infection with E. coli O157:H7, but none of them described 
the effects of this infection on a genome-wide scale at two important sites in the gastro-
intestinal tractus, like we did in Chapter III. Previous research has aimed at unraveling 
effects of an EHEC infection on individual cell types. Studies using primary human 
colonic epithelial cells and Caco-2 cells showed that H7 flagellin recognition by TLR5 is 
the major factor inducing IL-8 production upon infection (Miyamoto et al. 2006; Fraser-
Pitt et al. 2011). This is found to be a downstream effect as a result of the activation of 
p38 and ERK MAP kinases and the nuclear translocation of the transcription factor NF-
κB (Berin et al. 2002). However, recent studies investigating the bovine TLR5 indicate 
that cattle express a functional TLR5 with different flagellin sensing qualities compared 
to human TLR5, and that other potentially intracellular expressed receptors may play a 
more important role in the bovine system to detect flagellin (Metcalfe et al. 2014, 
Osvaldova et al. 2014). Intestinal epithelial cells like the polarized T84 and HT-29 and 
non-polarized HeLa cells showed a significant increase in IL-8 and TNF production 
during infection with type IV pilus-expressing EHEC-strains (Ledesma et al. 2010). 
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Infection of human T84 and HEp-2 epithelial cells infected with EHEC O157:H7 and 
stimulation with IFN-γ revealed elimination of the IFN-γ-induced Stat1-tyrosine 
phosphorylation and disruption of the inducible protein expression of the Stat1-
dependent gene interferon regulatory factor 1. This results in an impaired host response 
as Stat1 cannot modulate the transcription of responsive genes (Ceponis et al. 2003). 
Models using the C. rodentium infection in mice found a strong Th1/Th17 response in the 
colon of infected animals, characterized by an increased expression of IL-1β, TNF, IL-12, 
IFN-γ, IL-17 and IL-22 (Higgins et al. 1999; Geddes et al. 2011; Zheng et al. 2008). 
Furthermore, strain-specific immunomodulation was described by Corbishley et al. 
(2014) for CD4+ T-cells, NK-cells and CD8+ and γδ T-cells.  
The RNA-Seq technology, which was used in our gene expression study, allows 
RNA analysis through cDNA sequencing at massive scale. While initial transcriptomics 
techniques largely relied on hybridization-based microarray technologies offering a 
limited ability to fully describe and quantify the diverse RNA molecules which are 
expressed from genomes over wide ranges of levels. Furthermore, RNA-Seq allows to 
work with minute RNA quantities and to provide quantification of RNA samples from 
even single cells. This gives us the opportunity to define complex biological networks in a 
wide range of biological specimens. With these networks in hand, data-driven RNA 
network models of cells and tissues can be used in an attempt to fully understand the 
biological pathways that are active in various physiological conditions (Ozsolak & Milos 
2011).  
However, this advantage can also be seen as a drawback since it is very hard to 
interpret data of a plethora of genes which seem to be affected. In addition, there are 
experimental considerations that have to be taken into account when performing this 
technique. The expression of genes is time and cell dependent, so the results compiled 
from this technique will lead to information that is only valuable for one time point, as 
these samples were taken at the time of euthanasia. A time course experiment starting 
from a few hours after ingestion, during colonization, until potential clearing of the 
bacterium could give extra valuable information. The cell dependency of the transcripts is 
important as only small amounts of RNA will be further processed and analyzed with 
this technique. A major point of concern is the subjectivity of the analysis, as the results 
can vary due to the multitude of algorithms available. Most of the approaches are correct, 
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but have to be tailored to the needs of the investigators in order to better capture the 
desired effect. This variability in methods, although at smaller scale, is also present in 
other RNA profiling approaches where reagents, personnel and techniques can lead to 
similar, although statistically different, results. Taking this into account, the downstream 
interpretation of data must show biological, clinical and regulatory functions which 
allows for drawing meaningful conclusions.  
The tissue specificity of this technique allowed us to discover that the gene-
transcripts in the Peyer’s patches are far more affected by an infection with E. coli 
O157:H7 than the gene-transcripts of the rectum. This was surprising because the 
terminal rectum is the predilection site of the bacterium, but this leaves space for two 
hypotheses. A first hypothesis could be that after oral intake, the bacteria pass through 
the gastro-intestinal tract and adhere –shortly- to the ileum and/or close to the Peyer’s 
patches while influencing the local gene expression. A second hypothesis could be that 
the bacteria colonize the lymphoid follicle-dense mucosa in the rectum (Naylor et al. 
2003) while secreting specific factors that are taken up by immune cells or into the 
numerous blood vessels and these factors are transported to the Peyer’s patches where 
they influence gene expression. The first hypothesis is plausible as fecal shedding 
gradually disappears after clearing of the rectal mucosa. Rybarczyk et al. (2015) has 
suggested that this might be due to a temporary presence or colonization of the bacteria 
of more cranial intestinal mucosal sites, which could be the Peyer’s patches. 
Furthermore, colonization of these sites is also supported by cases of diarrhea in EHEC-
infected calves. Here, ileal and colonic mucosae are also colonized with EHEC (Dean-
Nystrom et al. 1997) and some viable bacteria are even translocated to the mesenteric 
lymph nodes (Cray & Moon 1995). The second hypothesis is possible, but we could not 
find any report, recent or older, describing a direct link between the highly vasculated 
rectal mucosal tissue and the ileal Peyer’s patches in cattle. In humans it has been shown 
that the rectal route bypasses around two thirds of the first-pass metabolism as the 
rectum's venous drainage is two thirds systemic (middle and inferior rectal vein) and one 
third portal (superior rectal vein). As a result, compounds that are applied rectally can 
easily reach the circulatory system (de Boer et al. 1982). Furthermore, a study in mice 
confirmed that intrarectal immunization induces homing of lymphocytes by α4β7 integrin, 
which enables lymphocytes to migrate from the rectum into the small intestine (Agnello 
et al. 2013). A similar transport of factors or cells might be possible in cattle, but this 
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needs to be confirmed in experimental studies. Despite this, both hypotheses cannot 
explain why the effects on gene expression levels were only detected in the ileum and not 
in the RAJ, leaving a hiatus worth further investigating.   
The finding that a first infection has more effect on the gene transcription then a 
secondary exposure affirms our observations that a first infection primes the immune 
system making a second colonization lasting longer. In our study, we reported the results 
of an infection with a Stx-negative strain. Since Stxs have shown to provoke many effects 
on cellular level as described in Chapter 2.3, it might be useful to perform the experiment 
with different Stx-positive strains as strain-specific effects are conceivable (Corbishley et 
al. 2014).  
In our cytokine study (Chapter V), we described the effect of three different E. coli 
O157:H7 strains which were Stx-, Stx2+ or Stx1+Stx2+, as we analysed the release of the 
proinflammatory cytokines IL-6 and TNF-α and the chemokine CXCL8 by rectal 
epithelial cells and explants upon E. coli O157:H7 infection. Whereas, we could not 
observe an effect on these cytokines in our RNA-Seq study (Chapter III), we found clear 
effects on cells and tissue explants. This difference might be explained by the different 
time frames after infection/inoculation that were used in the different experiments. In the 
RNA-Seq study, samples were collected 14 days after a first or re-infection and mRNA 
was analysed. It is well know that the mRNA expression of cytokines is tightly regulated, 
as a failure to degrade proinflammatory cytokine transcripts might lead to chronic 
inflammation (Rattenberger, 2012). Moreover, the half-life of cytokine mRNA typically 
is in the range of hours rather than days (Iwasaki 2011, Villarete 1996). This knowledge, 
combined with the immune suppression by different (non-)LEE-encoded effectors upon 
attachment and colonization, might explain why we could not detect effects on 
proinflammatory cytokines 14 days after infection. Measurement of protein levels in the 
supernatants after six hours of incubation as we performed in Chapter V, gives an 
indication of what is happening shortly after infection. But seen the strong regulation of 
mRNA cytokine expression, it might be also interesting to study effects after longer 
periods of infection, like 12, 24 and 48 hours. However, this is not possible in this 
experimental setup due to bacterial overgrowth of the cells and tissues.    
Furthermore, our experimental work focused on the reduction of an E. coli 
O157:H7 infection in calves using bLF. We introduced the application of bLF on the 
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rectal mucosa of cattle to fully benefit from the positive effects of bLF as here, both the 
direct antibacterial and the immunomodulating effect of bLF can contribute to the 
reduction of shedding. bLF was first described in the late 1930’s (Sorensen & Sorensen 
1939) and since then tested and applied in many medical, veterinary and health-
promoting applications. Presently, LF is one of the center points in cancer research as it 
seems to have antineoplastic properties without adverse effects (Yin et al. 2013). But also 
in animal nutrition, LF used as an additive has shown its importance as it can improve 
nonspecific immunity and strengthen host defenses in weaned piglets (Wang et al. 2004). 
bLF is also available on the market in infant and follow-on formulae in European 
countries, Japan, Indonesia and many others (Morinaga Milk ®). In our study, we were 
the first to show that bLF can clear an E. coli O157:H7 infection in cattle, which is 
promising. But we recognize that the used rectal application method is inappropriate for 
treatment on farms, as all animals have to be treated individually rectally on a daily basis. 
Different strategies to reduce this workload were tested ranging from (1) higher doses of 
bLF for shorter durations over (2) development of a rectal bLF gel to minimize the 
number of applications to (3) formulation of pH-sensitive coated bLF pellets which can 
be mixed in feed. Firstly, a five times higher dose of bLF powder was applied on the 
rectum of infected animals, but this dose could not accelerate the clearance (Rybarczyk et 
al. 2015). Secondly, the rectal gel showed comparable results to powder for growth 
inhibition and bacterial attachment in vitro, but had inconsistent effects -possibly due to a 
weaker mucosal adherence- in a small group of animals (n = 3) in vivo (Rybarczyk 2016). 
Thirdly, the processing technique for coated pellets resulted in a denaturation of 33 % of 
bLF hampering the biological effects of bLF in vitro and was therefore not tested in vivo 
(Rybarczyk 2016). In short, the results of these experiments could not lead to an 
improvement of the application strategy and new approaches should be elaborated.  
A first investigation of the local immune responses in the rectum upon infection 
and subsequent treatment with bLF powder, disclosed the induction of mucosal IgA 
responses against EspA and EspB in treated animals only (Rybarczyk et al. 2015). In 
addition, our cytokine study (Chapter V) also revealed a part of this puzzle: bLF can 
restore the IL-6 levels which were disarrayed by E. coli O157:H7 back to normal in rectal 
epithelial cells and the RAJ explants. Since IL-6 is important for inducing production of 
IgA by B-cells (Macpherson et al. 2008), and is known to enhance IgA secretion (Mowat 
2003), this might explain how bLF can induce local immune responses.  
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These findings emphasize the immuno-modulatory effect of bLF in local tissues and 
performing the RNA-Seq technique on samples from animals infected with E. coli 
O157:H7 and treated with bLF could further assist to elucidate the full picture. A better 
understanding of the mechanism of clearing and modulation of the immunity might help 
to identify individual animals or groups of animals at risk. Individual animals which can 
highly affect the infection status of the herds on a farm are ‘supershedders’ (Arthur et al. 
2013) and identifying and treating these might be a step forward in eliminating E. coli 
O157:H7 from farms. The treatment of other animals in the same herd as a 
‘supershedder’ could also be a possible focus for intervention as we have shown that bLF 
can result in development of mucosal immune responses which cannot protect from 
infection but can facilitate the clearance. Three to four months old animals might be part 
of the focus as well, since they are no longer protected by maternal immunity and rectal 
immunization with EspA and/or EspB or other virulence factors of E. coli O157:H7 in 
combination with bLF might induce local antibodies as well. It has been shown that 
EHEC colonization in ruminants is age-dependent and animals between 8 and 18 
months old are more often infected, making them also a valuable target for intervention 
strategies. It might be possible that treating only these animals would significantly reduce 
the peril of all other animals on the same farm, but for now this is still a distant prospect.  
We performed a study to investigate the effect of bLF on Stx-producing strains. In 
our in vivo experiments, we used the Stx-negative E. coli O157:H7 NCTC12900 strain for 
biosafety reasons. Until now, we have no proof that bLF can also reduce or clear 
shedding of Stx-positive EHEC strains from colonized cattle. Therefore, we analyzed the 
effect of bLF on purified Stx and on its toxicity in Vero cells in Chapter VI. We observed 
that bLF could decrease free Stx2, but not Stx1, and that this effect was bLF 
concentration-dependent. Moreover, we could demonstrate that the receptor-binding B-
subunit of Stx2 is degraded by bLF. This is an important finding as strains producing 
Stx2 are more often associated with severe disease in humans compared to strains that 
produce only Stx1 or a combination of both toxins (Fuller et al. 2011). We also observed 
that bLF was able to mitigate the effect of cytotoxic EHEC in our in vitro model. This 
preliminary study is therefore a first step in the investigation of the possible use of bLF in 
treatment of infected humans, as new strategies are urgently needed. The use of 
antibiotics is discouraged as antibiotics promote the release of Stx from the bacteria by a 
cellular stress response, which results in increased cellular toxicity. It is still unclear if 
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bLF reduces release of the toxin or if it mainly acts by proteolytic degradation, but this 
might be worth investigating.  
In our cytokine study, we could observe a reduction in IL-6 by E. coli O157:H7 and 
supplementation with bLF seemed to restore the IL-6 levels (Chapter V). This effect 
might be the result of a partial degradation of Stx2 as observed in Chapter VI. However, 
it remains unclear why IL-8 and TNF-α were not restored to normal levels. Furthermore, 
we could not observe a clear difference between the Stx1+Stx2+ and the Stx2+ strain, as 
would be expected from the different effect of bLF on Stx1 and Stx2. 
An important point of consideration is that Stx can also modulate the immune 
response in cattle. Menge et al. (1999) demonstrated that Stx1 suppresses the mucosa-
associated immune response in young calves, while we have suggested that this mucosal 
immune response plays an important role in the clearance of the bacteria from the gut 
(Rybarczyk et al. 2015). In our cytokine study (Chapter V) we showed that an exposure 
to Stx2 followed by infection with an Stx-positive strain can strongly reduce the IL-6 
levels, which are important for the local immune response. Therefore, the question 
remains if bLF will be able to overpower the effect of Stx in the local mucosa. 
Nevertheless, this multifunctional protein exerts a direct bactericidal effect which is most 
likely independent of the presence of Stx.       
By and large, all these findings suggest that bLF will also affect the colonization of  
Stx-positive EHEC strains in ruminants, but experiments have to be performed to have 
an idea of the kinetics of this infection and possible clearance.  
In addition, our studies showing the antibacterial effect of bLF and the proteolytic 
effect on Stx2 open a window of opportunities for new applications. Since we have 
shown that bLF can clear an infection in vivo and that this antibacterial effect does not 
increase the toxicity of the bacteria in sensitive cells, the use of bLF in human EHEC-
cases might be worth considering. Therefore, the effect of bLF on more EHEC-strains 
should be investigated and more studies on cytotoxicity should be performed.   
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Summary 
 
Enterohemorrhagic Escherichia coli (EHEC) are zoonotic pathogens that cause 
several outbreaks associated with human disease every year. Symptoms can range from 
watery diarrhea to bloody diarrhea and severe hemorrhagic colitis, renal failure and 
hemolytic uremic syndrome. Cattle, the most important source of transmission to 
humans, harbor the bacteria in their intestines without showing clinical symptoms. 
Different studies have tried to map the infection status of farms and of individual animals 
within herds but this seems to be complex as the infection rates of individual animals can 
vary widely in time. Cattle do not seem to develop a protective immune response after an 
initial exposure to the bacteria, making them susceptible for re-infections. It is generally 
accepted that EHEC is capable of modulating the host immune responses by a variety of 
factors, which probably causes the absence of a protective immune response. In this 
thesis, we investigated different aspects of immune modulation by EHEC.  
Furthermore, different research groups have tried to reduce the risk of transmission 
of the pathogen to humans by reducing the carriage rates in cattle. All these strategies 
showed only limited effects. Therefore, we tested an innovative strategy to reduce EHEC 
colonization in cattle using bovine lactoferrin (bLF) which combines immunomodulating 
properties together with antibacterial effects.    
Chapter I of this thesis provides a comprehensive overview of the current literature. 
In order to gain insight in the mechanisms by which EHEC can modulate immune 
responses, the effects of different immunomodulating EHEC factors are described. 
Furthermore, the current knowledge on bLF was reviewed in this chapter.    
Chapter II describes the aims of the experimental workthat was performed during 
this PhD thesis. The focus of this thesis to investigate the suppression of the immune 
response in cattle by E. coli O157:H7 and the role of bLF in modifying this suppressed 
response.   
In Chapter III, the suppression of the bovine immune system was investigated by 
RNA-Seq. Calves were experimentally infected and re-infected and RNA was extracted 
from recto-anal junction (RAJ) tissues, the major colonization site, and ileal Peyer’s 
patches (I+PP) tissues, the gateway to the immune system. This was compared to the 
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RNA expression in control animals. A striking difference in gene expression was 
observed in the I+PP after a first infection compared to non-infected control animals. 
The effects were less pronounced in the RAJ or after a re-infection. These findings 
motivate the hypothesis of a suppression of the bovine immune response after an initial 
colonization with E. coli O157:H7. 
Chapter IV describes the use of bLF as an antibacterial and immunomodulating 
protein in experimentally infected calves. bLF was applied directly on the rectal mucosa, 
the most important colonization site, or orally and the effects on systemic immune 
responses against EHEC type III secretion system (T3SS) proteins EspA, EspB and 
intimin were investigated. All groups developed serum responses, but no clear differences 
could be observed between the groups although animals in the rectal group ceased 
shedding fast and remained negative, whereas no beneficial effect of bLF on bacterial 
shedding was observed in the oral group. The results indicate that the use of bLF as a 
rectal treatment can be a useful strategy to preclude further transmission of EHEC 
infections from cattle to humans. The mechanism behind this effect might be, at least 
partly, due to stimulation of the local immune responses by bLF, as no systemic effect 
was observed.    
Further research on the modulation of immune responses in cattle was performed 
in Chapter V by analysis of cytokine release (IL-6, IL-8 and TNF-α) in the supernatants 
of rectal epithelial cells, which were exposed to Shiga toxin 2 (Stx2) and bLF and 
subsequently inoculated with different E. coli O157:H7 strains. The release of pro-
inflammatory cytokines and chemokines was also studied in tissue explants from the 
RAJ and I+PP, incubated with E. coli O157:H7, bLF and/or Stx. In rectal epithelial cells, 
the incubation with E. coli O157:H7 strains reduced both IL-6 and IL-8 levels and 
increased TNF-α levels. bLF was able to restore the IL-6 but not the IL-8 levels and 
induced the release of supplementary TNF-α. Inoculation of tissue explants with E. coli 
O157:H7 (Stx-) induced the secretion of IL-6 and IL-8 in the RAJ and of IL-8 in the 
I+PP, while reducing only IL-6 in the I+PP. bLF could again restore IL-6, but 
overstimulated IL-8 secretion. TNF-α was slightly decreased by E. coli O157:H7 (Stx-) in 
RAJ and increased in I+PP explants. The differences between rectal epithelial cells and 
RAJ explants support an effect of other (immune) cells, which are only present in the 
complex explant environment.  
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Since Chapter IV showed promising results in the reduction of EHEC in cattle and 
LF is recently in the center of attention as a possible therapy for numerous diseases in 
humans, Chapter VI is a pilot study investigating the possible use of bLF against EHEC 
infections in humans. Many human cases have described that the use of antibiotics in 
EHEC infected patients is contra-indicated because of the increased risk for severe 
outcome due to a higher release of Stx by the bacteria. In this chapter, the non-toxic 
concentration of bLF for use in Vero-cell cultures was determined. Futhermore, a bLF 
concentration-dependent decrease of active, cell-free Stx2, but not Stx1 in EHEC cultures 
was observed. When only colonizing bacteria were taken into account, cytotoxicity could 
be significantly reduced by 10 and 1 mg/ml bLF during 48 hours. This effect of bLF at 
least partly results from degradation of the Stx2 receptor-binding B-subunit. 
Chapter VII provides a general discussion, highlighting the pro’s and contra’s of 
the experimental studies and gives suggestions for future research.The results of the 
research in this thesis show that E. coli O157:H7 can indeed suppress the immune 
response in cattle. bLF seems to be able to restore disarrayed cytokine expression back to 
normal levels and was able to clear an E. coli O157:H7 infection in calves, probably due 
to both the antibacterial and immunomodulating effect of the protein. bLF might also 
become part of a novel treatment strategy of EHEC-infected patients as it does not induce 
an increased toxicity in vitro as seen for antibiotics. However, further research is needed 
to establish an efficacious treatment.  
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Enterohemorrhagische Escherichia coli (EHEC) zijn zoönotische pathogenen die 
jaarlijks verantwoordelijk zijn voor uitbraken met een aantal ziektegevallen tot gevolg. 
De symptomen kunnen variëren van waterige diarree tot bloederige diarree en ernstige 
hemorrhagische colitis, nierfalen en hemolytisch uremisch syndroom. Runderen zijn de 
belangrijkste bron van overdracht van de bacteriën naar de mens, omdat ze drager zijn 
van de bacteriën in hun darmen zonder klinische symptomen te vertonen.   
Verschillende studies hebben de infectiestatus van bedrijven en van individuele 
dieren binnen een kudde proberen in kaart brengen, maar dit blijkt heel complex omdat 
de infectiegraad van individuele dieren sterk kan variëren in de tijd. Runderen lijken geen 
beschermende immuunresponsen te ontwikkelen na een eerste blootstelling aan de 
bacteriën, wat hen vatbaar maakt voor herinfecties. Het is algemeen aanvaard dat EHEC 
in staat is om de immuunresponsen van de gastheer te beïnvloeden door verschillende 
factoren, dit veroorzaakt waarschijnlijk de afwezigheid van een beschermende 
immuunrespons. In deze thesis hebben we de verschillende aspecten van 
immunomodulatie door EHEC onderzocht.      
Verder hebben verschillende onderzoeksgroepen geprobeerd om het risico van 
overdracht van de bacterie naar de mens te verminderen door het verminderen van de 
hoeveelheid bacteriën in de runderen. Al deze strategieën vertoonden slechts beperkte 
effecten. Daarom hebben we een innovatieve strategie getest om de EHEC kolonisatie in 
runderen in te perken. Hiervoor hebben we gebruik gemaakt van boviene lactoferrine 
(bLF), een eiwit dat immunomodulerende eigenschappen combineert met antibacteriële 
effecten.   
In hoofdstuk I van deze thesis werd een uitgebreid overzicht gegeven van de 
huidige literatuur. Om meer inzicht te krijgen in de mechanismen waardoor EHEC de 
immuunresponsen kan moduleren, werden de effecten van verschillende 
immunomodulerende EHEC factoren beschreven. Verder werd ook de huidige kennis 
m.b.t. bLF in dit hoofdstuk beschreven. 
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Hoofdstuk II beschrijft de doelen van het experimentele werk dat werd uitgevoerd 
tijdens dit doctoraatsonderzoek. De focus van deze thesis lag op het onderzoek naar de 
onderdrukking van de immuunrespons bij runderen door E. coli O157:H7 en de rol die 
bLF kan spelen om deze onderdrukte respons te normaliseren. 
In hoofdstuk III werd de onderdrukking van het boviene immuun systeem 
onderzocht door RNA-Seq. Kalveren werden experimenteel geïnfecteerd en 
geherinfecteerd en RNA werd geëxtraheerd uit weefsels van de recto-anale junctie (RAJ), 
de belangrijkste kolonisatieplaats, en uit de ileale Peyerse platen (I+PP), de 
toegangspoort naar het immuunsysteem. Dit RNA werd vergeleken met de RNA 
expressie van controledieren. Een opvallend verschil in de genexpressie werd gezien in de 
I+PP na een eerste infectie in vergelijking met niet-geïnfecteerde controle dieren. De 
effecten waren minder uitgesproken in de RAJ en na een herinfectie. Deze bevindingen 
ondersteunen de hypothese van een suppressie van de boviene immuunrespons na een 
initiële kolonisatie met EHEC.  
Hoofdstuk IV beschrijft het gebruik van bLF als een antibacterieel en 
immunomodulerend eiwit in experimenteel geïnfecteerde kalveren. bLF werd 
rechtstreeks op de rectale mucosa, de belangrijkste kolonisatieplaats, of oraal toegediend 
en de effecten op de systemische immuunresponsen tegen EHEC type III secretie systeem 
proteïnen EspA, EspB en intimine werden onderzocht. Alle groepen vertoonden 
serumresponsen, maar er konden geen duidelijke verschillen tussen de groepen worden 
gezien. Desalniettemin stopten alle dieren in de rectaal behandelde groep snel met 
uitscheiden en bleven ze negatief terwijl er geen gunstig effect voor oraal toegediende 
bLF kon worden gevonden. Deze resultaten tonen aan dat het gebruik van rectaal 
toegediende bLF een nuttige strategie kan zijn om verdere transmissie van EHEC 
infecties van runderen naar mensen te verminderen. Het mechanisme verantwoordelijk 
voor dit effect is waarschijnlijk ten minste deels te wijten aan de stimulatie van lokale 
immuunresponsen door bLF, aangezien geen stimulatie van systemische responsen werd 
waargenomen.  
Verder onderzoek naar de modulering van immuunresponsen in runderen werd 
uitgevoerd in Hoofdstuk V door de analyse van de vrijstelling van cytokines (IL-6, IL-8 
en TNF-α) in het supernatans van rectale epitheliale cellen, die werden blootgesteld aan 
Shiga toxine 2 (Stx2) en bLF en vervolgens geïnoculeerd met verschillende E. coli 
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O157:H7 stammen. De vrijstelling van proinflammatoire cytokines en chemokines werd 
ook bestudeerd in weefselexplanten van de RAJ en de I+PP, geïnoculeerd met E. coli 
O157:H7, bLF en/of Stx. In rectale epitheliale cellen verminderde de incubatie met de E. 
coli O157:H7 stammen zowel IL-6 als IL-8 concentraties en verhoogde ze de TNF-α 
concentraties. bLF kon het IL-6 niveau normaliseren, maar de IL-8 concentratie bleef 
onveranderd. Voor TNF-α werd een toename waargenomen door bLF. Inoculatie van 
weefsel explanten met E. coli O157:H7 (Stx-) induceerde de vrijstelling van IL-6 en IL-8 
in de RAJ en van IL-8 in de I+PP. De IL-6 concentratie nam af in de I+PP. bLF kon 
opnieuw de IL-6 concentratie normaliseren, maar zorgde voor een overstimulatie van IL-
8 secretie. TNF-α werd licht verminderd door E. coli O157:H7 (Stx-) in de RAJ en nam 
toe in de I+PP explanten. De verschillen tussen de rectale epitheliale cellen en de RAJ 
explanten tonen aan dat er een effect is van andere (mogelijks immuun-) cellen, die alleen 
aanwezig zijn in het complexe weefsel van de explanten.  
Omdat Hoofdstuk IV veelbelovende resultaten aangaf voor de reductie van EHEC 
in runderen en LF recent in de aandacht is gekomen als mogelijke therapie voor 
verschillende ziektebeelden bij de mens werd in Hoofdstuk VI een pilootstudie 
uitgevoerd waarbij gekeken werd naar het mogelijke gebruik van bLF tegen EHEC 
infecties bij de mens. In verschillende patiënten heeft men aangetoond dat het gebruik 
van antibiotica bij een EHEC-infectie kan leiden tot een verhoogde kans op een 
verergering van het ziektebeeld door een hogere vrijstelling van Stx door de bacteriën. In 
dit hoofdstuk werd een niet-toxische concentratie van bLF voor gebruik in Vero-cellijnen 
uitgetest. Verder werd een bLF concentratie-afhankelijke afname van actieve, cel-vrije 
Stx2 in EHEC culturen geobserveerd. Wanneer men enkel naar de kolonizerende 
bacteriën keek, kon de cytotoxiciteit significant verminderd worden door het gebruik van 
10 en 1 mg/ml bLF tijdens 48 uur behandeling. Dit effect wordt ten minste deels 
toegeschreven aan de degradatie van de Stx2 receptor-bindende subeenheid.  
Hoofdstuk VII geeft een algemene discussie weer, waarin de voor- en nadelen van 
de experimentele studies worden besproken en suggesties worden gegeven voor 
toekomstig onderzoek. De resultaten van het onderzoek in dit doctoraatswerk bevestigen  
dat E. coli O157:H7 de immuun respons in runderen kan onderdrukken. bLF lijkt in staat 
om de verstoorde cytokine expressie opnieuw te normaliseren en kon ook een E. coli 
O157:H7 infectie in kalveren klaren. Dit is waarschijnlijk te wijten aan zowel het 
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antibacterieel als het immunomodulerend effect van het eiwit. bLF kan eveneens 
onderdeel worden van een nieuwe behandelingsstrategie voor EHEC-geïnfecteerde 
patiënten aangezien dit niet resulteert in een verhoogde toxiciteit zoals voor antibiotica 
het geval is. Verder onderzoek is nodig om een efficiënte behandeling te ontwikkelen.
 
 
  
 
 
 
 
 
 
References
  
 
  
References 
167 
 
References 
 
A 
Anderson M.W., Zhao S., Ai W.Z., Tibshirani R., Levy R., Lossos I.S., Natkunam Y. (2010). C-C chemokine 
receptor 1 expression in human hematolymphoid neoplasia. American Journal of Clinical Pathology, 
133(3), pp.473–483. 
André P., Castriconi R., Espéli M., Anfossi N., Juarez T., Hue S., Conway H., Romagné F.,Dondero A., Nanni M., 
Caillat-Zucman S., Raulet D.H., Bottino C., Vivier E., Moretta A., Paul P. (2004). Comparative analysis of 
human NK cell activation induced by NKG2D and natural cytotoxicity receptors. European Journal of 
Immunology, 34(4). 
Andreoli S. & Bergstein J., (1982). Development of insulin-dependent diabetes mellitus during the hemolytic-
uremic syndrome. Journal of Pediatrics, 100(4), pp.541–5. 
Armstrong G.L., Hollingsworth J., Morris, J.G. (1996). Emerging foodborne pathogens: Escherichia coli O157:H7 
as a model of entry of a new pathogen into the food supply of the developed world. Epidemiologic 
reviews, 18(1), pp.29–51. 
Arnold R., Cole M., McGhee J. (1977). Bactericidal effector for human lactoferrin. Science, 197, pp.263–265. 
Arthur T.M., Bosilevac J.M., Brichta-Harhay D.M., Kalchayanand N., Shackelford S.D., Wheeler T.L., Koohmaraie 
M. (2007a). Effects of a minimal hide wash cabinet on the levels and prevalence of Escherichia coli 
O157:H7 and Salmonella on the hides of beef cattle at slaughter. Journal of Food Protection, 70(5), 
pp.1076–9. 
Arthur T.M., Bosilevac J.M., Brichta-Harhay D.M., Guerini M.N., Kalchayanand N., Shackelford S.D., Wheeler 
T.L., Koohmaraie M. (2007b). Transportation and lairage environment effects on prevalence, numbers, 
and diversity of Escherichia coli O157:H7 on hides and carcasses of beef cattle at processing.  Journal of 
Food Protection, 70(2), pp.280–6. 
Arthur T.M., Ahmed R., Chase-Topping M., Kalchayanand N., Schmidt J.W., Bono J.L. (2013). Characterization of 
Escherichia coli O157:H7 strains isolated from supershedding cattle. Applied and Environmental 
Microbiology, 79(14), pp.4294–4303. 
Artym J., Zimecki M., Paprocka M., Kruzel M.L.  (2003a). Orally administered lactoferrin restores humoral 
immune response in immunocompromised mice. Immunology Letters, 89(1), pp.9–15. 
Artym J., Zimecki M., Kruzel M.L. (2003b). Reconstitution of the cellular immune response by lactoferrin in 
cyclophosphamide-treated mice is correlated with renewal of T cell compartment. Immunobiology, 
207(3), pp.197–205. 
B 
Baker E.N. & Baker H.M. (2005). Molecular structure, binding properties and dynamics of lactoferrin. Cellular 
and Molecular Life Sciences, 62(22), pp.2531–2539. 
Baker H.M. & Baker E.N., (2004). Lactoferrin and Iron: Structural and dynamic aspects of binding and release. 
BioMetals, 17(3), pp.209–216. 
Barnett Foster D. (2013). Modulation of the enterohemorrhagic E. coli virulence program through the human 
gastrointestinal tract. Virulence, 4(4), pp.315–23.  
Barrett T.J., Green J.H., Griffin P.M., Pavia A.T., Ostroff S.M., Wachsmuth I.K. (1991). Enzyme-linked 
immunosorbent assays for detecting antibodies to Shiga-like toxin I, Shiga-like toxin II, and Escherichia 
References 
168 
 
coli O157:H7 lipopolysaccharide in human serum. Current Microbiology, 23(4), pp.189–195. 
Baruch K., Gur-Arie L., Nadler C., Koby S., Yerushalmi G., Ben-Neriah Y. Yogev O., Shaulian E., Guttman C., 
Zarivach R., Rosenshine I. (2011). Metalloprotease type III effectors that specifically cleave JNK and NF-κB. 
The EMBO journal, 30(1), pp.221–231.  
Baveye S., Elass E., Fernig D.G., Blanquart C., Mazurier J., Legrand D. (2000). Human lactoferrin interacts with 
soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced 
by the CD14-lipopolysaccharide complex. Infection and Immunity, 68(12), pp.6519–6525. 
Beeckman D.S.A., Van Droogenbroeck C.M.A.D, De Cock B.J.A., Van Oostveldt P., Vanrompay D.C.G. (2007). 
Effect of ovotransferrin and lactoferrins on Chlamydophila psittaci adhesion and invasion in HD11 chicken 
macrophages. Veterinary Research, 38(5), pp.729–739. 
Bellamy W., Takase M., Kawase K., Shimamura S., Tomita M. (1992). Antibacterial spectrum of lactoferricin B, a 
potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. Journal of Applied 
Bacteriology., 73, pp.472–479. 
Bennett R. & Kokocinski T. (1978). Lactoferrin content of peripheral blood cells. British Journal of Haematology, 
39(4), pp.509–21. 
Berg, J.M., Tymoczko, J.L., Stryer, L. (2002). Biochemistry, 5th edition. Chapter 2, Biochemical Evolution. pp. 25-
34 
Berg J., McAllister T., Bach S., Stilborn R., Hancock D., LeJeune J. (2004). Escherichia coli O157:H7 excretion by 
commercial feedlot cattle fed either barley- or corn-based finishing diets. Journal of Food Protection, 
67(4), pp.666–671. 
Berger C.N., Crepin V.F., Baruch K., Mousnier A., Rosenshine I., Frankel G. (2012). EspZ of Enteropathogenic and 
Enterohemorrhagic Escherichia coli. mBio, 3(5), pp.1–12. 
Berin M.C., Darfeuille-Michaud A., Egan L.J., Miyamoto Y., Kagnoff M.F. (2002). Role of EHEC O157:H7 virulence 
factors in the activation of intestinal epithelial cell NFkB and MAP kinase pathways and the upregulated 
expression of interleukin 8. Cell Microbiology, 4(10), pp.635–647. 
Bi B.Y., Lefebvre A.M., Duś D., Spik G., Mazurier J. (1997). Effect of lactoferrin on proliferation and 
differentiation of the Jurkat human lymphoblastic T cell line. Archivum Immunologiae et Therapiae 
Experimentalis, 45(4), pp.315–20. 
Bitzan M., Moebius E., Ludwig K., Müller-Wiefel D.E., Heesemann J., Karch H. (1991). High incidence of serum 
antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. 
Journal of Pediatrics, 119(3), pp.380–5. 
Blasche S., Mörtl M., Steuber H., Siszler G., Nisa S., Schwarz F., Lavrik I., Gronewold T.M., Maskos K., 
Donnenberg M.S., Ullmann D., Uetz P., Kögl M. (2013). The E. coli Effector Protein NleF Is a Caspase 
Inhibitor. PLoS ONE, 8(3), p.e58937. 
Blease S.C., French A.T., Knight P.A., Gally D.L., Pemberton A.D. (2009). Bovine intelectins: cDNA sequencing 
and expression in the bovine intestine. Research in Veterinary Science, 86(2), pp.254–256.  
Boerlin P., McEwen S.A., Boerlin-Petzold F., Wilson J.B., Johnson R.P., Gyles C.L. (1999). Associations between 
virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. Journal of clinical 
microbiology, 37(3), pp.497–503. 
Bosilevac J.M., Nou X., Barkocy-Gallagher G.A., Arthur T.M., Koohmaraie M. (2006). Treatments using hot water 
instead of lactic acid reduce levels of aerobic bacteria and Enterobacteriaceae and reduce the prevalence 
of Escherichia coil O157:H7 on preevisceration beef carcasses. Journal of  Food Protection, 69(8), 
pp.1808–13. 
Bouchard B., Ormandy C.J., Di Santo J.P., Kelly P.A. (1999). Immune system development and function in 
References 
169 
 
prolactin receptor-deficient mice. Journal of  Immunology., 163(2), pp.576–582. 
Brashears M.M., Galyean M.L., Loneragan G.H., Mann J.E., Killinger-Mann K. (2003). Prevalence of Escherichia 
coli O157:H7 and performance by beef feedlot cattle given Lactobacillus direct-fed microbials. Journal of 
Food Protection, 66(5), pp.748–54. 
Bridger P.S., Mohr M., Stamm I., Fröhlich J., Föllmann W., Birkner S., Metcalfe H., Werling D., Baljer G., Menge 
C.  (2010). Primary bovine colonic cells: A model to study strain-specific responses to Escherichia coli. 
Veterinary Immunology and Immunopathology, 137(1-2), pp.54–63. 
Brigotti M., Carnicelli D., Ravanelli E., Barbieri S., Ricci F., Bontadini A., Tozzi A.E., Scavia G., Caprioli A., Tazzari 
P.L. (2008). Interactions between Shiga toxins and human polymorphonuclear leukocytes. Journal of 
leukocyte biology, 84(4), pp.1019–1027. 
Britigan B.E., Lewis T.S., Waldschmidt M., McCormick M.L., Krieg M. (2001). Lactoferrin binds CpG-containing 
oligonucleotides and inhibits their immunostimulatory effects on human B cells. Journal of immunology 
(Baltimore, Md. : 1950), 167(5), pp.2921–2928. 
Broxmeyer H.E., Smithyman A., Eger R.R., Meyers P.A., de Sousa M. (1978). Identification of lactoferrin as the 
granulocyte-derived inhibitor of colony-stimulating activity production. Journal of Experimental Medicine, 
148(4), pp.1052–1067. 
Brüssow H., Canchaya C., Hardt W.-D., Bru H. (2004). Phages and the Evolution of Bacterial Pathogens : from 
Genomic Rearrangements to Lysogenic Conversion Phages and the Evolution of Bacterial Pathogens : 
from Genomic Rearrangements to Lysogenic Conversion. Microbiology and molecular biology reviews, 
68(3), pp.560–602. 
Buchko S.J., Holley R.A., Olson W.O., Gannon V.P., Veira D.M. (2000). The effect of different grain diets on fecal 
shedding of Escherichia coli O157:H7 by steers. Journal of Food Protection, 63(11), pp.1467–74. 
Bullen J.J., Rogers H.J. & Leigh L. (1972). Iron-binding proteins in milk and resistance to Escherichia coli infection 
in infants. British Medical Journal, 1(5792), pp.69–75. 
Burk C., Dietrich R., Acar G., Moravek M., Bulte M., Martlbauer E. (2003). Identification and characterization of 
a new variant of Shiga toxin 1 in Escherichia coli ONT : H19 of bovine origin. Journal of Clinical 
Microbiology, 41(5), pp.2106–2112.  
Burland V., Shao Y., Perna N.T., Plunkett G., Sofia H.J., Blattner F.R. (1998). The complete DNA sequence and 
analysis of the large virulence plasmid of Escherichia coli O157:H7. Nucleic Acids Research, 26(18), 
pp.4196–4204. 
Busch U., Hörmansdorfer S., Schranner S., Huber I., Bogner K.H., Sing A. (2007). Enterohemorrhagic Escherichia 
coli excretion by child and her cat. Emerging Infectious Diseases, 13(2), pp.348–349. 
Buvens G., Possé B., De Schrijver K., De Zutter L., Lauwers S., Piérard D. (2011). Virulence profiling and 
quantification of verocytotoxin-producing Escherichia coli O145:H28 and O26:H11 isolated during an ice 
cream-related hemolytic uremic syndrome outbreak. Foodborne Pathogens and Disease, 8(3), pp.421–6. 
C 
Callaway T.R., Anderson R.C., Edrington T.S., Bischoff K.M., Genovese K.J., Poole T.L., Byrd J.A., Harvey R.B., 
Nisbet D.J. (2004). Effects of sodium chlorate on antibiotic resistance in Escherichia coli O157:H7. 
Foodborne Pathogens and Disease, 1(1), pp.59–63. 
Callaway T.R., Edrington T.S., Brabban, Andrew D, Anderson R.C., Rossman M.L., Engler M.J., Carr M., Genovese 
K.J., Keen J.E., Looper M.L., Kutter E.M., Nisbet D.J. (2008). Bacteriophage isolated from feedlot cattle can 
reduce Escherichia coli O157:H7 populations in ruminant gastrointestinal tracts. Foodborne Pathogens 
And Disease, 5(2), pp.183–91. 
References 
170 
 
Callaway T.R., Carr M.A., Edrington T.S., Anderson R.C., Nisbet D.J. (2011). Diet, Escherichia coli O157:H7, and 
Cattle: A Review After 10 Years. Current Issues in Molecular Biology, 11, pp.67–80. 
Callaway T.R., Anderson R., Anderson T.J., Poole T.L., Bischoff K.M., Kubena L.F., Nisbet D.J. (2001). Escherichia 
coli O157:H7 beomes resistant to sodium chlorate in pure cultures, but not in mixed culture or in vivo. 
Journal of Applied Microbiology, 91(Stewart 1988), pp.427–434. 
Campellone K.G. & Leong J.M. (2003). Tails of two Tirs: Actin pedestal formation by enteropathogenic E. coli 
and enterohemorrhagic E. coli O157:H7. Current Opinion in Microbiology, 6(1), pp.82–90. 
Caprioli A., Morabito S., Brugère H., Oswald E. (2005). Enterohaemorrhagic Escherichia coli: emerging issues on 
virulence and modes of transmission. Veterinary Research, 36, pp.289–311. 
Caprioli A., Luzzi I., Seganti L., Marchetti M., Karmali M., Clarke I., Boyd B. (1994). Frequency and nature of 
Verocytotoxin-2 (Vt2) neutralizing activity (Na) in human and animal sera. Recent advantages in 
Verocytotoxin-Producing Escherichia coli infections, 1072, pp.353–356. 
Ceponis P.J.M., Ching J.C.Y., Pereira P.,Sherman P.M., McKay D.M. (2003). Enterohemorrhagic Escherichia coli 
O157:H7 Disrupts Stat1-Mediated Gamma Interferon Signal Transduction in Epithelial Cells. Infection and 
Immunity, 71(3), pp.1396–1404. 
Chapman P.A., Siddons C.A., Malo A.T.C., Harkin M.A. (1997). A 1-year study of Escherichia coli O157 in cattle, 
sheep, pigs and poultry. Epidemiology and Infection, 119, pp.245–250. 
Chapman P.A., Siddons C.A., Wright J., Norman P., Fox J., Crick E. (1993). Cattle as a possible source of 
verocytotoxin-producing Escherichia coli O157 infections in man. Epidemiology and Infection, 111, 
pp.439–447. 
Cheng J.B., Wang J.Q., Bu D.P., Liu G.L., Zhang C.G., Wei H.Y., Zhou L.Y., Wang J.Z. (2008). Factors affecting the 
lactoferrin concentration in bovine milk. Journal of dairy science, 91(3), pp.970–976. 
Cobbaut K., Berkvens D., Houf K., De Deken R., De Zutter L. (2009). Escherichia coli O157 Prevalence in Different 
Cattle Farm Types and Identification of Potential Risk Factors. Journal of Food Protection, 9, pp.1848–
1853. 
Cody S.H., Glynn M.K., Farrar J.A., Cairns K.L., Griffin P.M., Kobayashi J., Fyfe M., Hoffman R., King A.S., Lewis 
J.H., Swaminathan B., Bryant R.G., Vugia D.J. (1999). An Outbreak of Escherichia coli O157:H7 Infection 
from Unpasteurized Commercial Apple Juice. Annals of Internal Medicine, 130(3), pp.202–209. 
Cody S.H., Glynn M.K., Farrar J.A., Cairns K.L., Griffin P.M., Kobayashi J., Fyfe M., Hoffman R., King A.S., Lewis 
J.H., Swaminathan B., Bryant R.G., Vugia D.J. (1999). An Outbreak of Escherichia coli O157:H7 Infection 
from Unpasteurized Commercial Apple Juice. Annals of Internal Medicine, 130(3), pp.202–209. 
Corbishley A., Ahmad N.I., Hughes K., Hutchings M.R., McAteer, S.P., Connelley T.K., Brown H., Gally D.L., 
McNeilly T.N. (2014). Strain-dependent cellular immune responses in cattle following Escherichia coli 
O157:H7 colonization. Infection and Immunity, 82(12), pp.5117–5131. 
Cornick N.A., Booher S.L., Casey T.A., Moon H.W. (2000). Persistent Colonization of Sheep by Escherichia coli 
O157:H7 and Other E. coli Pathotypes. Applied and Environmental Microbiology, 66(11), pp.4926–4934. 
Corogeanu D., Willmes R., Wolke M., Plum G., Utermöhlen O., Krönke M. (2012). Therapeutic concentrations of 
antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German 
outbreak. BMC Microbiology, 12(160). 
Corrigan J.J. & Boineau F. (2001). Hemolytic-uremic syndrome. Pediatrics in review, 22(11), pp.365–9. 
Crane J., McNamara B. & Donnenberg M. (2001). Role of EspF in host cell death induced by enteropathogenic 
Escherichia coli. Cellular Microbiology, 3(4), pp.197–211. 
Cray W.C. & Moon H.W., 1995. Experimental infection of calves and adult cattle with Escherichia coli O157:H7. 
References 
171 
 
Applied and environmental microbiology, 61(4), pp.1586–90.  
Creus K.K., De Paepe B., Weis J., De Bleecker J.L. (2012). The multifaceted character of lymphotoxin β in 
inflammatory myopathies and muscular dystrophies. Neuromuscul Disorders, 22(8), pp.712–719. 
Crouch S.P., Slater K.J. & Fletcher J. (1992). Regulation of cytokine release from mononuclear cells by the iron-
binding protein lactoferrin. Blood, 80(1), pp.235–40.  
Croxen M.A. & Finlay B.B. (2010). Molecular mechanisms of Escherichia coli pathogenicity. Nature Reviews 
Microbiology, 8(1), pp.26–38. 
Cuesta Alonso E., Gilliland S. & Krehbiel C., (2007). Incidence and toxin production ability of Escherichia coli 
O157:H7 isolated from cattle trucks. Journal of Food Protection, 70(10), pp.2383–5. 
D 
Dahan S., Busuttil V., Imbert V., Peyron J.-F., Rampal P., Czerucka D. (2002). Enterohemorrhagic Escherichia coli 
infection induces interleukin-8 production via activation of mitogen-activated protein kinases and the 
transcription factors NF-kappaB and AP-1 in T84 cells. Infection and immunity, 70(5), pp.2304–10.  
Dargatz D.A., Wells S.J., Thomas L.A., Hancock D.D., Garber L.P. (1997). Factors Associated with the Presence of 
Escherichia coli O157 in Feces of Feedlot Cattle. Journal of Food Protection, 5, pp.466–470. 
Davis R. (1993). The mitogen-activated protein kinase signal transduction pathway. Journal of Biological 
Chemistry, 268(20), pp.14553–14556. 
Dean P., Scott J.A., Knox A.A., Quitard S., Watkins N.J., Kenny B. (2010). The enteropathogenic E. coli effector 
EspF targets and disrupts the nucleolus by a process regulated by mitochondrial dysfunction. PLoS 
Pathogens, 6(6). 
Dean P. & Kenny B., (2004). Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by 
two effector molecules and a bacterial surface protein. Molecular Microbiology, 54(3), pp.665–75. 
Dean-Nystrom, E.A., Bosworth B.T., Cray W.C., Moon H.W. (1997). Pathogenicity of Escherichia coli O157:H7 in 
the intestines of neonatal calves. Infection and Immunity, 65(5), pp.1842–1848. 
de Boer A.G., Moolenaar F., de Leede L.G., Breimer D.D. (1982). Rectal drug administration: clinical 
pharmacokinetic considerations. Clinical Pharmacokinetics 7(4), pp. 285-311. 
de la Rosa G., Yang D., Tewary P., Varadhachary A., Oppenheim J.J. (2008). Lactoferrin acts as an alarmin to 
promote the recruitment and activation of antigen-presenting cells and antigen-specific immune 
responses. Journal of Immunology., 180(10), pp.6868–76. 
Deng W., Puente J.L., Gruenheid S., Li Y., Vallance B.A., Vázquez A., Barba J., Ibarra J.A., O'Donnell P., 
Metalnikov P., Ashman K., Lee S., Goode D., Pawson T., Finlay B.B. (2004). Dissecting virulence: systematic 
and functional analyses of a pathogenicity island. Proceedings of the National Academy of Sciences of the 
United States of America, 101(10), pp.3597–602. 
Desjardins M. & Mazer B.D. (2013). B-cell memory and primary immune deficiencies: interleukin-21 related 
defects. Current Opinion in Allergy and Clinical Immunology, 13(6), pp.639–645. 
DeVinney R., Stein M., Reinscheid D., Abe A., Ruschkowski S., Brett Finlay B. (1999). Enterohemorrhagic 
Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine 
phosphorylated. Infection and Immunity, 67(5), pp.2389–2398. 
Dial E.J., Dohrman A.J., Romero J.J., Lichtenberger L.M. (2005). Recombinant human lactoferrin prevents 
NSAID-induced intestinal bleeding in rodents. Journal of Pharmacy and Pharmacology, 57(1), pp.93–9. 
Dibb-Fuller M.P., Best A., Stagg D.A., Cooley W.A., Woodward M.J. (2001). An in-vitro model for studying the 
References 
172 
 
interactions of Escherichia coli O157:H7 and other enteropathogens with bovine primary cell cultures. 
Journal of Medical Microbiology, 50, pp.759–769. 
Donnenberg M.S., Kaper J.B. & Finlay B.B. (1997). Interactions between enteropathogenic Escherichia coli and 
host epithelial cells. Trends in Microbiology, 5(3), pp.109–114. 
Dundas S., Todd W.T., Neill M.A., Tarr P.I. (2005). Using antibiotics in suspected haemolytic-uraemic syndrome: 
antibiotics should not be used in Escherichia coli O157:H7 infection. British Medical Journal, 330(7501), 
p.1209. 
Dundas S. & Todd W. (2000). Clinical presentation, complications and treatment of infection with 
verocytotoxin-producing Escherichia coli. Challenges for the clinician. Symposium series (Society for 
Applied Microbiology), 29, p.24s–30s. 
Dymecki S.M., Zwollo P., Zeller K., Kuhajda P., Desiderio S.V. (1992). Structure and developmental regulation of 
the B-lymphoid tyrosine kinase gene blk. Journal of Biological Chemistry, 267(7), pp.4815–4823. 
Dziarski R. & Gupta D. (2010). Review: Mammalian peptidoglycan recognition proteins (PGRPs) in innate 
immunity. Innate Immun., 16(3), pp.168–174. 
Dziva F., Mahajan A., Cameron P., Currie C., McKendrick I.J., Wallis T.S., Smith D.G., Stevens M.P. (2007). EspP, a 
Type V-secreted serine protease of enterohaemorrhagic Escherichia coli O157:H7, influences intestinal 
colonization of calves and adherence to bovine primary intestinal epithelial cells. FEMS Microbiol Lett, 
271(2), pp.258–264.  
E 
Edrington T.O.M.S., Callaway T.R., Ives S.A.M.E., Engler M.J., Looper M.L., Anderson R.C., Nisbet D.J. (2006). 
Seasonal Shedding of O157:H7 in Ruminants. Foodborne pathogens and disease, 3(4), pp.413–421. 
Efsa (2012). Scientific Opinion on bovine lactoferrin. EFSA Journal, 10(5), pp.2701–2727. 
Elass-Rochard E., Masson M., Mazurier J., Legrand D. (2002). Lactoferrin inhibits the lipopolysaccharide-induced 
expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infection and 
Immunity, 70(4), pp.1860–1866. 
Elass-Rochard E., Legrand D., Salmon V., Roseanu A., Trif M., Tobias P.S., Mazurier J., Spik G. (1998). Lactoferrin 
inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. 
Infection and Immunity, 66(2), pp.486–491. 
Elbasha E.H., Fitzsimmons T.D. & Meltzer M.I. (2000). Costs and benefits of a subtype-specific surveillance 
system for identifying Escherichia coli O157:H7 outbreaks. Emerging Infectious Diseases, 6(3), pp.293–
297. 
Elliott E.J. & Robins-Browne R.M. (2005). Hemolytic uremic syndrome. Current Problems in Pediatric and 
Adolescent Health Care, 35(8), pp.310–330. 
Ellison R.T., Giehl T. & Laforce F.M. (1988). Damage of the outer membrane of enteric gram-negative bacteria 
by lactoferrin and transferrin. Infection and Immunity, 56(11), pp.2774–2781. 
Elomaa O., Sankala M., Pikkarainen T., Bergmann U., Tuuttila A., Raatikainen-Ahokas A., Sariola H., Tryggvason 
K. (1998). Structure of the human macrophage MARCO receptor and characterization of its bacteria-
binding region. Journal of Biological Chemistry, 273, pp.4530–4538. 
Endo Y., Tsurug K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. (1988). Site of action of a Vero toxin (VT2) 
from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of 
the toxins. European journal of biochemistry, 171(1-2), pp.45–50. 
Enquist J., Sandén C., Skröder C., Mathis S.A., Leeb-Lundberg L.M. (2014). Kinin-stimulated B1 receptor 
References 
173 
 
signaling depends on receptor endocytosis whereas B2 receptor signaling does not. Neurochemical 
Research, 39(6), pp.1037–1047. 
European Bioinformatics Institute, 2015. Eggnog. Available at: 
http://eggnog.embl.de/version_3.0/cgi/members.py?search_term=Q7TQ03&group=opiNOG22486. 
F 
Fagerquist C.K. & Sultan O. (2010). Top-down proteomic identification of furin-cleaved α-subunit of Shiga toxin 
2 from Escherichia coli O157:H7 using MALDI-TOF-TOF-MS/MS. Journal of biomedicine & biotechnology, 
2010, pp. unknown. 
Feng P. (2015). Shiga toxin-producing Escherichia coli in fresh produce: A food safety dilemma. In 
Enterohemorrhagic Escherichia coli and other shiga toxin-producing E. coli. pp. 231–44. 
Ferens, W.A. & Hovde C.J. (2011). Escherichia coli O157:H7: Animal Reservoir and Sources of Human Infection. 
Foodborne Pathogens and Disease 8(4): 465–487. 
Fischer R., Debbabi H., Dubarry M., Boyaka P., Tomé D. (2006). Regulation of physiological and pathological Th1 
and Th2 responses by lactoferrin. Biochemistry and Cell Biology, 84(3), pp.303–11. 
Flores F.X., Jabs K., Thorne G.M., Jaeger J., Linshaw M.A., Somers M.J. (1997). Immune response to Escherichia 
coli O157:H7 in hemolytic uremic syndrome following salmonellosis. Journal of Pediatric Nephrology 
11(4), pp.488–490.  
Fortier L. & Sekulovic O. (2013). Importance of prophages to evolution and virulence of bacterial pathogens. 
Virulence, 4(5), pp.354–65.  
Fox J.T., Thomson D.U., Drouillard J.S., Thornton A.B., Burkhardt D.T., Emery D.A., Nagaraja T.G. (2009). Efficacy 
of Escherichia coli O157:H7 siderophore receptor/porin proteins-based vaccine in feedlot cattle naturally 
shedding E. coli O157. Foodborne Pathogens and Disease, 6(7), pp.893–9. 
Frankel G., Phillips A.D., Rosenshine I., Dougan G., Kaper J.B., Knutton S. (1998). Enteropathogenic and 
enterohaemorrhagic Escherichia coli: more subversive elements. Molecular Microbiology., 30(5), pp.911–
921. 
Fraser M.E., Chernaia M.M., Kozlov Y.V., James M.N. (1994). Crystal structure of the holotoxin from Shigella 
dysenteriae at 2.5 A resolution. Nature Structural & Molecular Biology, 1, pp.59–64. 
Fraser-Pitt D.J., Cameron P., McNeilly T.N., Boyd A., Manson E.D.T., Smith D.G.E. (2011). Phosphorylation of the 
epidermal growth factor receptor (EGFR) is essential for interleukin-8 release from intestinal epithelial 
cells in response to challenge with Escherichia coli O157 : H7 flagellin. Microbiology (Reading, England), 
157(Pt 8), pp.2339–47. 
Frazer D.M., Darshan D. & Anderson G.J. (2011). Intestinal iron absorption during suckling in mammals. 
Biometals, 24(3), pp.567–574. 
Friedrich A.W., Bielaszewska M., Zhang W.-L., Pulz M., Kuczius T., Ammon A., Karch H. (2002). Escherichia coli 
harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. The Journal of 
infectious diseases, 185, pp.74–84. 
Fuller C.A., Pellino C.A., Flagler M.J., Strasser J.E., Weiss A.A. (2011). Shiga toxin subtypes display dramatic 
differences in potency. Infection and Immunity, 79(3), pp.1329–1337. 
G 
Gao X., Wan F., Mateo K., Callegari E., Wang D., Deng W., Puente J., Li F., Chaussee M.S., Finlay B.B., Lenardo 
M.J., Hardwidge P.R. (2009). Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB 
References 
174 
 
function. PLoS Pathogens, 5(12), p.e1000708. 
Gao X., Wang X., Pham T.H., Feuerbacher L.A., Huang M., Olsen R., Mushegian A., Slawson C. (2014). NleB, a 
bacterial effector with glycosyltransferase activity targets GADPH function to inhibit NF-kappaB 
activation. Cell Host and Microbe, 13(1), pp.87–99. 
Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., Vinh D.C. (2003). Anti-tumour 
necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet, 3, 
pp.148–55. 
Gauld S.B., Dal Porto J.M. & Cambier J.C. (2002). B cell antigen receptor signaling: roles in cell development and 
disease. Science., 296(5573), pp.1641–1642. 
Geddes K., Rubino S.J., Magalhaes J.G., Streutker C., Le Bourhis L., Cho J.H., Robertson S.J., Kim C.J., Kaul R., 
Philpott D.J., Girardin S.E. (2011). Identification of an innate T helper type 17 response to intestinal 
bacterial pathogens. Nature medicine, 17(7), pp.837–844.  
Gerondakis S., Fulford T.S., Messina N.L., Grumont R.J. (2014). NF-κB control of T cell development. Nature 
immunology, 15(1), pp.15–25.  
Gifford J.L., Hunter H.N. & Vogel H.J. (2005). Lactoferricin: a lactoferrin-derived peptide with antimicrobial, 
antiviral, antitumor and immunological properties. Cellular and Molecular Life Sciences, 62(22), pp.2588–
2598.  
Grauke L.J., Kudva I.T., Yoon J.W., Hunt C.W., Williams C.J., Hovde C.J. (2002). Gastrointestinal Tract Location of 
Escherichia coli O157:H7 in Ruminants. Applied and Environmental Microbiology, 68(5), pp.2269–2277. 
Griener T.P., Strecker J.G., Humphries R.M., Mulvey G.L., Fuentealba C., Hancock R.E., Armstrong G.D. (2011). 
Lipopolysaccharide renders transgenic mice expressing human serum Amyloid P component sensitive to 
Shiga Toxin 2. PLoS ONE, 6(6). 
Grif K., Dierich M.P., Karch H., Allerberger F. (1998). Strain-specific differences in the amount of Shiga toxin 
released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory 
concentrations of antimicrobial agents. European Journal of Clinical Microbiology & Infectious Diseases, 
17, pp.761–766. 
Griffin P. & Tauxe R. (1991). The epidemiology of infections caused by Escherichia coli O157:H7, other 
enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiologic Reviews, 13, 
pp.60–98. 
Griffiths C.E., Cumberbatch M., Tucker S.C., Dearman R.J., Andrew S., Headon D.R., Kimber I. (2001). Exogenous 
topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in 
humans. British Journal of Dermatology, 144(4), pp.715–725. 
Griffiths E.A., Duffy L.C., Schanbacher F.L., Dryja D., Leavens A., Neiswander R.L., Qiao H., DiRienzo D., Ogra P. 
(2003). In vitro growth responses of bifidobacteria and enteropathogens to bovine and human 
lactoferrin. Digestive Diseases and Sciences, 48(7), pp.1324–32. 
Groves M. (1960). The isolation of a red protein from milk. Journal of American Chemistry Society, 82, pp.3345–
3350. 
Gruenheid S., Sekirov I., Thomas N.A., Deng W., O'Donnell P., Goode D., Li Y., Frey E.A., Brown N.F., Metalnikov 
P., Pawson T., Ashman K., Finlay B.B. (2004). Identification and characterization of NleA, a non-LEE-
encoded type III translocated virulence factor of enterohaemorrhagic Escherichia coli O157:H7. Molecular 
Microbiology., 51(5), pp.1233–49. 
Guillén C., McInnes I.B., Vaughan D.M., Kommajosyula S., Van Berkel P.H., Leung B.P., Aguila A., Brock J.H. 
(2002). Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. 
Journal of immunology, 168(8), pp.3950–3957.  
References 
175 
 
H 
Hamada D., Hamaguchi M., Suzuki K.N., Sakata I., Yanagihara I. (2010). Cytoskeleton-modulating effectors of 
enteropathogenic and enterohemorrhagic Escherichia coli: a case for EspB as an intrinsically less-ordered 
effector. Federation of European Biochemical Societies Journal , 277(11), pp.2409–2415.  
Hamada D., Kato T., Ikegami T., Suzuki K.N., Hayashi M., Murooka Y., Honda T., Yanagihara I. (2005). EspB from 
enterohaemorrhagic Escherichia coli is a natively partially folded protein. Federation of European 
Biochemical Societies Journal ,272(3), pp.756–768.  
Hancock D., Besser T., Lejeune J., Davis M., Rice D. (2001). The control of VTEC in the animal reservoir. 
International Journal of Food Microbiology, 66(1-2), pp.71–78. 
Hancock D.D., Besser T.E., Rice D.H., Herriott D.E., Tarr P.I. (1997). A longitudinal study of Escherichia coli O157 
in fourteen cattle herds. Epidemiology & Infection, 118 (2), pp.193-5. 
Hancock D.D., Besser T.E., Kinsel M.L., Tarr P.I., Rice D.H., Paros M.G. (1994). The prevalence of Escherichia coli 
0157. H7 in dairy and beef cattle in Washington State. Veterinary Microbiology, pp.199–207. 
Hardwidge P.R., Deng W., Vallance B.A., Rodriguez-Escudero I., Cid V.J., Molina M., Finlay B.B. (2005). 
Modulation of host cytoskeleton function by the enteropathogenic Escherichia coli and Citrobacter 
rodentium effector protein EspG. Infection and Immunity, 73(5), pp.2586–2594. 
Harwood N.E. & Batista F.D. (2010). Early events in B cell activation. Annual Review of Immunology, 28, pp.185–
210. 
Hauf N. & Chakraborty T. (2003). Suppression of NF-κB Activation and Proinflammatory cytokine expression by 
shiga toxin-producing Escherichia coli. The Journal of Immunology, 170, pp.2074–2082. 
Håversen L., Ohlsson B.G., Hahn-Zoric M., Hanson L.A., Mattsby-Baltzer I. (2002). Lactoferrin down-regulates 
the LPS-induced cytokine production in monocytic cells via NF-kappaB. Cellular Immunology, 220(2), 
pp.83–95.  
Head S.C., Karmali M.A. & Lingwood C.A. (1991). Preparation of VT1 and VT2 hybrid toxins from their purified 
dissociated subunits: Evidence for B subunit modulation of a subunit function. Journal of Biological 
Chemistry, 266(6), pp.3617–3621. 
Hemrajani C., Marches O., Wiles S., Girard F., Dennis A., Dziva F., Best A., Phillips A.D., Berger C.N., Mousnier A., 
Crepin V.F., Kruidenier L., Woodward M.J., Stevens M.P., La Ragione R.M., MacDonald T.T., Frankel G. 
(2008). Role of NleH, a type III secreted effector from attaching and effacing pathogens, in colonization of 
the bovine, ovine, and murine gut. Infection and Immunity, 76(11), pp.4804–13.  
Herold S., Karch H. & Schmidt H. (2004). Shiga toxin-encoding bacteriophages--genomes in motion. 
International Journal of Medical Microbiology, 294(2-3), pp.115–21. 
Heuvelink A.E., van Heerwaarden C., Zwartkruis-Nahuis J.T., van Oosterom R., Edink K., van Duynhoven Y.T., de 
Boer E. (2002). Escherichia coli O157 infection associated with a petting zoo. Epidemiology and Infection, 
129(02), pp.295–302.  
Higgins L.M., Frankel G., Douce G., Dougan G., MacDonald T.T. (1999). Citrobacter rodentium infection in mice 
elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel 
disease. Infection and Immunity, 67(6), pp.3031–3039. 
Hoey D.E., Sharp L., Currie C., Lingwood C.A., Gally D.L., Smith D.G. (2003). Verotoxin 1 binding to intestinal 
crypt epithelial cells results in localization to lysosomes and abrogation of toxicity. Cell Microbiol, 5(2), 
pp.85–97. 
Hoey D.E., Currie C., Else R.W., Nutikka A., Lingwood C.A., Gally D.L., Smith D.G. (2002). Expression of receptors 
for verotoxin 1 from Escherichia coli O157 on bovine intestinal epithelium. Journal of medical 
References 
176 
 
microbiology, 51(2), pp.143–9.  
Hoffman M.A., Menge C., Casey T.A., Laegreid W., Bosworth B.T., Dean-Nystrom E.A. (2006). Bovine immune 
response to shiga-toxigenic Escherichia coli O157:H7. Clin Vaccine Immunol, 13(12), pp.1322–1327.  
Holck A.L., Axelsson L., Rode T.M., Høy M., Måge I., Alvseike O., L'abée-Lund T.M., Omer M.K., Granum P.E., 
Heir E. (2011). Reduction of verotoxigenic Escherichia coli in production of fermented sausages. Meat 
Science, 89(3), pp.286–295.  
Holmes A., Mühlen S., Roe A.J., Dean P. (2010). The EspF effector, a bacterial pathogen’s swiss army knife. 
Infection and Immunity, 78(11), pp.4445–4453. 
House B., Kus J.V., Prayitno N., Mair R., Que L., Chingcuanco F., Gannon V., Cvitkovitch D.G., Barnett Foster D. 
(2009). Acid-stress-induced changes in enterohaemorrhagic Escherichia coli O157: H7 virulence. 
Microbiology, 155(9), pp.2907–2918. 
Hrudey S.E., Payment P., Huck P.M., Gillham R.W., Hrudey E.J. (2003). A fatal waterborne disease epidemic in 
Walkerton, Ontario: comparison with other waterborne outbreaks in the developed world. Water Science 
and Technology, 47(3), pp.7–14. 
Hunstad D.A. & Justice S.S. (2010). Intracellular lifestyles and immune evasion strategies of uropathogenic 
Escherichia coli. Annual Review of Microbiology, 64, pp.203–221. 
Huntington G.B. (1997). Starch Utilization by Ruminants: From Basics to the Bunk. Journal of Animal Science, 
75(3), pp.852–867. 
Hurley B.P., Jacewicz M., Thorpe C.M., Lincicome L.L., King A.J., Keusch G.T., Acheson D.W. (1999). Shiga toxin 1 
and 2 translocate differently across polarized intestinal epithelial cells. Infection and Immunity, 67(12), 
pp.6670–6677. 
Hurley B.P., Thorpe C.M. & Acheson D.W. (2001). Shiga toxin translocation across intestinal epithelial cells is 
enhanced by neutrophil transmigration. Infect Immun, 69(10), pp.6148–6155.  
Hwang S.J., Ballantyne C.M., Sharrett A.R., Smith L.C., Davis C.E., Gotto A.M. Jr., Boerwinkle E. (1997). 
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident 
coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation, 96(12), 
pp.4219–4225. 
I 
Ihekweazu C., Carroll K., Adak B., Smith G., Pritchard G.C., Gillespie I.A., Verlander N.Q., Harvey-Vince L., 
Reacher M., Edeghere O., Sultan B., Cooper R., Morgan G., Kinross P.T., Boxall N.S., Iversen A., Bickler G. 
(2012). Large outbreak of verocytotoxin-producing Escherichia coli O157 infection in visitors to a petting 
farm in South East England, 2009. Epidemiology and infection, 140(8), pp.1400–13. 
Iizumi Y., Sagara H., Kabe Y., Azuma M., Kume K., Ogawa M., Nagai T., Gillespie P.G., Sasakawa C., Handa H. 
2007. The Enteropathogenic E. coli Effector EspB Facilitates Microvillus Effacing and Antiphagocytosis by 
Inhibiting Myosin Function. Cell Host and Microbe, 2(6), pp.383–392. 
Inozume T., Mitsui H., Okamoto T., Matsuzaki Y., Kawakami Y., Shibagaki N., Shimada S. (2007). Dendritic cells 
transduced with autoantigen FCRLA induce cytotoxic lymphocytes and vaccinate against murine B-cell 
lymphoma. Journal of Investigative Dermatology, 127(12), pp.2818–2822. 
International Molecular Exchange Consortium, 2015. Available at: 
http://www.innatedb.com/getGeneCard.do?id=638183. 
Inozume T., Mitsui H., Okamoto T., Matsuzaki Y., Kawakami Y., Shibagaki N., Shimada S. (2012). Molecular 
mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated 
osteoclastogenesis. Journal of Biological Chemistry, 287(28), pp.23527–36. 
References 
177 
 
Inubushi T., Kawazoe A., Miyauchi M., Kudo Y., Ao M., Ishikado A., Makino T., Takata T. (2012). Molecular 
mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated 
osteoclastogenesis. Journal of Biological Chemistry, 287(28), pp.23527–36. 
Iwasaki H., Takeuchi O., Teraguchi S., Matsushita K., Uehata T., Kuniyoshi K., Satoh T., Saitoh T., Matsushita M., 
Standley D.M., Akira S. (2011). The IκB kinase complex regulates the stability of cytokine-encoding mRNA 
induced by TLR–IL-1R by controlling degradation of regnase-1. Nature Immunology 12(12), pp.1167-1175. 
J 
Jacob M.E., Callaway T.R. & Nagaraja T.G. (2009). Dietary interactions and interventions affecting Escherichia 
coli O157 colonization and shedding in cattle. Foodborne pathogens and disease, 6(7), pp.785–792. 
Jandhyala D., Thorpe C. & Magun B. (2012). Ricin and Shiga toxins: effects on host cell signal transduction. 
Current Topics in Microbiology and Immunology, 357, pp.41–65. 
Janeway C.A., Travers P., Walport M., Shlomchik M.J. (2005). Immunobiology: Chapter 11. Pathogens have 
evolved various means of evading or subverting normal host defenses. Garland Science Publishing, 
pp.462–470. 
Jenkins C., Chart H., Smith H.R., Hartland E.L., Batchelor M., Delahay R.M., Dougan G., Frankel G. (2000). 
Antibody response of patients infected with verocytotoxin-producing Escherichia coli to protein antigens 
encoded on the LEE locus. Journal of Medical Microbiology, 49(1), pp.97–101. 
Jenkins C. & Chart H. (1999). Serodiagnosis of infection with Verocytotoxin-producing Escherichia coli. Journal 
of Applied Microbiology, 86(4), pp.569–575. 
Johannes L. & Römer W., 2010. Shiga toxins - from cell biology to biomedical applications. Nature Reviews 
Microbiology, 8(2), pp.105–116. 
Johnson R., Cray W. & Johnson S. (1996). Serum Antibody Responses of Cattle following Experimental Infection 
with Escherichia coli O157:H7. Infection and Immunity, 64(5), pp.1879–1883. 
Joris M.A., Vanrompay D., Verstraete K., De Reu K., De Zutter L., Cox E. (2013a). Use of Antibody Responses 
against Locus of Enterocyte Effacement (LEE)-Encoded Antigens To Monitor Enterohemorrhagic 
Escherichia coli Infections on Cattle Farms. Applied and Environmental Microbiology, 79(12): 3677-83. 
Joris M.A., Verstraete K., De Reu K., De Zutter L. (2013b). Longitudinal Follow-Up of the Persistence and 
Dissemination of EHEC on Cattle Farms in Belgium. Foodborne pathogens and disease, 10(4), pp.295–301. 
Joris, M.A. (2012). Prevalence, characterization and long-term follow up of Enterohemorrhagic Escherichia coli 
and type III secretion system specific antibodies in cattle. PhD dissertation Ghent University, Belgium. 
Jung H.C., Eckmann L., Yang S.K., Panja A., Fierer J., Morzycka-Wroblewska E., Kagnoff M.F. (1995). A distinct 
array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial 
invasion. The Journal of clinical investigation, 95(1), pp.55–65. 
K 
Kagnoff M.F. & Eckmann L. (1997). Perspectives Series : Host / Pathogen Interactions Epithelial Cells as Sensors 
for Microbial Infection. The Journal of Clinical Investigations, 100(1), pp.6–10. 
Kaper J., Nataro J. & Mobley H. (2004). Pathogenic Escherichia coli. Nature Reviews Microbiology, 2(2), pp.123–
40. 
Kaper J.B. (1998). Enterohemorrhagic Escherichia coli. Current opinion in microbiology, 1, pp.103–108. 
Karch H., Denamur E., Dobrindt U., Finlay B.B., Hengge R., Johannes L., Ron E.Z., Tønjum T., Sansonetti P.J., 
References 
178 
 
Vicente M. (2012). The enemy within us: lessons from the 2011 European Escherichia coli O104:H4 
outbreak. EMBO Molecular Medicine, 4(9), pp.841–848.  
Karch H., Strockbine N. & O’Brien A. (1986). Growth of Escherichia coli in the presence of trimethoprim-
sulfamethoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay. FEMS 
Microbiology Letters, 35, pp.141–5. 
Karimi M., Cao T.M., Baker J.A., Verneris M.R., Soares L., Negrin R.S. (2005). Silencing Human NKG2D, DAP10, 
and DAP12 Reduces Cytotoxicity of Activated CD8  T Cells and NK Cells. The Journal of Immunology, 175, 
pp.7819–7828. 
Karmali M. (2009). Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated 
hemolytic uremic syndrome. Kidney International Supplements, 112, pp.4–7. 
Karmali M.A., Steele B.T., Petric M., Lim C. (1983). Sporadic cases of haemolytic-uraemic syndrome associated 
with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet, 1(8325), pp.619–20. 
Karmali M.A., Petric M., Lim C., Cheung R., Arbus G.S. (1985). Sensitive method for detecting low numbers of 
verotoxin-producing Escherichia coli in mixed cultures by use of colony sweeps and polymyxin extraction 
of verotoxin. Journal of Clinical Microbiology, 22(4), pp.614–619.  
Karpman D., Békássy Z.D., Sjögren A.C., Dubois M.S., Karmali M.A., Mascarenhas M., Jarvis K.G., Gansheroff L.J., 
O'Brien A.D., Arbus G.S., Kaper J.B. (2002). Antibodies to intimin and Escherichia coli secreted proteins A 
and B in patients with enterohemorrhagic Escherichia coli infections. Pediatric nephrology (Berlin, 
Germany), 17, pp.201–211. 
Kato A., Rooney A.P., Furutani Y., Hirose S. (2010). Evolution of trappin genes in mammals. BMC Evolutionary 
Biology, 10(31): pp. unknown. 
Kaushik R.S., Begg A.A., Wilson H.L., Aich P., Abrahamsen M.S., Potter A., Babiuk L.A., Griebel P. (2008). 
Establishment of fetal bovine intestinal epithelial cell cultures susceptible to bovine rotavirus infection. 
Journal of Virological Methods, 148, pp.182–196. 
Kenny B., Ellis S., Leard A.D., Warawa J., Mellor H., Jepson M.A. (2002). Co-ordinate regulation of distinct host 
cell signalling pathways by multifunctional enteropathogenic Escherichia coli effector molecules. Mol 
Microbiol., 44(4), pp.1095–1107. 
Kenny B. & Jepson M. (2000). Targeting of an enteropathogenic Escherichia coli (EPEC) effector protein to host 
mitochondria. Cellular Microbiology, 2(6), pp.579–90. 
Kerner K., Bridger P.S., Köpf G., Fröhlich J., Barth S., Willems H., Bauerfeind R., Baljer G., Menge C. (2015). 
Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga 
toxoids as candidate vaccines in cattle. Veterinary Research, 46(1), pp.1–14. 
Kieckens E., Rybarczyk J., De Zutter L., Duchateau L., Vanrompay D., Cox E. (2015). Clearance of Escherichia coli 
O157:H7 Infection in Calves by Rectal Administration of Bovine Lactoferrin. Applied and Environmental 
Microbiology, 81(5), pp.1644–1651.  
Kijimoto-Ochiai S. (2002). CD23 (the low-affinity IgE receptor) as a C-type lectin: a multidomain and 
multifunctional molecule. Cellular and Molecular Life Sciences, 59(4), pp.648–664. 
Kijlstra A. & Jeurissen S.H. (1982). Modulation of classical C3 convertase of complement by tear lactoferrin. 
Immunology, 47(2), pp.263–270.  
Kim Y., Oh S. & Kim S.H. (2009). Released exopolysaccharide (r-EPS) produced from probiotic bacteria reduce 
biofilm formation of enterohemorrhagic Escherichia coli O157:H7. Biochemical and Biophysical Research 
Communications, 379(2), pp.324–329.  
Knobeloch K.P., Wright M.D., Ochsenbein A.F., Liesenfeld O., Löhler J., Zinkernagel R.M., Horak I., Orinska Z 
(2000). Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under 
References 
179 
 
suboptimal costimulatory conditions. Molecular Cell Biology, 20(15), pp.5363–5369. 
Koch C., Hertwig S., Lurz R., Appel B., Beutin L. (2001). Isolation of a lysogenic bacteriophage carrying the 
stx1OX3 gene, which is closely associated with Shiga toxin-producing Escherichia coli strains from sheep 
and humans. Journal of Clinical Microbiology, 39(11), pp.3992–3998. 
Konowalchuk J., Speirs J.I. & Stavric S. (1977). Vero response to a cytotoxin of Escherichia coli. Infection and 
Immunity, 18(3), pp.775–779. 
Krebs D.L. & Hilton D.J. (2001). SOCS proteins: negative regulators of cytokine signaling. Stem Cells, 19(5), 
pp.378–387. 
Kruzel M.L., Bacsi A., Choudhury B., Sur S., Boldogh I. (2006). Lactoferrin decreases pollen antigen-induced 
allergic airway inflammation in a murine model of asthma. Immunology, 119(2), pp.159–166. 
Kudva I.T., Hunt C.W., Williams C.J., Nance U.M., Hovde C.J. (1997). Evaluation of Dietary Influences on 
Escherichia coli O157 : H7. Applied and Environmental Microbiology, 63(10), pp.3878–3886. 
Kudva I.T., Hatfield P.G. & Hovde C.J. (1995). Effect of Diet on the Shedding of Escherichia coli O157-H7 in A 
Sheep Model. Applied and Environmental Microbiology, 61(4), pp.1363–1370.  
Kuhn K.A., Manieri N.A., Liu T.C., Stappenbeck T.S. (2014). IL-6 stimulates intestinal epithelial proliferation and 
repair after injury. PLoS ONE, 9(12), pp.1–18. 
Kuttruff S., Koch S., Kelp A., Pawelec G., Rammensee H.G., Steinle A. (2009). NKp80 defines and stimulates a 
reactive subset of CD8 T cells. Blood, 113(2), pp.358–369. 
L 
La Ragione R.M., Best A., Woodward M.J., Wales A.D. (2009). Escherichia coli O157:H7 colonization in small 
domestic ruminants. FEMS microbiology reviews, 33(2), pp.394–410. 
Lau C.K.Y., Krewulak K.D. & Vogel H.J., 2016. Bacterial ferrous iron transport: the Feo system. FEMS 
microbiology reviews, 40(2):273-98. 
Laury A.M., Alvarado M.V., Nace G, Alvarado C.Z., Brooks J.C., Echeverry A., Brashears M.M. (2009). Validation 
of a lactic acid- and citric acid-based antimicrobial product for the reduction of Escherichia coli O157: H7 
and Salmonella on beef tips and whole chicken carcasses. Journal of Food Protection, 72(10), pp.2208–11. 
Law R.J., Gur-Arie L., Rosenshine I., Finlay B.B. (2013). In Vitro and In Vivo Model Systems for Studying 
Enteropathogenic Escherichia coli Infections. Cold Spring Harbor Perspectives in Medicine, 3(3), 
pp.a009977–a009977. 
LeBrasseur N. (2006). Fight infection with oxidation. Journal of Cell Biology, 175(4), p.518. 
Ledesma M.A., Ochoa S.A., Cruz A., Rocha-Ramírez L.M., Mas-Oliva J., Eslava C.A., Girón J.A., Xicohtencatl-
Cortes J. (2010). The hemorrhagic coli pilus (HCP) of Escherichia coli O157:H7 is an inducer of 
proinflammatory cytokine secretion in intestinal epithelial cells. PLoS ONE, 5(8):e12127. 
Lee R.C., Walters J.A., Reyland M.E., Anderson S.M. (1999). Constitutive activation of the prolactin receptor 
results in the induction of growth factor-independent proliferation and constitutive activation of signaling 
molecules. Journal of Biological Chemistry, 274(15), pp.10024–10034. 
Lee S.M., Kok K.H., Jaume M., Cheung T.K., Yip T.F., Lai J.C., Guan Y., Webster R.G., Jin D.Y., Peiris J.S. (2014). 
Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. 
Proceedings of the National Academy of Sciences of the United States of America, 11(10), pp.3793–3798. 
Legler D.F., Loetscher M., Roos R.S., Clark-Lewis I., Baggiolini M., Moser B. (1998). B cell-attracting chemokine 1, 
a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via 
References 
180 
 
BLR1/CXC5. Journal of Expermental Medicine, 187(4), pp.655–660. 
Legrand D. & Mazurier J. (2010). A critical review of the roles of host lactorferrin in immunity. Biometals, 23, 
pp.365–376. 
LeJeune J. & Wetzel A. (2007). Preharvest control of Escherichia coli O157 in cattle. Journal of Animal Science, 
85(13 suppl), pp.E73–80. 
Lema M., Williams L. & Rao D. (2001). Reduction of fecal shedding of enterohemorrhagic Escherichia coli 
O157:H7 in lambs by feeding microbial feed supplement. Small Ruminants Research, 39(1), pp.31–39. 
Leung P.H., Peiris J.S., Ng W.W., Robins-Browne R.M., Bettelheim K.A., Yam W.C. (2003). A Newly Discovered 
Verotoxin Variant, VT2g, Produced by Bovine Verocytotoxigenic Escherichia coli. Applied and 
Environmental Microbiology, 69(12), pp.7549–7553. 
Levay P.F. & Viljoen M. (1995). Lactoferrin: a general overview. Haematologica, 80, pp.252–267. 
Levine M.M., Xu J.G., Kaper J.B., Lior H., Prado V., Tall B., Nataro J., Karch H., Wachsmuth K. (1987). A DNA 
probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause 
hemorrhagic colitis and hemolytic uremic syndrome. Journal of Infectious Diseases, 156(1), pp.175–82. 
Lewis S.B., Cook V., Tighe R., Schüller S. (2015). Enterohemorrhagic Escherichia coli colonization of human 
colonic epithelium in vitro and ex vivo. Infection and Immunity, 83(3), pp.942–949. 
Li M., Rosenshine I., Yu H.B., Nadler C., Mills E., Hew C.L., Leung K.Y. (2006). Identification and characterization 
of NleI, a new non-LEE-encoded effector of enteropathogenic Escherichia coli (EPEC). Microbes and 
Infection, 8(14-15), pp.2890–2898. 
Li Q. & Verma I.M. (2002). NF-kappaB regulation in the immune system. Nature reviews. Immunology, 2(10), 
pp.725–34.  
Li R.W. & Schroeder S.G. (2012). Cytoskeleton remodeling and alterations in smooth muscle contractility in the 
bovine jejunum during nematode infection. Functional & Integrative Genomics, 12(1), pp.35–44. 
Li Y., Frey E., Mackenzie A.M., Finlay B.B. (2000). Human response to Escherichia coli O157:H7 infection: 
antibodies to secreted virulence factors. Infection and immunity, 68(9), pp.5090–5.  
Lim J.Y., Sheng H., Seo K.S., Park Y.H., Hovde C.J. (2007). Characterization of an Escherichia coli O157:H7 
plasmid O157 deletion mutant and its survival and persistence in cattle. Appl Environ Microbiol, 73(7), 
pp.2037–2047.  
Lingwood C.A., Law H., Richardson S., Petric M., Brunton J.L., De Grandis S., Karmali M. (1987). Glycolipid 
binding of purified and recombinant Escherichia coli produced verotoxin in vitro. Journal of Biological 
Chemistry, 262(18), pp.8834–9. 
Lingwood C. (1994). Verotoxin-binding in human renal sections. Nephron, 66(1), pp.21–8. 
Ludwig K., Grabhorn E., Bitzan M., Bobrowski C., Kemper M.J., Sobottka I., Laufs R., Karch H., Müller-Wiefel D.E. 
(2002). Saliva IgM and IgA are a sensitive indicator of the humoral immune response to Escherichia coli 
O157 lipopolysaccharide in children with enteropathic hemolytic uremic syndrome. Pediatric Research, 
52(2), pp.307–313. 
Luisiri P., Lee Y.J., Eisfelder B.J., Clark M.R. (1996). Cooperativity and segregation of function within the Ig-
alpha/beta heterodimer of the B cell antigen receptor complex. Journal of Biological Chemistry, 271(9), 
pp.5158–5163. 
Lukjancenko O., Wassenaar T.M. & Ussery D.W. (2010). Comparison of 61 Sequenced Escherichia coli Genomes. 
Microbial Ecology, 60(4), pp.708–720. 
Luo Y., Van Nguyen U., de la Fe Rodriguez P.Y., Devriendt B., Cox E. (2015). F4+ ETEC infection and oral 
References 
181 
 
immunization with F4 fimbriae elicits an IL-17-dominated immune response. Veterinary Research, 
46(121), pp. unknown.  
Lynn T.V., Hancock D.D., Besser T.E., Harrison J.H., Rice D.H., Stewart N.T., Rowan L.L. (1998). The occurrence 
and replication of Escherichia coli in cattle feeds. Journal of dairy science, 81(4), pp.1102–8.  
M 
MacGillivray R.T., Moore S.A., Chen J., Anderson B.F., Baker H., Luo Y., Bewley M., Smith C.A., Murphy M.E., 
Wang Y., Mason A.B., Woodworth R.C., Brayer G.D., Baker E.N. (1998). Two high-resolution crystal 
structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron 
release. Biochemistry, 37(22), pp.7919–28.  
Macpherson A.J., McCoy K.D., Johansen F.E., Brandtzaeg P. (2008). The immune geography of IgA induction and 
function. Mucosal immunology, 1(1), pp.11–22. 
Magnuson B.A., Davis M., Hubele S., Austin P.R., Kudva I.T., Williams C.J., Hunt C.W., Hovde C.J. (2000). 
Ruminant gastrointestinal cell proliferation and clearance of Escherichia coli O157:H7. Infection and 
Immunity, 68(7), pp.3808–3814. 
Mahajan A. Currie C.G., Mackie S., Tree J., McAteer S., McKendrick I., McNeilly T.N., Roe A., La Ragione R.M., 
Woodward M.J., Gally D.L., Smith D.G. (2009). An investigation of the expression and adhesin function of 
H7 flagella in the interaction of Escherichia coli O157 : H7 with bovine intestinal epithelium. Cell 
Microbiology, 11(1), pp.121–137.  
Mainil J. (1999). Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals. Veterinary Research, 
30(2-3), pp.235–57. 
Mallya M., Campbell R.D. & Aguado B. (2006). Characterization of the five novel Ly-6 superfamily members 
encoded in the MHC, and detection of cells expressing their potential ligands. Protein Science, 15(10), 
pp.2244–2256. 
Malyukova I., Murray K.F., Zhu C., Boedeker E., Kane A., Patterson K., Peterson J.R., Donowitz M., Kovbasnjuk O. 
(2009). Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular 
transcytosis. American Journal of Physiology - Gastrointestinal and Liver, 21205, pp.78–92. 
Marchès O., Ledger T.N., Boury M., Ohara M., Tu X., Goffaux F., Mainil J., Rosenshine I., Sugai M., De Rycke J., 
Oswald E. (2003). Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector 
called Cif, which blocks cell cycle G2/M transition. Mol Microbiol., 50(5), pp.1553–67. 
Marchès O., Covarelli V., Dahan S., Cougoule C., Bhatta P., Frankel G., Caron (2008). EspJ of enteropathogenic 
and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis. Cellular Microbiology, 10(5), 
pp.1104–1115. 
Marie-Cardine A., Kirchgessner H., Bruyns E., Shevchenko A., Mann M., Autschbach F., Ratnofsky S., Meuer S., 
Schraven B. (1999). SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer 
regulating human T cell activation. Journal of Expermental Medicine, 189(8), pp.1181–1194. 
Martinez M.B., Taddei C.R., Ruiz-Tagle A., Trabulsi L.R., Girón J.A. (1999). Antibody response of children with 
enteropathogenic Escherichia coli infection to the bundle-forming pilus and locus of enterocyte 
effacement- encoded virulence determinants. Journal of Infectious Diseases, 179(1), pp.269–274. 
Masson P.L. & Heremans J.F. (1971). Lactoferrin in milk from different species. Comparative Biochemistry and 
Physiology -- Part B: Biochemistry and, 39(1). 
Mattsby-Baltzer I., Roseanu A., Motas C., Elverfors J., Engberg I., Hanson L.A. (1996). Lactoferrin or a fragment 
thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatric 
Research, 40(2), pp.257–62.  
References 
182 
 
McDonald K.J., Cameron A.J., Allen J.M., Jardine A.G. (2002). Expression of Fc alpha/mu receptor by human 
mesangial cells: a candidate receptor for immune complex deposition in IgA nephropathy. Biochemical 
and Biophysical Research Communications, 290(1), pp.438–442. 
McKnight A.J. & Gordon S. (1998). The EGF-TM7 family: unusual structures at the leukocyte surface. Journal of 
Leukocyte Biology, 63(3), pp.271–280. 
McNamara B.P., Koutsouris A., O'Connell C.B., Nougayréde J.P., Donnenberg M.S., Hecht G. (2001). 
Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier 
function. Journal of Clinical Investigation, 107(5), pp.621–629. 
Melton-Celsa A.R. (2015). Shiga toxin (Stx) classification, structure, and function. In Enterohemorrhagic 
Escherichia coli and other shiga toxin-producing E. coli. pp. 37–54. 
Menge C., Loos D., Bridger P.S., Barth S., Werling D., Baljer G. (2015). Bovine macrophages sense Escherichia 
coli Shiga toxin 1. Innate Immunity, 21(6), pp.655–64. 
Menge C., Wieler L.H., Schlapp T., Baljer G. (1999). Shiga Toxin 1 from Escherichia coli Blocks Activation and 
Proliferation of Bovine Lymphocyte Subpopulations In Vitro. Infection and Immunity, 67(5), pp.2209–
2217. 
Menge C., Stamm I., Blessenohl M., Wieler L.H., Baljer G. (2003). Verotoxin 1 from Escherichia coli Affects 
Gb3/CD77+ Bovine Lymphocytes Independent of Interleukin-2, Tumor Necrosis Factor-α, and Interferon-
α. Experimental biology and medicine, 228(4), pp.377–386. 
Metcalfe H.J., La Ragione R.M., Smith D.G.E., Werling D. (2014). Functional characterisation of bovine TLR5 
indicates species-specific recognition of flagellin. Veterinary Immunology and Immunopathology 57, 
pp.197-205. 
Metz-Boutigue M.H., Jollès J., Mazurier J., Schoentgen F., Legrand D., Spik G., Montreuil J., Jollès P. (1984). 
Human lactotransferrin: Amino acid sequence and structural comparisons with other transferrins. 
European Journal of Biochemistry, 145(3), pp.659–676. 
Meyers J.H., Sabatos C.A., Chakravarti S., Kuchroo V.K. (2005). The TIM gene family regulates autoimmune and 
allergic diseases. Trends in Molecular Medicine, 11(8): 362-9. 
Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M. (2012). IL-6/IL-6 receptor system and its role in 
physiological and pathological conditions. Clinical Science, 122(4), pp.143–59.. 
Miossec P., Korn T. & Kuchroo V.K. (2009). Interleukin-17 and Type 17 Helper T Cells. The new england journal 
of medicine, 361(9), pp.888–898. 
Misyurina O., Asper D.J., Deng W., Finlay B.B., Rogan D., Potter A.A. (2010). The role of Tir, EspA, and NleB in 
the colonization of cattle by Shiga toxin producing Escherichia coli O26:H11. Canadian Journal of 
Microbiology, 56(9), pp.739–47. 
Miyake Y., Ishikawa E., Ishikawa T., Yamasaki S. (2010). Self and nonself recognition through C-type lectin 
receptor, Mincle. Self Nonself Journal, 1(4), pp.310–313. 
Miyamoto Y., Iimura M., Kaper J.B., Torres A.G., Kagnoff M.F. (2006). Role of Shiga toxin versus H7 flagellin in 
enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cellular Microbiology, 
8(5), pp.869–879. 
Miyauchi H., Hashimoto S., Nakajima M., Shinoda I., Fukuwatari Y., Hayasawa H. (1998). Bovine Lactoferrin 
Stimulates the Phagocytic Activity of Human Neutrophils: Identification of Its Active Domain. Cellular 
Immunology, 187(1), pp.34–37.  
Miyazawa K., Mantel C., Lu L., Morrison D.C., Broxmeyer H.E. (1991). Lactoferrin-lipopolysaccharide 
interactions. Effect on Lactoferrin Binding to Monocyte / Macrophage-Differentiated HL-60 cells. Journal 
of immunology, 146, pp.723–729. 
References 
183 
 
Mohammed J., Frasca S. Jr., Cecchini K., Rood D., Nyaoke A.C., Geary S.J., Silbart L.K. (2007). Chemokine and 
cytokine gene expression profiles in chickens inoculated with Mycoplasma gallisepticum strains Rlow or 
GT5. Vaccine, 25(51), pp.8611–8621. 
Montreuil J., Tonnelat J. & Mullet S. (1960). Preparation et propietes de la lactosiderophiline (lactotransferrine) 
du lait de femme. Biochimica et biophysica acta, 45, pp.413–21. 
Morato E.P., Leomil L., Beutin L., Krause G., Moura R.A., Pestana de Castro A.F. (2009). Domestic cats constitute 
a natural reservoir of human enteropathogenic Escherichia coli types. Zoonoses Public Health., 56(5), 
pp.229–37. 
Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and 
cytotoxicity assays. Journal of Immunological Methods, 65(1-2), pp.55–63. 
Mowat, A.M. (2003). Anatomical basis of tolerance and immunity to intestinal antigens. Nature reviews. 
Immunology, 3(4), pp.331–341. 
Moxley R. (2004). Escherichia coli 0 1 57:H7: an update on intestinal colonization and virulence mechanisms. 
Animal Health Research Reviews, 511(1), pp.15–33. 
Mukaida N., Mahe Y. & Matsushima K. (1990). Cooperative interaction of nuclear factor “kappa”B (NF-’kappa'B) 
and sis- Regulatory enhancer binding protein-like factor (C/EBP) binding elements in activating the 
Interleukin-8 gene by pro- inflammatory cytokines. Journal of Biological Chemistry, 265(34), pp.21128–
21133. 
Murata A., Shimazu T., Yamamoto T., Taenaka N., Nagayama K., Honda T, Sugimoto H., Monden M., Matsuura 
N., Okada S. (1998). Profiles of circulating inflammatory- and anti-inflammatory cytokines in patients with 
hemolytic uremic syndrome due to E. coli O157 infection. Cytokine, 10(7), pp.544–548.  
Murdock C., Chikindas M. & Matthews K. (2010). The Pepsin Hydrolysate of Bovine Lactoferrin Causes a 
Collapse of the Membrane Potential in Escherichia coli O157:H7. Probiotics Antimicrob Proteins, 2(2), 
pp.112–9. 
Murdock C.A. & Matthews K.R. (2002). Antibacterial activity of pepsin-digested lactoferrin on foodborne 
pathogens in buffered broth systems and ultra-high temperature milk with EDTA. Journal of Applied 
Microbiology, 93(5), pp.850–856. 
N 
Nart P., Holden N., McAteer S.P., Wang D., Flockhart A.F., Naylor S.W., Low J.C., Gally D.L., Huntley J.F. (2008). 
Mucosal antibody responses of colonized cattle to Escherichia coli O157-secreted proteins, flagellin, outer 
membrane proteins and lipopolysaccharide. FEMS Immunology and Medical Microbiology, 52(1), pp.59–
68.  
NaserEddin A., Shamriz O., Keller B., Alzyoud R.M., Unger S., Fisch P., Prus E., Berkun Y., Averbuch D., Shaag A., 
Wahadneh A.M., Conley M.E., Warnatz K., Elpeleg O., Stepensky P. (2015). Enteroviral Infection in a 
Patient with BLNK Adaptor Protein Deficiency. Journal of Clinical Immunology, 35(4), pp.356–360. 
Nastasijevic I., Mitrovic R. & Buncic S. (2008). Occurrence of Escherichia coli O157 on hides of slaughtered 
cattle. Letters in Applied Microbiology, 46(1), pp.126–131. 
National Center for Biotechnology Information Gene, 2014. CCL19 chemokine (C-C motif) ligand 19 [ Homo 
sapiens (human) ].  
Naylor S.W., Roe A.J., Nart P., Spears K., Smith D.G., Low J.C., Gally D.L. (2005). Escherichia coli O157 : H7 forms 
attaching and effacing lesions at the terminal rectum of cattle and colonization requires the LEE4 operon. 
Microbiology, 151(Pt 8), pp.2773–2781. 
References 
184 
 
Naylor S.W., Nart P., Sales J., Flockhart A., Gally D.L., Low J.C. (2007). Impact of the direct application of 
therapeutic agents to the terminal recta of experimentally colonized calves on Escherichia coli O157:H7 
shedding. Applied and Environmental Microbiology, 73(5), pp.1493–1500.  
Naylor S.W., Low J.C., Besser T.E., Mahajan A., Gunn G.J., Pearce M.C., McKendrick I.J., Smith D.G., Gally D.L. 
(2003). Lymphoid follicle-dense mucosa at the terminal rectum is the principal site of colonization of 
enterohemorrhagic Escherichia coli O157:H7 in the bovine host. Infection and immunity, 71(3), pp.1505–
12.  
NCBI Reference Sequence Database (2008). CD180 CD180 molecule.  
NCBI Reference Sequence Database (2012). LTA. 
Newton H.J., Pearson J.S., Badea L., Kelly M., Lucas M., Holloway G., Wagstaff K.M., Dunstone M.A., Sloan J., 
Whisstock J.C., Kaper J.B., Robins-Browne R.M., Jans D.A., Frankel G., Phillips A.D., Coulson B.S., Hartland 
E.L. (2010). The type III effectors NieE and NleB from enteropathogenic E. coli and Ospz from shigella 
block nuclear translocation of NF-κB p65. PLoS Pathogens, 6(5), pp.1–16. 
Nordenfelt P. & Tapper H. (2001). Phagosome dynamics during phagocytosis by neutrophils. Journal of 
Leukocyte Biology, 268(23), pp.6083–6096. 
O 
O'Brien A.O., Lively T.A., Chen M.E., Rothman S.W., Formal S.B. (1983). Escherichia coli O157:H7 strains 
associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like 
cytotoxin. Lancet, 1(8326), p.702. 
O'Brien A.D., LaVeck G.D., Thompson M.R., Formal S.B. (1982). Production of Shigella dysenteriae type 1-like 
cytotoxin by Escherichia coli. Journal of Infectious Disease, 146, pp.763–69. 
O'Donnell J.M., Thornton L., McNamara E.B., Prendergast T., Igoe D., Cosgrove C. (2002). Outbreak of Vero 
cytotoxin-producing Escherichia coli O157 in a child day care facility. Communicable disease and public 
health, 5(1), pp.54–8. 
O’Neill L.A., Golenbock D. & Bowie A.G. (2013). The history of Toll-like receptors - redefining innate immunity. 
Nature reviews. Immunology, 13(6), pp.453–60.  
Ochoa T.J., Noguera-Obenza M., Ebel F., Guzman C.A., Gomez H.F., Cleary T.G. (2003). Lactoferrin Impairs Type 
III Secretory System Function in Enteropathogenic Escherichia coli. Infection and Immunity, 71(9), 
pp.5149–5155. 
Ogawa M., Shimizu K., Nomoto K., Tanaka R., Hamabata T., Yamasaki S., Takeda T., Takeda Y. (2001). Inhibition 
of in vitro growth of Shiga toxin-producing Escherichia coli O157:H7 by probiotic Lactobacillus strains due 
to production of lactic acid. International Journal of Food Microbiology, 68(1-2), pp.135–40. 
Ogura Y., Ooka T., Iguchi A., Toh H., Asadulghani M., Oshima K., Kodama T., Abe H., Nakayama K., Kurokawa K., 
Tobe T., Hattori M., Hayashi T. (2009). Comparative genomics reveal the mechanism of the parallel 
evolution of O157 and non-O157 enterohemorrhagic Escherichia coli. Proceedings of the National 
Academy of Sciences of the United States of America, 106(42), pp.17939–17944. 
Oh S.M., Hahm D.H., Kim I.H., Choi S.Y. (2001). Human Neutrophil Lactoferrin trans-Activates the Matrix 
Metalloproteinase 1 Gene through Stress-activated MAPK Signaling Modules. Journal of Biological 
Chemistry, 276(45), pp.42575–42579. 
Ohya T., Marubashi T. & Ito H. (2000). Significance of fecal volatile fatty acids in shedding of Escherichia coli 
O157 from calves: experimental infection and preliminary use of a probiotic product. Journal of 
Veterinary Medical Science, 62(11), pp.1151–1155. 
Online Mendelian Inheritance in Man (2004). SSC4D scavenger receptor cysteine rich family, 4 domains.  
References 
185 
 
Orskov E. (1986). Starch digestion and utilization in ruminants. Journal of Animal Science, 63(5), pp.1624–33. 
Ostroff S., Kobayashi J. & Lewis J. (1989). Infections with Escherichia coli O157:H7 in Washington State. The first 
year of statewide disease surveillance. Journal of the American Medical Association, 262(3), pp.355–9. 
Osvaldova A., Woodman S., Patterson N., Offord V., Mwangi D., Gibson A.J., Matiasovic J., Werling D. (2014). 
Replacement of two aminoacids in the bovine Toll-like receptor 5 TIR domain with their human 
counterparts partially restores functional response to flagellin. Developmental and Comparative 
Immunology 47, pp. 90-94. 
Otto B.R., Verweij-van Vught A.M. & MacLaren D.M. (1992). Transferrins and heme-compounds as iron sources 
for pathogenic bacteria. Critical Reviews in Microbiology, 18(3), pp.217–233. 
Ozsolak F. & Milos P.M. (2011). RNA sequencing: advances, challenges and opportunities. Nature Reviews 
Genetics, 12(2), pp.87–98. 
P 
Pallen M.J., Beatson S.A. & Bailey C.M. (2005). Bioinformatics analysis of the locus for enterocyte effacement 
provides novel insights into type-III secretion. BMC microbiology, 5, p.9.  
Pallett M.A., Berger C.N., Pearson J.S., Hartland E.L., Frankel G. (2014). The type III secretion effector NleF of 
enteropathogenic Escherichia coli activates NF-κB early during infection. Infection and Immunity, 82(11), 
pp.4878–4888. 
Palomino D.C.T. & Marti L.C. (2015). Chemokines and immunity. Einstein (Sao Paolo), 13(3), pp.469–473.  
Paton A.W., Paton J.C. & Manning P. (1993). Polymerase chain reaction amplification, cloning and sequencing 
of variant Escherichia coli Shiga-like toxin type II operons. Microbial pathogenesis, 15(1), pp.77–82.  
Paton A.W., Beutin L. & Paton J.C. (1995). Heterogeneity of the amino-acid sequences of Escherichia coli shiga-
like toxin type-I operons. Gene, 153(1), pp.71–74. 
Pavia A.T., Nichols C.R., Green D.P., Tauxe .V., Mottice S., Greene K.D., Wells J.G., Siegler R.L., Brewer E.D., 
Hannon D., et al. (1990). Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 
infections in institutions for mentally retarded persons: clinical and epidemiologic observations. Journal 
of Pediatrics, 116(4), pp.544–51. 
Pawlaczyk K., Polubinska A, Numata N, Nakayama M, Pecoits-Filho R, Czekalski S, Lindholm B, Breborowicz A. 
(2008). Vascular endothelial growth factor in dialysate in relation to intensity of peritoneal inflammation. 
International Journal of Artificial Organs, 31(6), pp.535–44. 
Pelanda R., Braun U., Hobeika E., Nussenzweig M.C., Reth M. (2002). B cell progenitors are arrested in 
maturation but have intact VDJ recombination in the absence of Ig-alpha and Ig-beta. Journal of 
Immunology, 169(2), pp.865–872. 
Penney N., Bigwood T., Barea H., Pulford D., LeRoux G., Cook R., Jarvis G., Brightwell G. (2007). Efficacy of a 
peroxyacetic acid formulation as an antimicrobial intervention to reduce levels of inoculated Escherichia 
coli O157:H7 on external carcass surfaces of hot-boned beef and veal. Journal of Food Protection, 70(1), 
pp.200–3. 
Peralta-Ramírez J., Hernandez J.M., Manning-Cela R., Luna-Muñoz J., Garcia-Tovar C., Nougayréde J.P., Oswald 
E., Navarro-Garcia F. (2008). EspF interacts with nucleation-promoting factors to recruit junctional 
proteins into pedestals for pedestal maturation and disruption of paracellular permeability. Infection and 
Immunity, 76(9), pp.3854–3868. 
Perkins N.D. (2007). Integrating cell-signalling pathways with NF-kappaB and IKK function. Nature reviews. 
Molecular cell biology, 8(1), pp.49–62. 
References 
186 
 
Persad, A.K. & LeJeune, J.T. (2014). Animal Reservoirs of Shiga Toxin-Producing Escherichia coli. In 
Enterohemorrhagic Escherichia coli and other shiga toxin-producing E. coli. pp.211-30. 
Persson S., Olsen K.E., Ethelberg S., Scheutz F. (2007). Subtyping method for Escherichia coli Shiga toxin 
(Verocytotoxin) 2 variants and correlations to clinical manifestations. Journal of Clinical Microbiology, 
45(6), pp.2020–2024. 
Philpott D.J., Ackerley C.A., Kiliaan A.J., Karmali M.A., Perdue M.H., Sherman P.M. (1997). Translocation of 
verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. The 
American journal of physiology, 273(6 Pt 1), pp.G1349–58.  
Piérard D., Muyldermans G., Moriau L., Stevens D., Lauwers S. (1998). Identification of New Verocytotoxin Type 
2 Variant B-Subunit Genes in Human and Animal Escherichia coli Isolates. Journal of Clinical Microbiology, 
36(11), pp.3317–3322. 
Pinheiro da Silva F., Aloulou M., Benhamou M., Monteiro R.C. (2008). Inhibitory ITAMs: a matter of life and 
death. Trends Immunology, 29(8), pp.366–373. 
Poggi A. & Zocchi M.R. (2014). NK cell autoreactivity and autoimmune diseases. Frontiers in immunology, 5(27), 
pp. unknown. 
Pritts T., Hungness E., Wang Q., Robb B., Hershko D., Hasselgren P.O. (2002). Mucosal and enterocyte IL-6 
production during sepsis and endotoxemia--role of transcription factors and regulation by the stress 
response. American journal of surgery, 183(4), pp.372–83.  
Proulx F., Turgeon J.P., Litalien C., Mariscalco M.M., Robitaille P., Seidman E. (1998). Inflammatory mediators in 
Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. The Pediatric Infectious 
Disease Journal, 17(10), pp.899–904. 
Proulx F., Seidman E.G. & Karpman D. (2001). Pathogenesis of Shiga toxin-associated hemolytic uremic 
syndrome. Pediatric research, 50(2), pp.163–71.  
Pruimboom-Brees I.M., Morgan T.W., Ackermann M.R., Nystrom E.D., Samuel J.E., Cornick N.A., Moon H.W. 
(2000). Cattle lack vascular receptors for Escherichia coli O157:H7 Shiga toxins. Proceedings of the 
National Academy of Sciences of the United States of America, 97(19), pp.10325–10329. 
Q 
Quintrell N., Lebo R., Varmus H., Bishop J.M., Pettenati M.J., Le Beau M.M., Diaz M.O., Rowley J.D. (1987). 
Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in 
hemopoietic cells. Molecular Cell Biology, 7(6), pp.2267–2275. 
R 
Rabinovitz B.C., Gerhardt E., Tironi Farinati C., Abdala A., Galarza R., Vilte D.A., Ibarra C., Cataldi A., Mercado 
E.C. (2012). Vaccination of pregnant cows with EspA, EspB, gamma-intimin, and shiga-toxin 2 proteins 
from Escherichia coli O157:H7 induces high levels of specific colostral antibodies that are transferred to 
newborn calves. Journal of Dairy Science, 95, pp.3318–3326. 
Rahn K., Renwick S.A., Johnson R.P., Wilson J.B., Clarke R.C., Alves D., McEwen S., Lior H., Spika J. (1997). 
Persistence of Escherichia coli O157 : H7 in dairy cattle and the dairy farm environment. Epidemiology 
and infection, 119(2), pp.251–259. 
Rainard P. (1993). Activation of the classical pathway of complement by binding of bovine lactoferrin to 
unencapsulated Streptococcus agalactiae. Immunology, 79(4), pp.648–652. 
Rattenbacher B., Bohjanen P.R. (2012). Evaluating Posttranscriptional Regulation of Cytokine Genes. Methods 
in Molecular Biology 820, pp.71-89. 
References 
187 
 
Rehli M., Krause S.W. & Andreesen R. (2002). The Membrane-Bound Ectopeptidase CPM as a Marker Of 
Macrophage Maturation in vitro And in vivo . Advances in Experimental Medicine and Biology, 477, 
pp.205–216. 
Reiss G., Kunz P., Koin D., Keeffe E.B. (2006). Escherichia coli O157:H7 infection in nursing homes: review of 
literature and report of recent outbreak. Journal of American Geriatric Society, 54(4), pp.680–4. 
Rex S., Kraemer S., Grieb G., Emontzpohl C., Soppert J., Goetzenich A., Rossaint R., Bernhagen J., Stoppe C. 
(2014). The role of macrophage migration inhibitory factor in critical illness. Mini Reviews in Medicinal 
Chemistry, 14(14), pp.1116–1124. 
Ribeiro L.F., Barbosa M.M., de Rezende Pinto F., Guariz C.S., Maluta R.P., Rossi J.R., Rossi G.A., Lemos M.V., do 
Amaral LA. (2016). Shiga toxigenic and enteropathogenic Escherichia coli in water and fish from pay-to-
fish ponds. Letters in Applied Microbiology, 62(3), pp.216–20. 
Riley L.W., Remis R.S., Helgerson S.D., McGee H.B., Wells J.G., Davis B.R., Hebert R.J., Olcott E.S., Johnson L.M., 
Hargrett N.T., Blake P.A., Cohen M.L. (1983). Hemorrhagic colitis associated with a rare Escherichia coli 
serotype. New English Journal of Medicine, 308(12), pp.681–5. 
Robins-Browne R.M. & Hartland E.L. (2002). Escherichia coli as a cause of diarrhea. Journal of Gastroenterology 
and Hepatology (Australia), 17(4), pp.467–475. 
Robson J.D., Davidson D. & Veillette A. (2004). Inhibition of the Jun N-terminal protein kinase pathway by SHIP-
1, a lipid phosphatase that interacts with the adaptor molecule Dok-3. Molecular Cell Biology, 24(6), 
pp.2332–2343. 
Rosenberger G., Dirksen G., Grunder H.D., Grunert E., Krause D., Stober M. (1979). Clinical examination of 
cattle. Reprint by Blackwell Science Ltd in 1995. 
Roxas J.L., Wilbur J.S., Zhang X., Martinez G., Vedantam G., Viswanathan V.K. (2012). The enteropathogenic 
Escherichia coli-secreted protein EspZ inhibits host cell apoptosis. Infection and Immunity, 80(11), 
pp.3850–3857. 
Rozema E.A., Stephens T.P., Bach S.J., Okine E.K., Johnson R.P., Stanford K., McAllister T.A. (2009). Oral and 
rectal administration of bacteriophages for control of Escherichia coli O157:H7 in feedlot cattle. Journal 
of Food Protection, 72, pp.241–250. 
Ruchaud-Sparagano M.H., Mühlen S., Dean P., Kenny B. (2011). The enteropathogenic E. coli (EPEC) Tir effector 
inhibits NF-κB activity by targeting TNFα receptor-associated factors. PLoS Pathogens, 7(12): e1002414. 
Rumi M.V., Irino K., Deza N., Huguet M.J., Bentancor A.B. (2012). First isolation in Argentina of a highly virulent 
Shiga toxin-producing Escherichia coli O145:NM from a domestic cat. Journal of Infection in Developing 
Countries, 6(4), pp.358–63. 
Rybarczyk J., Kieckens E., De Zutter L., Remon J.P., Vanrompay D., Cox E. (2015). Effects of lactoferrin treatment 
on Escherichia coli O157:H7 rectal colonization in cattle. Veterinary Microbiology, S0378-1135(2015).  
Rybarczyk J. (2016). Lactoferrin, a novel strategy for clearing Escherichia coli O157:H7 colonization in cattle. 
PhD dissertation for Ghent University, Belgium. 
S 
Sáez de Guinoa J., Barrio L., Mellado M., Carrasco Y.R. (2011). CXCL13/CXCR5 signaling enhances BCR-triggered 
B-cell activation by shaping cell dynamics. Blood, 118(6), pp.1560–1569. 
Samadpour M., Stewart J., Steingart K., Addy C., Louderback J., McGinn M., Ellington J., Newman T. (2002). 
Laboratory investigation of an E. coli O157:H7 outbreak associated with swimming in Battle Ground Lake, 
Vancouver, Washington. Journal of Environmental Health, 64(10), pp.16–20. 
References 
188 
 
Samba-Louaka A., Nougayrède J.P., Watrin C., Oswald E., Taieb F. (2009). The enteropathogenic Escherichia coli 
effector Cif induces delayed apoptosis in epithelial cells. Infection and Immunity, 77(12), pp.5471–5477. 
Samuel J.E. & Gordon V.M. (1994). Evidence that proteolytic separation of Shiga-like toxin type IIv A subunit 
into A1 and A2 subunits is not required for toxin activity. Journal of Biological Chemistry, 269(7), 
pp.4853–4859. 
Samuelsen Ø., Haukland H.H., Ulvatne H., Vorland L.H. (2004). Anti-complement effects of lactoferrin-derived 
peptides. FEMS Immunology and Medical Microbiology, 41(2), pp.141–148. 
Santos A.S. & Finlay B.B. (2015). Bringing down the host: Enteropathogenic and enterohaemorrhagic 
Escherichia coli effector-mediated subversion of host innate immune pathways. Cellular Microbiology, 
17(3), pp.318–332. 
Scheller J., Garbers C. & Rose-John S. (2014). Interleukin-6: From basic biology to selective blockade of pro-
inflammatory activities. Seminars in Immunology, 26(1), pp.2–12.  
Scheutz F., Teel L.D., Beutin L., Piérard D., Buvens G., Karch H., Mellmann A., Caprioli A., Tozzoli R., Morabito S., 
Strockbine N.A., Melton-Celsa A.R., Sanchez M., Persson S., O'Brien A.D. (2012). Multicenter evaluation of 
a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. Journal of 
Clinical Microbiology, 50(9), pp.2951–2963. 
Schillace R.V., Andrews S.F., Liberty G.A., Davey M.P., Carr D.W. (2002). Identification and characterization of 
myeloid translocation gene 16b as a novel a kinase anchoring protein in T lymphocytes. Journal of 
Immunology, 168(4), pp.1590–1599. 
Schmid-Hempel P. (2009). Immune defence, parasite evasion strategies and their relevance for “macroscopic 
phenomena” such as virulence. Philosophical transactions of the Royal Society of London, 364(1513), 
pp.85–98. 
Schmidt H., Scheef J., Morabito S., Caprioli A., Wieler L.H., Karch H. (2000). A new Shiga toxin 2 variant (Stx2f) 
from Escherichia coli isolated from pigeons. Applied and Environmental Microbiology, 66(3), pp.1205–
1208. 
Schüller S., Lucas M. & Kaper J. (2009). The ex vivo response of human intestinal mucosa to enteropathogenic 
Escherichia coli infection. Cell Microbiology, 11(3), pp.521–530.  
Scotland S.M., Day N.P., Willshaw G.A., Rowe B. (1980). Cytotoxic enteropathogenic Escherichia coli. Lancet, 
1(8159), p.90. 
Scotland S.M., Smith H.R., Willshaw G.A., Rowe B. (1983). Vero cytotoxin production in strain of Escherichia coli 
is determined by genes carried on bacteriophage. Lancet, 2(8343), p.216. 
Scotland S., Smith H. & Rowe B. (1985). Two distinct toxins active on Vero cells from Escherichia coli O157. 
Lancet, 2(8460), pp.885–6. 
Segura-Alvarez M., Richter H., Conraths F.J., Geue L. (2003). Evaluation of Enzyme-Linked Immunosorbent 
Assays and a PCR Test for Detection of Shiga Toxins for Shiga Toxin-Producing Escherichia coli in Cattle 
Herds. Journal of Clinical Microbiology, 41(12), pp.5760–5763. 
Serra-Moreno R., Jofre J. & Muniesa M. (2007). Insertion site occupancy by stx2 bacteriophages depends on the 
locus availability of the host strain chromosome. Journal of Bacteriology, 189(18), pp.6645–6654. 
Sfeir R.M., Dubarry M., Boyaka P.N., Rautureau M., Tomé D. (2004). The Mode of Oral Bovine Lactoferrin 
Administration Influences Mucosal and Systemic Immune Responses in Mice. Journal of Nutrition 134(2),  
pp.403–409. 
Sheng H., Knecht H.J., Kudva I.T., Hovde C.J. (2006). Application of Bacteriophages To Control Intestinal 
Escherichia coli O157:H7 Levels in Ruminants. Applied and Environmental Microbiology, 72(8), pp.5359–
5366.  
References 
189 
 
Sheng H., Wang J., Lim J.Y., Davitt C., Minnich S.A., Hovde C.J. (2011). Internalization of Escherichia coli O157:h7 
by bovine rectal epithelial cells. Frontiers of Microbiology, 22(2):32. 
Shere J.A., Kaspar C.W., Bartlett K.J., Linden S.E., Norell B., Francey S., Schaefer D.M. (2002). Shedding of 
Escherichia coli O157:H7 in Dairy Cattle Housed in a Confined Environment following Waterborne 
Inoculation. Applied and Environmental Microbiology, 68(4), pp.1947–1954. 
Shibuya A., Sakamoto N., Shimizu Y., Shibuya K., Osawa M., Hiroyama T., Eyre H.J., Sutherland G.R., Endo Y., 
Fujita T., Miyabayashi T., Sakano S., Tsuji T., Nakayama E., Phillips J.H., Lanier L.L., Nakauchi (2000). Fc 
alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nature Immunology, 1(5), pp.441–446. 
Shimazaki K.,Uji K., Tazume T., Kumura H., Shimo-Oka T. (2000). Approach to identification and comparison of 
the heparin-interacting sites of lactoferrin using synthetic peptides. In Lactoferrin: Structure, Function and 
Applications. pp. 37–46. 
Shin K., Yamauchi K., Teraguchi S., Hayasawa H., Tomita M., Otsuka Y., Yamazaki S. (1998). Antibacterial activity 
of bovine lactoferrin and its peptides against enterohaemorrhagic Escherichia coli O157:H7. Letters in 
Applied Microbiology, 26(6), pp.407–411. 
Shin K., Wakabayashi H., Yamauchi K., Yaeshima T., Iwatsuki K. (2008). Recombinant Human lntelectin Binds 
Bovine Lactoferrin and Its Peptides. Biological & Pharmaceutical Bulletin, 31(8), pp.1605–1608. 
Siegler R.L. (1994). Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome.   Journal 
of Pediatrics, 125(4), pp.511–8. 
Siegler R.L., Griffin P.M., Barrett T.J., Strockbine N.A. (1993). Recurrent hemolytic uremic syndrome secondary 
to Escherichia coli O157:H7 infection. Pediatrics, 91(3), pp.666–8. 
Slutsker L., Ries A.A., Greene K.D., Wells J.G., Hutwagner L., Griffin P.M. (1997). Escherichia coli O157:H7 
Diarrhea in the United States: Clinical and Epidemiologic Features. Annals of Internal Medicine, 126(7), 
pp.505–513.  
Smith W.E., Kane A.V., Campbell S.T., Acheson D.W., Cochran B.H., Thorpe C.M. (2003). Shiga Toxin 1 Triggers a 
Ribotoxic Stress Response Leading to p38 and JNK Activation and Induction of Apoptosis in Intestinal 
Epithelial Cells Shiga Toxin 1 Triggers a Ribotoxic Stress Response Leading to p38 and JNK Activation and 
Induction of Apoptosis . Infection and Immunity, 71(3), pp.1497–1504. 
Sockett P., Goebel S.E., Varela N.P., Guthrie A., Wilson J., Guilbault L.A., Clark W.F. (2004). Verotoxigenic 
Escherichia coli: Costs of illness-in-Canada, including long-term health outcomes. Journal of Food 
Protection, 77(2), pp.216–226. 
Sorensen M. & Sorensen S. (1939). The proteins in whey. Comptes Rendus des Travaux du Laboratoire 
Carlsberg, 23, pp.55–99. 
Spacek L.A., Hurley B.P., Acheson D.W., Granok A., Currie A., Doing K., Sears C.L. (2004). Shiga Toxin–Producing 
Escherichia coli as a Possible Etiological Agent of Chronic Diarrhea. Clinical Infectious Diseases, 39, pp.46–
48. 
Spadaro M., Caorsi C., Ceruti P., Varadhachary A., Forni G., Pericle F., Giovarelli M. (2008). Lactoferrin, a major 
defense protein of innate immunity, is a novel maturation factor for human dendritic cells. Federation of 
American Societies for Experimental Biology Journal, 22(8), pp.2747–2757.  
Spik G., Strecker G., Fournet B., Bouquelet S., Montreuil J., Dorland L., van Halbeek H., Vliegenthart J.F. (1982). 
Primary structure of the glycans from human lactotransferrin. European journal of biochemistry / FEBS, 
121(2), pp.413–419. 
St John A.L. & Abraham S.N. (2009). Salmonella disrupts lymph node architecture by TLR4-mediated 
suppression of homeostatic chemokines. Nature Medicine, 15(11), pp.1259–1265. 
Ståhl A.L., Sartz L., Nelsson A., Békássy Z.D., Karpman D. (2009). Shiga toxin and lipopolysaccharide induce 
References 
190 
 
platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic 
syndrome. PLoS ONE, 4(9): e6990. 
Stamm, I., Mohr, M., Bridger, P.S., Schröpfer, E., König, M., Stoffregen W.C., Dean-Nystrom E.A., Baljer G., 
Menge C. (2008). Epithelial and Mesenchymal Cells in the Bovine colonic Mucosa differ in their 
Responsisveness to Escherichia coli Shiga Toxin 1. Infection and Immunity, 76(11), pp. 5381-91. 
Stanford K., Bach S., Baah J., McAllister T. (2014). A mixture of Lactobacillus casei, Lactobacillus lactis, and 
Paenibacillus polymyxa reduces Escherichia coli O157:H7 in finishing feedlot cattle. Journal of Food 
Protection, 77(5), pp.738–44. 
Steijns J. & van Hooijdonk A. (2000). Occurrence, structure, biochemical properties and technological 
characteristics of lactoferrin. British Journal of Nutrition, 84(Suppl 1), pp.S11–7. 
Stein C. (2005). Factsheet on E.coli: WHO Initiative to Estimate the Global Burden of Foodborne Diseases. 
http://www.who.int/foodsafety/foodborne_disease/ecoli.pdf 
Steiner T.S., Nataro J.P., Poteet-Smith C.E., Smith J.A., Guerrant R.L. (2000). Enteroaggregative Escherichia coli 
expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. Journal of Clinical 
Investigation, 105(12), pp.1769–77. 
Stevens M. & Frankel G. (2015). The locus of enterocyte effacement and associated virulence factors of 
Enterohemorrhagic Escherichia coli. In Enterohemorrhagic Escherichia coli. pp. 97–130. 
Stevens M.P., van Diemen P.M., Frankel G., Phillips A.D., Wallis T.S. (2002a). Efa1 influences colonization of the 
bovine intestine by shiga toxin-producing Escherichia coli serotypes O5 and O111. Infection and 
Immunity, 70(9), pp.5158–5166. 
Stevens M.P., Marchès O., Campbell J., Huter V., Frankel G., Phillips A.D., Oswald E., Wallis T.S. (2002b). Intimin 
, Tir , and Shiga Toxin 1 Do Not Influence Enteropathogenic Responses to Shiga Toxin-Producing 
Escherichia coli in Bovine Ligated Intestinal Loops. Infection and Immunity, 70(2), pp.945–952. 
Stevens M.P., van Diemen P.M., Dziva F., Jones P.W., Wallis T.S. (2002). Options for the control of 
enterohaemorrhagic Escherichia coli in ruminants. Microbiology, 148, pp.3767–3778. 
Storset A.K., Slettedal I.O., Williams J.L., Law A., Dissen E. (2003). Natural killer cell receptors in cattle: a bovine 
killer cell immunoglobulin-like receptor multigene family contains members with divergent signaling 
motifs. European Journal of Immunology, 33(4), pp.980–990. 
Striz I., Brabcova E., Kolesar L., Sekerkova A. (2014). Cytokine networking of innate immunity cells: a potential 
target of therapy. Clinical Science, 126, pp.593–612. 
Swainson L.A., Mold J.E., Bajpai U.D., McCune J.M. (2010). Expression of the autoimmune susceptibility gene 
FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell 
death-1. Journal of Immunology, 184(7), pp.3639–3647. 
T 
Tahamtan Y., Kargar M., Namdar N., Rahimian A., Hayati M., Namavari M.M. (2011). Probiotic inhibits the 
cytopathic effect induced by Escherichia coli O157:H7 in Vero cell line model. Letters in applied 
microbiology, 52(5), pp.527–31.  
Talbot S., De Brito Gariépy H., Saint-Denis J., Couture R. (2012). Activation of kinin B1 receptor evokes 
hyperthermia through a vagal sensory mechanism in the rat. Journal of Neuroinflammation, 9(214), 
pp.unknown. 
Tam P. & Lingwood C. (2007). Membrane cytosolic translocation of verotoxin A1 subunit in target cells. 
Microbiology, 153(8), pp.2700–10. 
References 
191 
 
Tamamis P. & Floudas C. (2014). Elucidating a Key Component of Cancer Metastasis: CXCL12 (SDF-1α) Binding 
to CXCR4. Journal of Chemical Information and Modeling, 54(4), pp.1174–1188. 
Tanaka H., Toyoda N., Adachi E., Takeda T. (2000). Immunologic evaluation of an Escherichia coli O157-infected 
pregnant woman. A case report. Journal of Reproductive Medicine, 45(5), pp.442–4. 
Tarr P.I., Gordon C.A. & Chandler W.L. (2005). Shiga-toxin-producing Escherichia coli and haemolytic uraemic 
syndrome. Lancet, 365(9464), pp.1073–1086. 
Taylor K.A., O'Connell C.B., Luther P.W., Donnenberg M.S. (1998). The EspB protein of enteropathogenic 
Escherichia coli is targeted to the cytoplasm of infected HeLa cells. Infection and Immunity, 66(11), 
pp.5501–5507. 
Tesh V.L., Burris J.A., Owens J.W., Gordon V.M., Wadolkowski E.A., O'Brien A.D., Samuel J.E. (1993). 
Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infection and 
Immunity, 61(8), pp.3392–3402. 
Tesh V.L., Ramegowda B. & Samuel J.E., (1994). Purified Shiga-like toxins induce expression of proinflammatory 
cytokines from murine peritoneal macrophages. Infection and Immunity, 62(11), pp.5085–5094.  
Thanabalasuriar A., Koutsouris A., Weflen A., Mimee M., Hecht G., Gruenheid S. (2011). The bacterial virulence 
factor NleA is required for the disruption of intestinal tight junxtions by Enteropathogenic E. coli. Cell, 
12(1), pp.31–41. 
Theurer C. (1986). Grain processing effects on starch utilization by ruminants. Journal of Animal Science, 63(5), 
pp.1649–62. 
Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., Hession C., Schneider P., Sizing I.D., Mullen 
C., Strauch K., Zafari M. Benjamin C.D., Tschopp J., Browning J.L., Ambrose C. (2001). BAFF-R, a newly 
identified TNF receptor that specifically interacts with BAFF. Science., 293(5537 ), pp.2108–2111. 
Thomson D.U., Loneragan G.H., Thornton A.B., Lechtenberg K.F., Emery D.A., Burkhardt D.T., Nagaraja T.G. 
(2009). Use of a siderophore receptor and porin proteins-based vaccine to control the burden of 
Escherichia coli O157:H7 in feedlot cattle. Foodborne pathogens and disease, 6(7), pp.871–7.  
Thorpe C.M., Hurley B.P., Lincicome L.L., Jacewicz M.S., Keusch G.T., Acheson D.W. (1999). Shiga toxins 
stimulate secretion of interleukin-8 from intestinal epithelial cells. Infection and Immunity, 67(11), 
pp.5985–5993. 
Tildesley M.J., Gally D.L., McNeilly T.N., Low J.C., Mahajan A., Savill N.J. (2012). Insights into mucosal innate 
responses to Escherichia coli O157 : H7 colonization of cattle by mathematical modelling of excretion 
dynamics. Journal of the Royal Society Interface, 9(68), pp.518–527.  
Tittor A.W. (2003). Efficacy of electrostatically sprayed Activin, hot water, high pressure water and lactic acid 
individually and used in a multihurdle approach to remove Escherichia coli O157:H7 from beef tissues. 
PhD dissertation for Texas Tech University. 
Tkalcic S., Zhao T., Harmon B.G., Doyle M.P., Brown C.A., Zhao P. (2003). Fecal shedding of enterohemorrhagic 
Escherichia coli in weaned calves following treatment with probiotic Escherichia coli. J Food Prot., 66(7), 
pp.1184–9. 
Tomita M., Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase (1991). Potent antibacterial peptides 
generated by pepsin digestion of bovine lactoferrin. Journal of dairy science, 74, pp.4137–4142. 
Torres A.G., Milflores-Flores L., Garcia-Gallegos J.G., Patel S.D., Best A., La Ragione R.M., Martinez-Laguna Y., 
Woodward M.J. (2007). Environmental regulation and colonization attributes of the long polar fimbriae 
(LPF) of Escherichia coli O157:H7. International Journal of Medical Microbiology, 297(3), pp.177–185. 
Torso L.M., Voorhees R.E., Forest S.A., Gordon A.Z., Silvestri S.A., Kissler B., Schlackman J., Sandt C.H., Toma P., 
Bachert J., Mertz K.J., Harrison L.H. (2015). Escherichia coli O157:H7 Outbreak Associated with Restaurant 
References 
192 
 
Beef Grinding. Journal of Food Protection, 78(7), pp.1272–9. 
Trapnell C., Pachter L. & Salzberg S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 
25(9), pp.1105–1111. 
Trofa A.F., Ueno-Olsen H., Oiwa R., Yoshikawa M. (1999). Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 29(5), 
pp.1303–1306. 
Tseng J., Eisfelder B.J. & Clark M.R. (1997). B-cell antigen receptor-induced apoptosis requires both Ig alpha and 
Ig beta. Blood., 89(5), pp.1513–1520. 
Tu X., Nisan I., Yona C., Hanski E., Rosenshine I. (2003). EspH, a new cytoskeleton-modulating effector of 
enterohaemorrhagic and enteropathogenic Escherichia coli. Molecular Microbiology, 47(3), pp.595–606. 
Tutenel A.V., Pierard D., Uradzinski J., Jozwik E., Pastuszczak M., Van Hende J., Uyttendaele M., Debevere J., 
Cheasty T., Van Hoof J., De Zutter L. (2002). Isolation and characterization of enterohaemorrhagic 
Escherichia coli O157:1H7 from cattle in Belgium and Poland. Epidemiology and infection, 129(1), pp.41–
7. 
Tutenel A.V., Pierard D., Van Hoof J., De Zutter L. (2003). Molecular characterization of Escherichia coli O157 
contamination routes in a cattle slaughterhouse. Journal of Food Protection, 66(9), pp.1564–9. 
Tzipori S., Robins-Browne R.M., Gonis G., Hayes J., Withers M., McCartney E. (1985). Enteropathogenic 
Escherichia coli enteritis: evaluation of the gnotobiotic piglet as a model of human infection. Gut, 26(6), 
pp.570–8.  
Tzipori S., Gibson R. & Montanaro J. (1989). Nature and distribution of mucosal lesions associated with 
enteropathogenic and enterohemorrhagic Escherichia coli in piglets and the role of plasmid-mediated 
factors. Infection and Immunity, 57(4), pp.1142–1150. 
U 
UniProt, 2015. T-cell immunoglobulin and mucin domain-containing protein 4: by similarity. Available at: 
http://www.uniprot.org/uniprot/Q96H15. 
V 
Vande Walle K. (2010). Insights in the immune response against Escherichia coli O157:H7 infection in sheep, 
PhD dissertation for Ghent University, Belgium. 
Vande Walle K., Yekta M.A., Verdonck F., De Zutter L., Cox E. (2011). Rectal inoculation of sheep with E. coli 
O157:H7 results in persistent infection in the absence of a protective immune response. Veterinary 
Microbiology, 147(3-4), pp.376–382.  
Vande Walle K., Vanrompay D. & Cox E. (2013). Bovine innate and adaptive immune responses against 
Escherichia coli O157:H7 and vaccination strategies to reduce faecal shedding in ruminants. Veterinary 
Immunology and Immunopathology, 152(1-2), pp.109–120.  
Vande Walle K., De Zutter L. & Cox E. (2011). Oral infection with a Shiga toxin-negative Escherichia coli O157:H7 
strain elicits humoral and cellular responses but does not protect sheep from colonisation with the 
homologous strain. Vet Microbiol, 148(2-4), pp.317–322.  
Van Donkersgoed J., Hancock D., Rogan D., Potter A.A. (2005). Escherichia coli O157H7 vaccine field trial in 9 
feedlots in Alberta and Saskatchewan. Can Vet J, 46, pp.724–728. 
van Diemen P.M., Dziva F., Abu-Median A., Wallis T.S., van den Bosch H., Dougan G., Chanter N., Frankel G., 
Stevens M.P. (2007). Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity 
References 
193 
 
in cattle but do not protect against intestinal colonisation by enterohaemorrhagic Escherichia coli 
O157:H7 or O26:H-. Veterinary Immunology and Immunopathology, 116(1-2), pp.47–58. 
van Zelm M.C., Reisli I., van der Burg M., Castaño D., van Noesel C.J., van Tol M.J., Woellner C., Grimbacher B., 
Patiño P.J., van Dongen J.J., Franco J.L. (2006). An antibody-deficiency syndrome due to mutations in the 
CD19 gene. N Engl J Med., 354(18), pp.1901–1912. 
Venkitanarayanan K., Zhao T. & Doyle M. (1999). Antibacterial effect of lactoferricin B on Escherichia coli 
O157:H7 in ground beef. Journal of Food Protection, 62(7), pp.747–50. 
Vilches C. & Parham P. (2002). KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annual 
Review of Immunology, 20, pp.217–251. 
Villarete, L.H., Remick D.G. (1996). Transcriptional and Post-transcriptional Regulation of interleukin-8. 
American Journal of Pathology 149(5), pp.1685-1693. 
Vilte D.A., Larzábal M., Garbaccio S., Gammella M., Rabinovitz B.C., Elizondo A.M., Cantet R.J., Delgado F., 
Meikle V., Cataldi A., Mercado E.C (2011). Reduced faecal shedding of Escherichia coli O157:H7 in cattle 
following systemic vaccination with gamma-intimin C280 and EspB proteins. Vaccine, 29(23), pp.3962–
3968.  
Vossenkämper A., Marchès O., Fairclough P.D., Warnes G., Stagg A.J., Lindsay J.O., Evans P.C., Luong le A., Croft 
N.M., Naik S., Frankel G., MacDonald T.T. (2010). Inhibition of NF-κB signaling in human dendritic cells by 
the enteropathogenic Escherichia coli effector protein NleE. Journal of immunology (Baltimore, Md. : 
1950), 185(7), pp.4118–4127. 
W 
Wada T., Aiba Y., Shimizu K., Takagi A., Miwa T., Koga Y. (1999). The therapeutic effect of bovine lactoferrin in 
the host infected with Helicobacter pylori. Scandinavian Journal of Gastroenterology, 34(3), pp.238–243. 
Wade W., Thom B. & Evans N. (1979). Cytotoxic enteropathogenic Escherichia coli. Lancet, 2(8154), pp.1235–6. 
Wagner P.L., Livny J., Neely M.N., Acheson D.W., Friedman D.I., Waldor M.K. (2002). Bacteriophage control of 
Shiga toxin 1 production and release by Escherichia coli. Molecular Microbiology, 44(4), pp.957–970. 
Wagner P.L., Neely M.N., Zhang X., Acheson D.W., Waldor M.K., Friedman D.I. (2001). Role for a Phage 
Promoter in Shiga Toxin 2 Expression from a Pathogenic Escherichia coli. Journal of Bacteriology, 183(6), 
pp.2081–2085.  
Wakabayashi H., Oda H., Yamauchi K., Abe F. (2014). Lactoferrin for prevention of common viral infections. 
Journal of Infection and Chemotherapy, 20(11), pp.666–671. 
Walch M., Dotiwala F., Mulik S., Thiery J., Kirchhausen T., Clayberger C., Krensky A.M., Martinvalet D., 
Lieberman J. (2014). Cytotoxic Cells Kill Intracellular Bacteria through Granulysin-Mediated. Cell Press, 
157(6), pp.1309–1323. 
Walterspiel J.N., Ashkenazi S., Morrow A.L., Cleary T.G. (1992). Effect of subinhibitory concentrations of 
antibiotics on extracellular Shiga-like toxin I. Infection, 20(1), pp.25–9. 
Wan F., Weaver A., Gao X., Bern M., Hardwidge P.R., Lenardo M.J. (2011). IKKβ phosphorylation regulates RPS3 
nuclear translocation and NF-κB function during Escherichia coli O157:H7 infection. Nature Immunology, 
12(4), pp.335–343. 
Wang K.X. & Denhardt D.T. (2008). Osteopontin: role in immune regulation and stress responses. Cytokine 
Growth Factor Review, 19(5-6), pp.333–345. 
Wang Y., Shan T., Xu Z., Liu J., Feng J. (2004). Effect of lactoferrin on the growth performance, intestinal 
morphology, and expression of PR-39 and protegrin-1 genes in weaned piglets. Journal of Animal Science, 
References 
194 
 
84(10), pp.2636–2641. 
Ward P.P., Paz E. & Conneely O.M. (2005). Multifunctional roles of lactoferrin: A critical overview. Cellular and 
Molecular Life Sciences, 62(22), pp.2540–2548. 
Watson A., Gubbels J.A.A. & Egland K.A. (2011). Sushi domain containing 2 (SUSD2): A plasma membrane 
protein on breast cancer cells that interacts with galectin-1. Proceedings of the 102nd Annual Meeting of 
the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer 
Res 2011;71(8 Suppl):Abstract nr 3054. 
Weinstein D.L., Jackson M.P., Samuel J.E., Holmes R.K., O'Brien A.D. (1988). Cloning and sequencing of a Shiga-
like toxin type II variant from an Escherichia coli strain responsible for edema disease of swine. Journal of 
Bacteriology, 170(9), pp.4223–4230. 
Welinder-Olsson C. & Kaijser B. (2005). Enterohemorrhagic Escherichia coli (EHEC). Scandinavian Journal of 
Infectious Disease, 37(6-7), pp.405–16. 
Wells J.G., Shipman L.D., Greene K.D., Sowers E.G., Green J.H., Cameron D.N., Downes F.P., Martin M.L., Griffin 
P.M., Ostroff S.M., et al. (1991). Isolation of Escherichia coli Serotype 0157:H7 and Other Shiga-Like-
Toxin-Producing E. coli from Dairy Cattle. Journal of Clinical Microbiology, 29(5), pp.985–989. 
Westerholt S., Hartung T., Tollens M., Güstrau A., Oberhoffer M., Karch H., Klare B., Pfeffer K., Emmrich P., 
Oberhoffer R. (2000). Inflammatory and immunological parameters in children with haemolytic uremic 
syndrome (HUS) and gastroenteritis-pathophysiological and diagnostic clues. Cytokine, 12(6), pp.822–7.  
White J.R., Imburgia C., Dul E., Appelbaum E., O'Donnell K., O'Shannessy D.J., Brawner M., Fornwald J., Adamou 
J., Elshourbagy N.A., Kaiser K., Foley J.J., Schmidt D.B., Johanson K., Macphee C., Moores K., McNulty D., 
Scott G.F., Schleimer R.P., Sarau H.M. (1997). Cloning and functional characterization of a novel human 
CC chemokine that binds to the CCR3 receptor and activates human eosinophils. Journal of Leukocyte 
Biology, 62(5), pp.667–675. 
Whitney G., Wang S., Chang H., Cheng K.Y., Lu P., Zhou X.D., Yang W.P., McKinnon M., Longphre M. (2001). A 
new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling 
properties similar to CD33. European Journal of Biochemistry, 268(23), pp.6083–6096. 
Wilbur J.S., Byrd W., Ramamurthy S., Ledvina H.E., Khirfan K., Riggs M.W., Boedeker E.C., Vedantam G., 
Viswanathan V.K. (2015). The Secreted Effector Protein EspZ Is Essential for Virulence of Rabbit 
Enteropathogenic Escherichia coli. Infection and Immunity, 83(3), pp.1139–1149.  
Wilson M., Seymour R. & Henderson B. (1998). Bacterial perturbation of cytokine networks. Infection and 
Immunity, 66(6), pp.2401–2409. 
Wong A.R., Pearson J.S., Bright M.D., Munera D., Robinson K.S., Lee S.F., Frankel G., Hartland E.L. (2011). 
Enteropathogenic and enterohaemorrhagic Escherichia coli: even more subversive elements. Molecular 
Microbiology, 80(6), pp.1420–39. 
Wu B., Jin M., Zhang Y., Wei T., Bai Z. (2011). Evolution of the IL17 receptor family in chordates: a new 
subfamily IL17REL. Immunogenetics, 63, pp.835–845. 
Wu J., Nilsson A., Jönsson B.A., Stenstad H., Agace W., Cheng Y., Duan R.D. (2006). Intestinal alkaline 
sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity. 
Biochemistry Journal, 394(1), pp.299–308. 
Y 
Yamauchi K., Wakabayashi H., Shin K., Takase M. (2006). Bovine lactoferrin: benefits and mechanism of action 
against infections. Biochemistry and Cell Biology, 84(3), pp.291–296.  
Yan D., Wang X., Luo L., Cao X., Ge B. (2012). Inhibition of TLR signaling by a bacterial protein containing 
References 
195 
 
immunoreceptor tyrosine-based inhibitory motifs. Nature Immunology, 13(11), pp.1063–1071. 
Yates J.L., Racine R., McBride K.M., Winslow G.M. (2013). T cell-dependent IgM memory B cells generated 
during bacterial infection are required for IgG responses to antigen challenge. Journal of Immunology, 
191(3), pp.1240–1249. 
Yekta M.A., Cox E., Goddeeris B.M., Vanrompay D. (2011). Reduction of Escherichia coli O157:H7 excretion in 
sheep by oral lactoferrin administration. Veterinary Microbiology, 150(3-4), pp.373–378.  
Yekta M.A., Verdonck F., Van Den Broeck W., Goddeeris B., Cox E., Vanrompay D. (2010). Lactoferrin inhibits E. 
coli O157:H7 growth and attachment to intestinal epithelial cells. Veterinarni Medicina, 55(8), pp.359–
368. 
Yekta M.A. (2011). New strategies for prevention of E. coli O157:H7 infection in sheep. PhD dissertation for 
Ghent University. 
Yen H., Ooka T., Iguchi A., Hayashi T., Sugimoto N., Tobe T. (2010). Nlec, a type III secretion protease, 
compromises NF-kB activation by targeting p65/rela. PLoS Pathogens, 6(12): e1001231. 
Yin C.M., Wong J.H., Xia J., Ng T.B. (2013). Studies on anticancer activities of lactoferrin and lactoferricin. 
Current Protein & Peptide Science, 14(6): 492-503.Younts-Dahl S.M., Osborn G.D., Galyean M.L., Rivera 
J.D., Loneragan G.H., Brashears M.M. (2005). Reduction of Escherichia coli O157 in finishing beef cattle by 
various doses of Lactobacillus acidophilus in direct-fed microbials. J Food Prot., 68(1), pp.6–10. 
Z 
Zhang X., McDaniel A.D., Wolf L.E., Keusch G.T., Waldor M.K., Acheson D.W. (2000). Quinolone antibiotics 
induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. The Journal of 
Infectious Diseases, 181, pp.664–670. 
Zhang Y., Lima C.F. & Rodrigues L.R. (2014). Anticancer effects of lactoferrin: Underlying mechanisms and 
future trends in cancer therapy. Nutrition Reviews, 72(12), pp.763–773. 
Zheng Y., Valdez P.A., Danilenko D.M., Hu Y, Sa S.M., Gong Q., Abbas A.R., Modrusan Z., Ghilardi N., de Sauvage 
F.J., Ouyang W. (2008). Interleukin-22 mediates early host defense against attaching and effacing 
bacterial pathogens. Nature medicine, 14(3), pp.282–9.  
Zimecki M., Mazurier J., Spik G., Kapp J.A. (1995). Human lactoferrin induces phenotypic and functional changes 
in murine splenic B cells. Immunology, 86(1), pp.122–127.  
 
 
  
 
  
 
 
 
 
 
 
Curriculum Vitae &  
Bibliography 
  
 
Curriculum Vitae & Bibliography 
 
199 
 
Curriculum Vitae 
 
Evelien Kieckens was born on October 28th, 1987 in Aalst, Belgium. In 2011, 
Evelien obtained her Master’s degree in Biomedical Sciences, Major Degeneration and 
Regeneration from the University of Ghent, Belgium. During her master training in the 
Tissue Engineering Group of the University of Ghent, Evelien worked on dynamic cell 
culture methods and performed research on cell-biomaterial interactions and cell 
viability. In Januari 2012, Evelien started her doctoral studies at the Laboratory of 
Immunology, at the Faculty of Veterinary Medicine of Ghent University, where she 
spend a 4-years PhD study focusing on the immunomodulation of the bovine host by E. 
coli O157:H7 and the effects of bovine lactoferrin on this modulation. Evelien Kieckens is 
author and co-author of several publications in peer-reviewed international journals and 
she has actively participated in several international conferences.     
  
Curriculum Vitae & Bibliography 
 
200 
 
Bibliography 
 
Publications in peer-reviewed international journals 
Kieckens E., Rybarczyk J., De Zutter L., Duchateau L., Vanrompay D., Cox E. (2015). 
Clearance of Escherichia coli O157:H7 infection in calves by rectal administration of 
bovine lactoferrin. Applied and Environmental Microbiology 81 (5): 1644-51. 
Rybarczyk J., Kieckens E., De Zutter L., Remon J.P., Vanrompay D., Cox E. (2015). 
Effects of lactoferrin treatment on Escherichia coli O157:H7 rectal colonization in cattle. 
Veterinary Microbiology pii: S0378-1135(15)30119-X. doi:10.1016/j.vetmic.2015.12.013. 
Kieckens E., Rybarczyk J., Barth S.A., Menge C., Cox E., Vanrompay D. (2016) Effect 
of lactoferrin release and bioactivity of Shiga toxins from different Escherichia coli 
O157:H7 strains. Accepted in Veterinary Microbiology  
Kieckens E., Rybarczyk J., Li R.W., Vanrompay D., Cox E. (2016). Potential 
immunosuppressive effects of Escherichia coli O157:H7 experimental infection on the 
bovine host. Submitted to BMC genomics.  
Rybarczyk J., Kieckens E., Vanrompay D., Cox E., 2016. In vitro and in vivo studies on 
the antimicrobial effect of lactoferrin against Escherichia coli O157:H7. Submitted to 
Veterinary Microbiology.  
 
Participation in international conferences 
VTEC 2012, 8th International Symposium on Shiga Toxin (Verocytotoxin) Producing 
Escherichia coli Infections. 6-9 May 2012. Amsterdam, The Nederlands. (participation) 
Kieckens E., Rybarczyk J., De Zutter L., Vanrompay D., Cox E. Curative treatment of 
E. coli O157:H7 infected sheep with lactoferrin. BSFM 20-21 September 2012. Brussels, 
Belgium. (abstract and poster presentation) 
Rybarczyk J., Kieckens E., De Zutter L.,Remon J.P., Vanrompay D., Cox E. Clearance 
of Escherichia coli O157:H7 infection in calves by rectal administration of bovine 
lactoferrin. AREA 2013, 5th Symposium on Antimicrobial Resistance in Animals and the 
Environment. 30 June- 3 July 2013. Ghent, Belgium. (abstract and poster presentation) 
Kieckens E., Rybarczyk J., De Zutter L., Remon J.P., Vanrompay D., Cox E. Effect of 
bovine lactoferrin on antibody responses in E. coli O157:H7 infected cattle. IVIS 2013, 
International Veterinary Immunology Symposium. 29 August -3 September 2013. Milan, 
Italy. (abstract and poster presentation)  
Rybarczyk J., Kieckens E., De Zutter L., Remon J.P., Vanrompay D., Cox E. 
Lactoferrin as a new treatment approach of E. coli O157:H7 infected ruminants. 12th 
Curriculum Vitae & Bibliography 
 
201 
 
International conference on Lactoferrin: structure, function and applications. 6-10 
October 2013. Rome, Italy. (abstract and poster presentation) 
Kieckens E., Rybarczyk J., Li R.W., Vanrompay D., Cox E. Fecal shedding and gene 
expression profile suggest suppression of the immunity in calves after an oral infection 
with Escherichia coli O157:H7. 3th International OneHealth Congress. 15-18 March 2015. 
Amsterdam, The Netherlands. (oral presentation) 
Kieckens E., Rybarczyk J., Li R.W., Vanrompay D., Cox E. Immune suppression by 
Escherichia coli O157:H7 in calves after an oral infection: a study of fecal shedding and 
gene expression. 3th International Congress of Bacteriology and Infectious Diseases. 4-6 
August 2015. Valencia, Spain. (abstract and poster presentation) – Award for Best Poster 
Presentation. 
Kieckens E., Rybarczyk J., Li R.W., Vanrompay D., Cox E. Immune suppression in 
calves after an oral infection with Escherichia coli O157:H7. ECMIS 2015, E. coli and the 
Mucosal Immune System. Ghent, Belgium. (oral presentation) 
Rybarczyk J., Kieckens E., De Zutter L., Remon J.P., Vanrompay D., Cox E. Rectal 
administration of lactoferrin powder clears Escherichia coli O157:H7 in calves and enables 
an EspA and EspB-specific immune response. ECMIS 2015, E. coli and the Mucosal 
Immune System. Ghent, Belgium. (oral presentation) 
Kieckens E., Rybarczyk J., Barth S., Menge C., Cox E., Vanrompay D. Effects of bovine 
lactoferrin on release and bioactivity of Shiga toxins from different E. coli O157:H7 
strains. BSFM 15-16 September 2016. Brussels, Belgium. (poster presentation) 
 
  
 
  
 
 
 
 
 
 
 
 
Dankwoord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Dankwoord 
205 
 
Dit is het dan, na het schrijven van het wetenschappelijk deel van mijn PhD-boekje 
is het eindelijk tijd voor het meest gelezen gedeelte en door sommigen meest 
geapprecieerde deel: het dankwoord. Het is zeker niet eenvoudig om niemand te vergeten 
en iedereen op gepaste wijze te bedanken, daarom is dit deeltje extra lijvig geworden.  
Allereerst wil ik graag mijn promotor Prof. Dr. Eric Cox bedanken voor het 
vertrouwen dat hij in mij heeft gesteld. Prof. Cox, ik weet dat u bij onze eerste 
ontmoeting niet erg hoog opliep met het doorzettingsvermogen van Masters Biomedische 
Wetenschappen, maar hopelijk is die twijfel nu volledig weggenomen. Bedankt voor het 
eindeloos nalezen van al die FOD verslagen, artikels, posters en natuurlijk mijn PhD-
boekje. Eerlijk gezegd heb ik nooit begrepen hoe u zo rustig kan blijven zo dicht bij een 
deadline, maar ik heb zeker geleerd om alles te relativeren . Ook bedankt voor uw 
kritische opmerkingen en nieuwe ideeën tijdens een van onze vele vergaderingen, ze 
vormden een belangrijke bijdrage aan deze thesis. 
Prof. Dr. Daisy Vanrompay, als copromotor wil ik u graag bedanken voor de kans 
die u me gegeven heeft om mijn weg in het wetenschappelijk onderzoek verder te 
vervolgen. Zowel tijdens mijn PhD als nu kan ik steeds op uw steun en verfrissende 
ideeën rekenen. Bedankt dat uw deur steeds openstaat! 
Prof. Dr. Lieven De Zutter, u was eveneens copromotor van het EHEC-clearance 
project. Bedankt dat ik steeds terecht kon in uw labo en dat u me bijstond met goede raad 
i.v.m. tellen en herkennen van bacteriële kolonies indien nodig. Ik heb veel van u geleerd 
over voedselveiligheid.   
Furthermore, I would like to thank all the members of the examination committee 
Prof. Dr. Piet Deprez, Prof. Dr. Herman Favoreel, Dr. ir. Koen De Reu, Prof. Dr. ir. 
Stefaan De Smet, and Prof. Dr. Christian Menge for finding time during their busy 
daily work scheme to read my PhD thesis and give constructive comments.  
Tijdens mijn doctoraat heb ik regelmatig samengewerkt met andere diensten. 
Joanna en ik waren geen dierenarts en verzorgen van kalveren was helemaal nieuw voor 
ons. Bedankt Bart Pardon en Bonnie Valgaeren dat we steeds op jullie koeien-kennis 
beroep mochten doen . Van het labo Veterinaire Volksgezondheid en Voedselveiligheid 
wil ik graag Carine, Martine en Sandra bedanken voor hun technische ondersteuning en 
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praktische tips. Bavo, bedankt om mee te gaan om staaltjes te gaan nemen. Nog een paar 
dagen en het is ook jouw beurt. Succes! 
Ook naar mijn collega’s op mijn nieuwe werkplek aan de Coupure gaat een 
woordje van dank uit. Bedankt Annelien en Ine om me vanaf dag 1 op te nemen in de 
groep en in te wijden in de Immuno-habbits en ervoor te zorgen dat ik me onmiddellijk 
op mijn gemak voelde. Anh, you are a wonderfull person, I admire your keep-calm-good-
vibes-no-matter-what attitude . Cindy, jou wacht nu nog de lastige taak om alle 
resultaten samen te schrijven tot een verhaal. Ik ben er zeker van dat je het goed zal doen, 
en als je raad nodig hebt of het even niet meer ziet zitten, je weet me te vinden . Succes! 
Michelle, sinds kort werken we samen op een project maar vanaf dag 1 weet ik al dat we 
het goed met elkaar gaan kunnen vinden . We worden een topteam! Sarah, ik heb je 
jammer genoeg maar even mogen leren kennen, maar je pipetten zijn in veilige handen 
bij mij . Veel succes op je nieuwe job! Tho, I wish you all the best with your future 
fishy-experiments !    
Joanna, my University-godmother … I can dedicate a whole page to you but I 
will be concise and write it in 1 paragraph. I still remember when I arrived in Merelbeke 
and you had to explain me all the practical things in the lab and stables... And now again 
in Coupure… It might feel like I’m stalking you because we are again sharing an office 
like before .  It was always a pleasure to share the practical work with you both in the 
lab and in the stables. We’ll probably never forget all days and weekends we spend 
struggling in the stables with the calves, transporting liters of milk and tons of hay and 
straw. I couldn’t have had a better shit-digging friend to share my PhD with…  
This part is dedicated to the people I’ve spend so much time with during and after 
work: the Greek-Egyptian-Italian-Polish-Belgian-Cuban-Vietnamese-Chinese office-
dudes: Anastasia, Bakr, Elisa, Gosia, Joanna (again ), Michael, Pedro, Ut and Yu. 
Thanks to all of you! I was always happy to go to work and no matter in which continent 
of the world I will be, I will always have a place to stay . Anastasia, dudie, I still 
remember you first word in Dutch “g*dverdomme”. We had a lot of fun-times and I 
know we’ll still have them when we go out for coffee . Good luck with you PhD! 
Thanks Bakr, for all the advices you gave me during my PhD. Elisa, my delicious slice of 
Italian Pizza! We had such a big fun during your/my bachelorette, and afterwards on 
your/my wedding. Thanks for letting me to discover such nice places and restaurants in 
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Italy and also for all the lovely drinks, home-made Italian lunches with and without zia 
Carmella, dinners, barbecues and free vet-visits for Lola. Now your time has come to 
change your life again. I wish you and Paolo all the best with your new life and your 
baby-to-come in Switzerland. I will miss you guys! See you soon when we are coming for 
a visit and some skiing! Gosia’ke, my running mate! Since you are fluently speaking 4 
languages, I will try to do the same . J'admire vos compétences d'organisation. Until 
now it is still unclear to me how you can manage a very busy full time job with 3 children 
and renovations of your home . Bedankt om er altijd voor ons te zijn met je luisterend 
oor, zelfs al had je het zelf soms minder makkelijk. Like Ut once said: you are the glue 
that sticks us together. Jesteś prawdziwym przyjacielem!! (hopelijk heeft Google translate 
me niet in de steek gelaten met dit laatste ) Succes met het laatste deel van je PhD, het 
einde komt in zicht! Hopelijk kunnen we nog veel (stads)loopkes samen doen. Michael, 
voordat jij kwam was ik het enige Belgje in onze exotische bureau . Ik ben blij dat jij 
me komt opvolgen en ik wens je alle geluk toe met je PhD! Never give up, je komt er 
zeker . Veel succes ook met de voorbereidingen van je Belgisch-Nederlandse trouw met 
Brigitta! Pedro, Pedrito, Pedritino, cojones! It has been a while since we saw each other, 
but I still remember your bull-capturing-throwing-lasso skills like in the movies. I hope 
our paths will cross again and when they do, we’ll go out to eat steak, cojones ! Uttie, 
thanks for being our tower of strength in the office. You were there behind your desk full 
of papers on the first day I arrived and you still are. Although, some of your habits have 
changed: fish sauce and ‘balut’ were replaced by broodjes mozzarella, spaghetti and 
waffles. If you ever go back to Vietnam, let me know so I can send you survival packages 
with Belgo-Italian food . Thanks for helping me out with the mean blotting-machine ! 
Yu, my Chinese friend, I didn’t know that Chinese weddings are not about dancing but 
about playing games. Thanks for making me bridesmaid and good luck back there in 
China!   
En dan nu een woordje van dank voor al mijn (ex-)collega’s van het labo 
Immunologie in Merelbeke. Rudy, of Rudietjen voor de vrienden, merci om altijd voor 
mij klaar te staan, om me te helpen met het werk in de stallen, screenings en 
autoclaveren. Niet te veel stressen en dan komt je welverdiende pensioen nog sneller 
dichterbij ! Simonneke, thanks voor alle “efforkes” die je gedaan hebt bij de 
bloednames en de screenings. Samen “op den boer gaan” en dan nog een stinkende 
hippie/metal lifter met lederen broek meenemen blijft toch geweldig . Griet, merci 
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voor de praktische hulp in het labo, voor je hulp met ELISA’s op ontelbare platen en 
hulp bij PBMC’s isoleren toen ik opnieuw een groentje was. Vanuit mijn keukenraam zie 
ik alle dagen mijn rabarber staan en dan denk ik eens aan u . Charlotteke, jij oneindige 
dierenvriend. Merci om te helpen om de organisatie van het labo in goede banen te 
leiden. Als uw verbouwingen rond zijn en uw “boomschelleke” staat te pronken als 
salontafel, dan kom ik zeker eens kijken. Wordt het trouwens geen tijd om aan trouwen 
te denken ? Cliffie/Cliffster, jij bent altijd de vrolijke krullenbol van het labo. Je weet 
mensen altijd op te beuren. Geniet samen met Manou van jullie zoontje! Ik vraag het nog 
1 keer: “Heeft Rune al krulletjes?” . Hanneke, ik zie ons daar nog altijd staan op die 2de 
januari 2012. Allebei als nieuwe rekruten, al had jij wel al eerder in het labo gewerkt. 
Onze “samen uit, samen thuis” liep uiteindelijk niet volledig gelijk maar ik ben blij dat ik 
je heb leren kennen. Verzorg die knie zodat we binnenkort nog eens onze dansbenen 
kunnen gebruiken! Jochen/JL23, merci om de koffie-met-extra-veel-starbucks-siroopkes-
pauzes zo plezant te maken. Hopelijk krijg je snel alles afgerond en dan kan je emigreren 
naar Catalonië om daar je droomvrouw (groot, blond en Catalaans) te vinden . 
Steffi’ke, hoewel het misschien niet altijd plezant is, blijven doorbijten en dan kom je er 
wel. Veel succes met je PhD nog en hopelijk kunnen we binnenkort eens een bbq’ke ofzo 
doen als ik jullie nieuwe tijger kom bezoeken. Hanske, doe het nog goed met je PhD en 
met de voetbal. Denk er aan: deelnemen is belangrijker dan winnen ;). Raquelleke, I 
don’t know many people who can combine a scientific carrier with a busy nightlife. Keep 
dancing salsa and enjoy life as you do, the PhD will follow . Mizan, Haixiu, Jonas and 
Robert, our newest colleagues, good luck with your future scientific careers. You will do 
great! 
Voor praktische, logistieke en allerlei andere ondersteuning kon ik ook rekenen op 
de 2 beste secretaresses ter wereld! Merci Ann en Sarah voor al jullie hulp, tips en geduld 
als ik weer eens bij jullie kwam zagen over iets. Sarah, bedankt voor de gezellige 
wandelingetjes onder de middag en ik heb bij het babysitten ingezien dat 3 kinderen, 2 
honden, 2 katten en 1 goudvis toch wat van het goede teveel zijn voor mij .  
Bert, bedankt voor al je hulp maar vooral de hulp met mijn flow-cytometrie. Het is 
nog steeds een beetje “hokus pokus” wat je doet, maar gaandeweg zal het wel duidelijk 
worden zeker… Wanneer zet je die Elvis-pruik nog eens op ? Annelies, je werkt 
intussen al een jaar of 2 niet meer in Merelbeke, maar ik ben blij dat we nog af en toe 
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eens samen gaan lunchen. Bedankt om me bij het begin van mijn PhD te tonen hoe je 
dingen moet aanpakken om ze gedaan te krijgen. Je inzicht en inlevingsvermogen hebben 
me ook daarna nog veel geholpen. Tot binnenkort! Michaela, bedankt voor je hulp met 
de EspB-sequenties en de fold changes. Hoewel je ook al eventjes weg bent, is je 
Oostenrijkse kruimel-kaastaart met appel nog steeds een van mijn favoriete desserts! 
Vesna, bedankt voor je hulp op die bewuste slachtdag met het transport van onze dieren 
die geen stap vooruit of achteruit wilden zetten.  
Naast alle collega’s kan ik natuurlijk mijn familie en vrienden niet vergeten. 
Bedankt mama en papa voor jullie onvoorwaardelijke steun, om me de kans te geven 
verder te studeren en natuurlijk ook om mijn gezaag en frustraties te aanhoren. Schattie, 
ondertussen ook mijn man, hoewel ik dat nog steeds niet zeg  merci voor alle geduld, 
ook als ik op oudejaarsavond nog tot 20u een artikel moest verbeteren en al die weekends 
naar de kalveren ging. Nu is er eindelijk meer tijd voor leuke dingen en Lola! Maria en 
Richard, ik kom al zolang bij jullie over de vloer dat ik me een tweede dochter voel . 
Merci om altijd te vragen hoe het ging op het werk en dan toch niet verder door te vragen 
als ik er geen zin in had . Karolientje, die loopjes met Lola en Zina op vrijdagavond en 
op zondag hebben echt geholpen om alle stress eens eventjes te vergeten. Jou en Pieter 
wacht nu een nieuwe uitdaging. Ik zal mijn best doen om de perfecte PhD-tante te zijn 
. Annelien, Fabs, Joyce, Sofie, Bert, Joris, Koen, Pieter, Maarten (x2) en Stijn merci 
om de weekends altijd zo goed op te vullen, zodat ik altijd voldoende afleiding had om 
volledig (niet) uitgerust aan de werkweek te beginnen!      
 
Evelien, 20 september 2016     
 
  
 
 
  
 
 
 
